Starch based systems for the colonic delivery of bioactive peptides by Gough, Ronan
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Starch based systems for the colonic delivery of bioactive peptides
Author(s) Gough, Ronan
Publication date 2018
Original citation Gough, R. 2018. Starch based systems for the colonic delivery of
bioactive peptides. PhD Thesis, University College Cork.
Type of publication Doctoral thesis
Rights © 2018, Ronan Gough.
http://creativecommons.org/licenses/by-nc-nd/3.0/












A thesis presented to the National University of Ireland, Cork, for the degree of 
Doctor of Philosophy 
 
Ronan Gough 




Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland 
Supervisors: Dr. André Brodkorb, Dr. Song Miao and Dr. Mary C. Rea 
 
School of Microbiology, University College Cork, Co. Cork, Ireland 
Head of School: Prof. Gerald F. Fitzgerald 










List of abbreviations………………………………………………….....……….xiii 
 
List of figures………………………………………..……………………...…….xvi 
 




Literature review: Oral delivery of bioactive proteins and peptides .................... 1 
1.1. Abstract ............................................................................................................. 2 
1.2. Introduction ....................................................................................................... 2 
1.3. Delivery systems ............................................................................................... 6 
1.3.1. Pro-peptides ............................................................................................... 6 
1.3.2. Structural modification............................................................................... 7 
1.3.3. Enzyme inhibitors ...................................................................................... 8 
1.3.4. Absorption/permeation enhancers .............................................................. 9 
1.3.5. Bioadhesive systems ................................................................................ 10 
iii 
 
1.3.6. Protective matrices/coatings/carriers with controlled release .................. 11 
1.3.7. Nanoparticles............................................................................................ 16 
1.3.8. Lipid based systems including emulsions ................................................ 18 
1.4. Commercial oral peptide delivery systems ..................................................... 20 
1.5. Conclusions ..................................................................................................... 24 
1.6. References ....................................................................................................... 24 
 
Chapter 2 
A simple method for the purification of nisin ........................................................ 39 
2.1. Abstract ........................................................................................................... 40 
2.2. Introduction ..................................................................................................... 40 
2.3. Materials and methods .................................................................................... 44 
2.3.1. Production of nisin from a culture ........................................................... 44 
2.3.2. Purification of nisin from a culture fermentate ........................................ 45 
2.3.3. Purification of nisin from a commercial nisin preparation ...................... 45 
2.3.4. Cell counts ................................................................................................ 46 
2.3.5. Lactose and lactic acid quantification ...................................................... 46 
2.3.6. Nisin quantification by reversed phase - high performance liquid 
chromatography (RP-HPLC) ............................................................................. 47 
2.3.7. Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI TOF MS) ....................................................................... 47 
2.3.8. Nisin quantification by activity assay ...................................................... 48 
iv 
 
2.3.9. Conductivity ............................................................................................. 48 
2.3.10. Quantification of total protein ................................................................ 49 
2.4. Results and discussion .................................................................................... 49 
2.5. Conclusion ...................................................................................................... 53 
2.6. References ....................................................................................................... 53 
 
Chapter 2 supplementary material 
S2.1. Introduction ................................................................................................... 57 
S2.2. Materials and methods .................................................................................. 57 
S2.3. Results ........................................................................................................... 58 
S2.4. Conclusion .................................................................................................... 59 
S2.5. References ..................................................................................................... 59 
 
Chapter 3 
Simulated gastrointestinal digestion of nisin and interaction between nisin and 
bile ............................................................................................................................. 60 
3.1. Abstract ........................................................................................................... 61 
3.2. Introduction ..................................................................................................... 61 
3.3. Materials and methods .................................................................................... 63 
3.3.1. Materials ................................................................................................... 63 
3.3.2. Simulated digestion .................................................................................. 64 
v 
 
3.3.3. Determination of the effect of the presence of bile during digestion on the 
activity of the digestion products ....................................................................... 65 
3.3.4. Reversed phase - high performance liquid chromatography (RP-HPLC) 65 
3.3.5. Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI TOF MS) ....................................................................... 66 
3.3.6. Activity Assay .......................................................................................... 66 
3.3.7. Atomic force microscopy (AFM) ............................................................ 67 
3.3.8. Turbidity ................................................................................................... 67 
3.3.9. Dynamic light scattering .......................................................................... 68 
3.4. Results and discussion .................................................................................... 68 
3.4.1. Simulated digestion .................................................................................. 68 
3.4.2. Analysis of nisin fragments ...................................................................... 69 
3.4.3. Nisin interaction with bile and other surfactants ..................................... 74 
3.5. Conclusions ..................................................................................................... 79 
3.6. References ....................................................................................................... 80 
 
Chapter 4 
Entrapment of nisin in starch for colonic delivery using spray coating and co-
spray drying .............................................................................................................. 84 
4.1. Abstract ........................................................................................................... 85 
4.2. Introduction ..................................................................................................... 86 
4.3. Materials and methods .................................................................................... 91 
vi 
 
4.3.1. Materials ................................................................................................... 91 
4.3.2. Preparation of nisin .................................................................................. 91 
4.3.3. Preparation of gelatinised starch .............................................................. 91 
4.3.4. Production of cores for spray coating ...................................................... 92 
4.3.5. Spray coating ............................................................................................ 93 
4.3.6. Co-spray drying ........................................................................................ 94 
4.3.7. Simulated digestion .................................................................................. 94 
4.3.8. Breakup of retrograded HACS by enzymatic and chemical approaches . 95 
4.3.9. Reversed-phase high performance liquid chromatography...................... 95 
4.3.10. Physical characterisation ........................................................................ 96 
4.3.11. Biological activity assay ........................................................................ 97 
4.3.12. Insoluble solids ...................................................................................... 98 
4.3.13. Entrapment efficiency ............................................................................ 98 
4.4. Results and discussion .................................................................................... 99 
4.4.1. Preparation of gelatinised starch .............................................................. 99 
4.4.2. Production of cores ................................................................................ 100 
4.4.3. Spray coating .......................................................................................... 102 
4.4.4. Co-spray drying ...................................................................................... 106 
4.5. Conclusions ................................................................................................... 108 






Entrapment of nisin in a starch gel and fermentation of starch by 
Ruminococcus bromii ............................................................................................. 115 
5.1. Abstract ......................................................................................................... 116 
5.2. Introduction ................................................................................................... 117 
5.3. Materials and methods .................................................................................. 120 
5.3.1 Materials .................................................................................................. 120 
5.3.2. Preparation of nisin ................................................................................ 120 
5.3.3. Reversed-phase high performance liquid chromatography.................... 121 
5.3.4. Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI TOF MS) ..................................................................... 121 
5.3.5. Production of starch gels ........................................................................ 122 
5.3.6. Simulated chewing ................................................................................. 122 
5.3.7. Digestion ................................................................................................ 123 
5.3.8. Insoluble solids ...................................................................................... 124 
5.3.9. Entrapment efficiency ............................................................................ 125 
5.3.10. Microscopy ........................................................................................... 125 
5.3.11. Bacterial fermentation .......................................................................... 125 
5.4. Results and discussion .................................................................................. 127 
5.4.1. Initial gel entrapment and comparison with previous work ................... 127 
5.4.2. Optimisation of gel entrapment .............................................................. 128 
5.4.3. Bacterial fermentation ............................................................................ 129 
viii 
 
5.4.4. Simulated chewing ................................................................................. 132 
5.4.5. Simulated digestion ................................................................................ 133 
5.5. Conclusions ................................................................................................... 135 
5.6. References ..................................................................................................... 136 
 
Chapter 6 
Fluorescent labelling of nisin to determine its localisation in starch gels ......... 141 
6.1. Abstract ......................................................................................................... 142 
6.2. Introduction ................................................................................................... 143 
6.3. Methods ......................................................................................................... 145 
6.3.1. Preparation of nisin ................................................................................ 145 
6.3.2. Labelling ................................................................................................ 146 
6.3.3. Matrix-assisted laser desorption/ionization time of flight mass 
spectroscopy (MALDI TOF MS) ..................................................................... 147 
6.3.4. Heat treatments....................................................................................... 148 
6.3.5. Spectrophotometry ................................................................................. 148 
6.3.6. Reversed-phase high performance liquid chromatography.................... 148 
6.3.7. Activity Assay ........................................................................................ 149 
6.3.8. Entrapment of nisin in starch gel ........................................................... 150 
6.3.9. Confocal microscopy ............................................................................. 150 
6.4. Results and discussion .................................................................................. 150 
6.5. Conclusions ................................................................................................... 157 
ix 
 
6.6. References ..................................................................................................... 157 
 
Chapter 7 
Oral delivery of nisin in resistant starch based matrices alters the gut 
microbiota in mice .................................................................................................. 160 
7.1. Abstract ......................................................................................................... 161 
7.2. Introduction ................................................................................................... 162 
7.3. Materials and methods .................................................................................. 166 
7.3.1. Reagents ................................................................................................. 166 
7.3.2. Preparation of nisin ................................................................................ 166 
7.3.3. Preparation of test diet pellets ................................................................ 167 
7.3.4. Feeding schedule and sample collection ................................................ 168 
7.3.5. DNA extraction, amplification and sequencing ..................................... 169 
7.3.6. Bioinformatics analysis .......................................................................... 170 
7.3.7. Preparation of faecal pellets for detection of nisin................................. 171 
7.3.8. Reversed phase - high performance liquid chromatography (RP-HPLC)
 .......................................................................................................................... 172 
7.3.9. Matrix-assisted laser desorption/ionization time of flight mass 
spectroscopy (MALDI TOF MS) ..................................................................... 172 
7.3.10. Activity assay ....................................................................................... 172 
7.3.11. Statistical analysis ................................................................................ 173 
7.4. Results ........................................................................................................... 173 
x 
 
7.4.1. Quantity of diets consumed and effect on weight gain .......................... 173 
7.4.2. Identification and quantification of intact nisin and nisin fragments in the 
faeces ................................................................................................................ 175 
7.4.3. HTS-based analysis of microbiota ......................................................... 178 
7.5. Discussion ..................................................................................................... 182 
7.6. Conclusions ................................................................................................... 189 
7.7. References ..................................................................................................... 190 
 
Chapter 8 
General discussion .................................................................................................. 199 


















The thesis submitted is my own work and has not been submitted for another degree, 
either at University College Cork or elsewhere. 
 
Signed: _____________ 
 Ronan Gough 
 




















Bioactive peptides have numerous health benefits, although if taken orally they may 
be digested during gastrointestinal (GI) transit. Encapsulation is an established 
method for oral delivery of bioactives. However, many current approaches arise 
from pharmaceutical applications and may be unsuitable for food due to the 
materials used, cost and scale of production. Therefore, in this project we set out to 
create a simple and clean-label encapsulation system, suitable for use in the food 
industry, which could deliver bioactive peptides to the colon. One potential clean-
label entrapment material is resistant starch, which is the portion of starch that resists 
digestion in the upper GI tract but can be digested by bacteria in the colon. As a 
model bioactive peptide, the well characterised antimicrobial peptide nisin was used; 
this peptide is normally digested during GI transit. To prepare the nisin a simple 
purification process was developed, which produced a powder containing ∼33% 
nisin from a nisin producing culture and also enriched a commercial nisin 
preparation over 30-fold to a purity of ∼58%. The digestion of nisin was 
characterised (in vitro) and 6 nisin fragments (4 of which are bioactive) were 
identified in the digestion products; it was also observed that nisin formed a complex 
with bile salts that effected its digestion. Nisin was entrapped in starch through 
multiple approaches based on spray coating, co-spray drying and gel entrapment. A 
simple approach based on gel entrapment was the most successful and it was shown 
in vitro to be capable of protecting a portion of the entrapped nisin during transit in 
the upper GI tract. Using a murine model, it was determined in vivo that a nisin 
entrapped in starch gel diet significantly (p < 0.001, n = 10) affected the relative 
abundance of 3 times as many genera from the lower GI tract than a control nisin in 
starch diet, despite the mice consuming 3-fold less nisin than the control diet. 
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The oral route is the most acceptable way to administer therapeutic 
compounds; however few bioactive proteins and peptides achieve a therapeutic 
effect when ingested. There are two major challenges in oral delivery of most 
bioactive proteins and peptides; when transit through the gastrointestinal tract (GIT) 
is required the challenge is protection from digestion and when systemic delivery is 
required the challenge is absorption. A range of strategies to enable the oral delivery 
of proteinaceous bioactives are discussed in this review, including the use of pro-
peptides, structural modification of the protein/peptide, protease inhibitors, 
absorbance/permeation enhancers, bioadhesive systems, emulsion/lipid based 
systems, nanoparticle based systems and controlled release systems. Despite the 
range of tools available to enable oral delivery, there are relatively few systems in 
commercial use or in commercial development, for applications in food or 
pharmaceutical products. The diversity between commercial systems designed for 
the same or similar proteins and peptides shows that clear optimal systems for oral 
delivery of proteins and peptides are yet to be developed, thus there is much 




Multiple studies have shown that the oral delivery of bioactives is preferred 
over more invasive routes such as injection (Stewart et al., 2016). However, few 
bioactive proteins and peptides are orally delivered effectively; only 4% of FDA 
approved therapeutic peptides are orally administered, with the majority being 
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administer intravenously, subcutaneously or intramuscularly (45%, 33%, and 14% 
respectively) (Usmani et al., 2017). To avail of their health benefits after ingestion, 
many bioactive proteins and peptides require delivery to a specific location in the 
GIT, as in the case of the colonic delivery of ciclosporin (Keohane, Rosa, Coulter, & 
Griffin, 2016), or they require absorption into the systemic circulation, as in the case 
of insulin (Oramed Pharmaceuticals, 2018). Therefore there are two primary 
challenges for the oral delivery of most bioactive proteins and peptides, namely 
protection from pH and proteases during transit through the GIT and absorption from 
the GIT. Both of these challenges do not occur in all proteins and peptides; a peptide 
can have a local activity in the GIT or their site of absorbance could be the mouth 
(Bernstein, 2008; Fretzen et al., 2016). 
Some bioactive peptides are stable at low pH and have an inherent resistant 
to digestion, such as those in which cleavage sites for particular enzymes are absence 
or inaccessibility, as in the case of isoleucine-proline-proline (IPP) (FitzGerald & 
Meisel, 2000) and plecanatide (Pitari, 2013). However, the vast majority of bioactive 
peptides are susceptible to digestion during gastro-intestinal transit (Segura-Campos, 
Chel-Guerrero, Betancur-Ancona, & Hernandez-Escalante, 2011), including peptides 
with significant potential health benefits such as insulin (Sonia & Sharma, 2014) and 
pediocin (Kheadr et al., 2010). 
Protein/peptide digestion begins in the stomach; gastric acid denatures and 
unfolds most proteins, thus allowing proteolytic enzymes better access to their 
respective cleavage sites. The protease pepsin is secreted in the stomach and is 
capable of cleaving 10-15% of the peptide bonds depending on the ingested 
proteins/peptides. The majority of protein/peptide digestion occurs in the small 
intestine, primarily due to proteases produced by the pancreas, which are secreted 
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into the small intestine (trypsin, chymotrypsin, elastase and carboxypeptidases A and 
B). Additionally there are aminopeptidases located on the surface (brush border) of 
the epithelium (Goodman, 2010). 
Proteinaceous materials are absorbed through enterocytes (intestinal 
absorptive cells) that are located in the epithelium of the small intestine. The uptake 
mechanisms are designed for amino acids, dipeptides and tripeptides. Without 
resorting to absorbance enhancers or cell penetrating peptides, there are limited 
possibilities for the uptake of larger peptides; primarily via the antigen sampling 
mechanism of microfold cells (M cells) and by passive diffusion of highly lipid-
soluble peptides into enterocytes (Miner-Williams, Stevens, & Moughan, 2014). 
Carbohydrate digestion and absorption in humans (excluding the GIT 
microbiota) is essentially limited to simple sugars, digestible dextrins, digestible 
starches and glycogen (Lunn & Buttriss, 2007). Carbohydrate digestion begins in the 
mouth with the digestion of complex carbohydrates with salivary α-amylase, which 
is subsequently deactivated by the acidic pH of the stomach. Carbohydrate digestion 
continues in the small intestine with α-amylase that is produced by the pancreas. 
This cleaves complex carbohydrates into di-, tri-, and oligosaccharides. Some dietary 
carbohydrates such as the disaccharides sucrose and lactose do not require α-amylase 
digestion. The di-, tri-, and oligosaccharides are broken down to monosacharides by 
brush border enzymes and then absorbed by the enterocytes (Goodman, 2010). 
Digestion of lipids begins in the mouth with lingual lipase and continues in 
the stomach with lingual lipase and gastric lipase, although only 15% of dietary 
lipids are digested at these stages. In the small intestine bile salts emulsify the lipids 
while pancreatic lipase and co-lipase work in conjunction to digest lipids. The 
products of lipolysis are transported by bile salt micelles to the enterocytes 
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(Goodman, 2010; Minekus et al., 2014). An overview of protein/peptide, 




Fig. 1.1. An overview of protein/peptide, carbohydrate and lipid digestion and absorption. Based on 
Minekus et al. (2014) and Goodman (2010). 
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The difference between proteins and peptides is purely one of size; generally 
molecules with more than 50 amino acid residues are referred to as proteins, 
however there is no clear-cut definition with bioactives such as insulin being referred 
to as a peptide and as a protein (Doonan, 2002). For brevity the word peptide will be 
used in this review to refer to proteins and peptides, as the majority of proteinaceous 
bioactives mentioned in this review are smaller than 50 amino acids. 
The oral delivery of bioactive peptides is a challenge for both the food and 
the pharmaceutical industries (Fosgerau & Hoffmann, 2015; Lau & Dunn, 2017; 
Mohan et al., 2015). The development of oral delivery systems for bioactive peptides 
dates to at least the 1920s, when studies on oral insulin delivery were performed 
(Harrison, 1923). The treatment of diabetes continues to be one of the main drivers 
of research in oral peptide delivery, with several systems in commercial development 
for the oral delivery of insulin (Diabetology, 2017a; Diasome Pharmaceuticals, 2017; 
Oramed Pharmaceuticals, 2018; Pozzilli, Raskin, & Parkin, 2010). 
The primary strategies employed in the oral delivery of bioactive peptides are 
pro-peptides, structural modification of the peptide, protease inhibitors, 
absorbance/permeation enhancers, bioadhesive systems, emulsion/lipid based 
systems, nanoparticle based systems and controlled release systems. 
 




The pro-peptide strategy involves ingesting a protein or peptide whose 
subsequent digestion in the gastrointestinal tract will produce peptides that are 
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bioactive; this can occur during the digestion of many common foodstuffs such as 
milk (Hartmann & Meisel, 2007). The antimicrobial peptide lactoferricin, which is 
active against Gram positive and negative bacteria, is produced during the digestion 
of the milk protein lactoferrin by pepsin in the stomach (Gifford, Hunter, & Vogel, 
2005). The antioxidant LVGDEQAVPAVCVP has been produced through the (in 
vitro) gastric and small intestinal digestion of mussels (Jung et al., 2007), while 
antihypertensive peptides ER and RPR were produced through the (in vitro) gastric 
and small intestinal digestion of pork (Escudero, Sentandreu, Arihara, & Toldra, 
2010). 
The antihypertensive lactotripeptides isoleucine-proline-proline (IPP) and 
valine-proline-proline (VPP) are produced by both processing and gastrointestinal 
digestion of milk proteins (Boelsma & Kloek, 2009). They have received much 
interest, as in addition to being sufficiently short to be absorbed normally, they have 
significant resistance to digestion as they have no cleavage sites for pepsin, trypsin, 
chymotrypsin or elastase (Goodman, 2010) and their C-terminal Pro-Pro gives them 
a general resistance to digestive enzymes including proline specific peptidases 
(FitzGerald & Meisel, 2000). However, a review by the European Food Safety 
Authority (EFSA) of 25 human intervention studies concluded there was no evidence 
of an effect of IPP and VPP on blood pressure (EFSA panel on dietetic products 
nutrition and allergies, 2012). 
 
1.3.2. Structural modification 
 
The linking of a peptide to one or more polyethylene glycol (PEG) chains is 
termed PEGylation (Veronese & Pasut, 2005). The PEGylation of peptides such as 
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calcitonin, glucagon-like peptide-1 (GLP-1) and insulin has been associated with 
greater proteolytic resistance and systemic retention without a negative impact on 
absorption or activity (Calceti, Salmaso, Walker, & Bernkop-Schnurch, 2004; Chae 
et al., 2008; Youn et al., 2006). 
Replacing L-amino acids amino acids with their enantiomers (D-amino acids) 
increases the proteolytic resistance of a peptide (Feng & Xu, 2016),  an example of 
which is the antiduretic desmopressin (Cvetkovic & Plosker, 2005). 
 Cyclisation of peptides increases proteolytic resistance by making the N and 
C terminals, which are normally targets for proteolysis, less accessible for 
exopeptidases; additionally cyclisation can allow stabilisation of conformations in 
which polar residues are exposed, making the molecule more lipid soluble, thus 
allowing absorption by passive diffusion, as in the case of cyclosporine (Nielsen et 
al., 2017). Methods used in producing cyclic peptides include creating an amide 
bond between the N and C terminals of the peptide and forming bonds such as 
disulfide, lactam, lactone and ether bridges between the side change of amino acids 
(Li & Roller, 2002). 
The B12 absorption pathway can be used to absorb peptides by conjugating 
the peptides to B12. This has been successfully used to enhance the absorbance of 
insulin (Clardy-James, Allis, Fairchild, & Doyle, 2012). However this approach is 
limited by the quantity of B12 that can be absorbed (1 to 1.5 μg/day) (Marie Sych, 
Lacroix, & Stevens, 2016) and needs to be performed in conjunction with a strategy 
to prevent proteolysis (Petrus, Fairchild, & Doyle, 2009). 
 




The mechanism that inhibitors use to inhibit the action of a protease include 
binding to the protease such that its structure is distorted, binding to the protease in 
the place of the substrate or depriving the protease of an essential co-factor such as a 
metal ion (Bernkop-Schnurch, 1998; Otlewski, Jelen, Zakrzewska, & Oleksy, 2005). 
A large range of inhibitors have been trialled for peptide delivery, ranging from 
traditional inhibitors such trypsin soybean inhibitor, Bowman-Birk inhibitor (BBI) 
and elastatinal to more recently characterised inhibitors such as ovomucoids 
(Agarwal, Nazzal, Reddy, & Khan, 2001; Laskowski et al., 1958; Marschutz & 
Bernkop-Schnurch, 2000; Tozaki et al., 1997). There are safety concerns regarding 
the side effects of inhibitors including disruption of the digestion of nutritive 
proteins and the stimulation of protease secretion caused by a feedback regulation, 
which results in hypertrophy and hyperplasia of the pancreas and ultimately 
cancerous tumours with prolonged use of inhibitors (Bernkop-Schnurch, 1998). 
 
1.3.4. Absorption/permeation enhancers 
 
Absorption enhancers used in the delivery of peptides include bile, (Michael 
et al., 2000), chitosan (Thanou, Verhoef, & Junginger, 2001), cell permeating 
peptides (Morishita et al., 2007), fatty acids (Leonard, Lynch, McKenna, & Brayden, 
2006; Maher, Leonard, Jacobsen, & Brayden, 2009), surfactants (Alama et al., 2016) 
and chelating agents (Morishita et al., 1993) including citric acid (Welling et al., 
2014). 
Despite differences in the initial effect, such as chelating agents depleting 
intracellular calcium and chitosan drawing the zona occludens-1 (ZO-1) and 
occludin into the cytoskeleton, most of the absorption enhancers ultimately achieve 
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their function through the opening of the epithelial tight junctions (Alama et al., 
2016; Leonard et al., 2006; Maher et al., 2009; Michael et al., 2000; Morishita et al., 
1993; Smith, Wood, & Dornish, 2004; Thanou et al., 2001; Welling et al., 2014). 
Other absorption mechanisms used for peptide delivery include increasing 
membrane fluidity using surfactants and inducing macropinocytosis using cell 
penetrating peptides (CPPs) (Alama et al., 2016; Morishita et al., 2007). 
The concentration of the absorption enhancer needs to be carefully adjusted 
to strike a balance between the degree of absorption and toxicity; also there is always 
the risk of unwanted molecules being absorbed alongside the molecule of interest 
(Aungst, 2012; Whitehead, Karr, & Mitragotri, 2008). 
One approach being used to circumvent the issue of nonspecific absorbance 
is directly conjugating a nutrient such as vitamin B12 or B7 (biotin) to the peptide or 
the peptide containing delivery system, which are then able to take advantage of the 
absorbance system for that nutrient (Petrus et al., 2009; Zhang et al., 2014). 
 
1.3.5. Bioadhesive systems 
 
These systems increase the residence/contact time of the peptide at the site of 
absorption; which increases the amount absorbed. Examples include those using 
lectins, polyacrylates and polysaccharides such as chitosan and hydroxyethyl 
cellulose, with adhesion occurring to the mucus layer or the epithelial cells 
(Bernkop-Schnurch & Krajicek, 1998; Gabor, Schwarzbauer, & Wirth, 2002; 
Grabovac, Guggi, & Bernkop-Schnurch, 2005; Zhang et al., 2006). 
 Much of the recent bioadhesive research has been on thiomers which are 
produced by addition of a thiol group bearing side chains to polymers such as 
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chitosan. They are capable of forming covalent bonds with the cysteine-rich 
subdomains of mucus glycoproteins, which is a stronger interaction than 
conventional bioadhesives (Bernkop-Schnurch, 2005; Bonengel & Bernkop-
Schnurch, 2014). 
 
1.3.6. Protective matrices/coatings/carriers with controlled release 
 
A peptide can be protected from digestion during GIT transit by entrapping it 
within a protective matrix. However this matrix could inhibit peptide activity and 
absorption. Therefore a mechanism for releasing the peptide from the matrix is 
required such as release that is triggered due to pH (pH release systems), release that 
happens continually at a controlled rate (time release systems) or release due to 
digestion by colonic bacteria (microbial release systems). 
The matrices in a pH release system are formulated to swell or dissolve at a 
particular pH, thus releasing the peptide. Natural polymers used in pH release system 
include alginate, chitosan and shellac (George & Abraham, 2007; Jing et al., 2017; 
Kraisit et al., 2013). The most commonly studied polymer for pH release system is 
methacrylate and its derivatives including poly(methacrylic acid-g-ethylene glycol) 
(Kamei et al., 2009; Tuesca, Reiff, Joseph, & Lowman, 2009) and copolymers of 2-
hydroxyethyl methacrylate and methacrylic acid (Mahkam, 2005), with a particular 
interest in the commercial Eudragit
®
 range (Jain, Panda, & Majumdar, 2005; Marais 
et al., 2013) 
The difference between the acidic pH in the stomach and neutral pH in the 
small intestine makes it possible to use pH triggered release to target the small 
intestine (Wang & Zhang, 2012). However, targeting of the colon with a pH 
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triggered release is more challenging as in the ileum of the small intestine the pH 
reaches pH 7.5 , then in the caecum/ascending colon it drops to pH 6.4 and then it 
rises along the colon to pH 7.0 in the descending colon, additionally there are person 
to person variations in these values (Evans et al., 1988). Due to this, delivery 
systems for the colon with a pH based release are normally designed so that they 
begin releasing in the ileum of the small intestine and are often referred to as ileo-
colonic delivery systems instead of colonic delivery systems (McConnell, Short, & 
Basit, 2008); this results in exposure to the proteases of the small intestine. An 
additional difficulty regarding pH based ileo-colonic release is that the delivery 
system is not exposed to pH > 7 for long enough to achieve release in a portion of 
individuals (Ibekwe et al., 2008; Ibekwe et al., 2006). 
Time release systems are normally based on a matrix that can swell in an 
aqueous solution. By altering the composition of the matrix including the degree of 
crosslinking and thickness, the rate of swelling and thus the rate of peptide release 
can be controlled. The natural polymers chitosan (Yuan, Jacquier, & O'Riordan, 
2018) and alginate (Liu, Chen, Xie, & Zhang, 2003) have been used in systems for 
the colonic delivery of insulin and bee venom peptide respectively. In gels composed 
of cross-linked alginate and chitosan, the ratio of alginate to chitosan determined the 
rate of release of bovine serine albumin (BSA) (Xu et al., 2007). Time release 
systems for the colonic delivery of insulin have also been produced based on 
hydroxypropyl methylcellulose (HPMC) and polymethacrylate (Del Curto et al., 
2011; Maroni et al., 2016). 
Time release systems have been combined with pH release systems (Del 
Curto et al., 2014; Liu et al., 2003). This approach is of particular use in colonic 
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delivery, as by having an outer pH release coating, time release can be delayed until 
the small intestine, which allows a greater portion of the peptide to reach the colon. 
There are approximately 4 × 10
13
 bacteria in the colon (Sender, Fuchs, & 
Milo, 2016) and these consume what escapes digestion or is indigestible in the upper 
gastrointestinal tract (Chassard & Lacroix, 2013). This fact allows for the possibility 
of using microbial release systems for colonic delivery, based on materials that are 
not digestible in the upper gastrointestinal tract but can be digested by colonic 
bacteria. 
 There was originally much interest in azopolymer based microbial release 
systems for colonic delivery (Saffran et al., 1986; Tozaki et al., 2001), however there 
are recent concerns that the metabolism of these can result in potentially 
carcinogenic by-products (Claus, Guillou, & Ellero-Simatos, 2016). 
Safer microbial release systems for colonic delivery of peptides have 
therefore been developed based on polymers of commonly used and food-grade 
polysaccharides including chitosan, pectin and starch (Atyabi, Inanloo, & Dinarvand, 
2005; Fetih et al., 2006; Pu et al., 2011; Zhang, Alsarra, & Neau, 2002). 
Chitosan is prepared by the deacetylation of chitin, a structural biopolymer 
found in the exoskeleton of arthropods and in the cell walls of fungi and yeast (Pillai, 
Paul, & Sharma, 2009). This is necessary as chitin is insoluble in almost all common 
solvents, whereas chitosan is soluble below pH 6 (Pillai et al., 2009). Solid gels are 
primarily produced through using a crosslinking agent such as glutaraldehyde 
(Mirzaei, Ramazani, Shafiee, & Danaei, 2013) or through ionic interactions with an 
oppositely charged polymer such as pectin (Chen et al., 2010). Chitosan has the 
additional advantages that it is mucoadhesive (Grabovac et al., 2005) and an 
absorbance enhancer (Smith et al., 2004). Peptides incorporated into chitosan based 
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colonic delivery systems include insulin (Yuan et al., 2018) and calcitonin (Fetih et 
al., 2006). 
 Pectins are a mixture of polysaccharides that are found in plant cell. For 
pectins the procedure required to create a solid gel depends on their degree of 
methyl-esterification (DM), which in turn depends the source of the pectin 
(Sriamornsak, 2003). High DM (>60%) pectins form gels at pH 2.8 to 3.5 and high 
soluble solids, whereas low DM (<40%) pectins require calcium or another divalent 
cation for gelation (Belitz, Grosch, & Schieberle, 2009; Sriamornsak, 2003). Pectin 
has been used for the colonic delivery of nisin (Ugurlu, Turkoglu, Gurer, & Akarsu, 
2007) and insulin (Cheng & Lim, 2004). 
Starch is comprised of the glucose polymers amylose and amylopectin. Both 
amylose and amylopectin are comprised of linear chains of glucose linked by α-1,4 
glycosidic bonds and these chains are branched by α-1,6 glycosidic bonds (Fig. 1.2). 
Amylose is infrequently branched while amylopectin is branched at 10 nm intervals. 
In its native form, starch is arranged into semi-crystalline starch granules, which are 
of 0.1 to 200 μm in diameter. If these granules are heated in the presence of water, 
the amylose and amylopectin dissociate, which leads to the granule exuding amylose 
and absorbing water, causing them to swell and ultimately dissipate. Subsequent 
cooling of the solution causes the amylose and amylopectin to re-associate, turning 
the solution into a solid gel. These two stages are referred to as gelatinisation and 
retrogradation (Fig 1.3). The strength of the gel is primarily related to its amylose 






                      
Fig. 1.2. Structure of amylose (A) and amylopectin (B). 
 
 
          
Fig. 1.3. Schematic representation of starch gelatinisation and retrogradation. The stages are as follows: native 
starch granules (A), swelling of granules during initial gelatinisation (B), amylose leaching and disruption of 
starch granules during further gelatinisation (C), re-association of amylose during initial retrogradation (D)  
increased association of amylose and re-association of amylopectin during further retrogradation. Image obtained 
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The portion of starch that resists digestion in the small intestine but can be 
fermented by the colonic microbiota is termed ‘resistant starch’ and varies between 
starch source and type (Bird, Lopez-Rubio, Shrestha, & Gidley, 2009). Resistant 
starch is classified into 4 types: type 1 resistant starch (RS1) is resistant due to 
physically inaccessibility, type 2 resistant starch (RS2) is resistant due to being in a 
granular form, type 3 resistant starch (RS3) is resistant due to retrogradation and type 
4 resistant starch (RS4) is resistant due to chemical modification (Sajilata, Singhal, 
& Kulkarni, 2006). 
When starch (or its component polymers) are used as a protective coating for 
colonic delivery, they are normally combined with a binder/plasticizer to control 
swelling in aqueous solution and increase structural integrity, with the most studied 
being ethyl cellulose (Freire et al., 2010; McConnell et al., 2007). Peptides that have 
been incorporated into starch based colonic delivery systems include hepatocyte 
growth factor (Pu et al., 2011) and insulin (Situ, Chen, Wang, & Li, 2014), with 




A nanoparticle is a particle that is measured on a nanometre (nm) scale and 
usually refers to particles below 1 μm (Buzea, Pacheco, & Robbie, 2007). The 
primary advantage of nano-sized delivery systems for peptides is their capacity to 
pass through the mucus and epithelial barriers, particularly if the appropriate 
absorbance/permeation enhancers are affixed on their surface (Date, Hanes, & 
Ensign, 2016). There are a large range of materials (including polylactic acid (PLA), 
polyethylene glycol (PEG), chitosan and alginate) and techniques (including 
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emulsification-solvent evaporation, interfacial polymerization and supercritical fluid 
technology) being investigated to produce nanoparticles for peptide delivery, with 
the optimum material and technique dependent on both the properties of the peptide 
and the desired properties of the product (Reis, Neufeld, Ribeiro, & Veiga, 2006). 
Initial protection during GIT transit is provided using the approaches 
described previously such as by PEGylation, protease inhibitors and coatings with 
pH mediated dissolution (Date et al., 2016; He et al., 2017; Malhaire et al., 2016; 
Zhang et al., 2017). 
 To limit impedance by the mucus layer two common approaches used are 
having a particle surface whose net charge is neutral and coating the surface with 
low molecular weight PEG. To transverse the epithelial cell layer there has been 
some success using conventional absorbance enhancers incorporated in the 
nanoparticle, particularly CPPs; however the approaches yielding the most interest 
are exploitation of the endocytosis and transcytosis systems (Lundquist & Artursson, 
2016; Malhaire et al., 2016). Incorporation of vitamin B12 onto the surface of insulin 
loaded nanoparticles allowed them to use the B12 transport system and be 
endocytosed by intestinal enterocytes (Chalasani et al., 2007). One particularly 
promising transcytosis approach is incorporating Fc into the surface of the 
nanoparticles, which results in them being transported across the intestinal 
epithelium (Pridgen et al., 2013). It is also possible for nanoparticles to be taken up 
by the M cells in the Peyer's patches in the same manner as any antigen entering the 
body, however, while some authors have highlighted the potential of this approach, 
others have claimed that there are insufficient M cells in the body to make this an 





1.3.8. Lipid based systems including emulsions 
 
Although lipids are not a specific system per se, their versatile properties give 
them a functional role in a wide range of systems. Lipids allow the solubilisation of 
hydrophobic peptides such as calcitonin and cyclosporine (Aguirre, Rosa, Coulter, & 
Brayden, 2015; Choc, 1997). 
 The rate of peptide release is determined by the rate of digestion of the 
emulsion by lipolysis. The longer the chain length of the fatty acids in an emulsion, 
the greater the resistance of the emulsion to lipolysis. Therefore the rate of release 
can be controlled through the composition of the emulsion (Giroux, Robitaille, & 
Britten, 2016). There are many ways that lipids can enhance the uptake of peptides; 
the fatty acid derivatives caprylate and caprate can dilate tight junctions (Leonard et 
al., 2006; Maher et al., 2009), nanoparticles made from lipids such as 
phosphatidylcholine can be absorbed into a cell by endocytosis and passive diffusion 
(Rao, Agarwal, & Shao, 2008) and by complexing a peptide with sodium N-[8-(2-
hydroxybenzoyl) amino] caprylate (SNAC) a lipophilic complex can form which is 
capable of transcellular absorption (Prem Victor, Paul, & Prakash Sharma, 2014). 
It is possible to incorporate hydrophilic peptides such as insulin in a lipid 
system through water in oil (w/o) or water in oil in water (w/o/w) double emulsions. 
(Cardenas-Bailon, Osorio-Revilla, & Gallardo-Velazquez, 2015; Li et al., 2017; 
Mutaliyeva et al., 2017). 
Self-emulsifying systems, commonly described as self-emulsifying drug 
delivery systems (SEDDS), are mixtures of peptides, lipids and surfactants that once 
dispersed in an aqueous solution and mildly agitated, form emulsions (Kohli et al., 
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2010). The emulsion droplets are commonly nano-sized (Kohli et al., 2010). Two 




) use SEDDS for the 
delivery of ciclosporin (Keohane et al., 2016; Ritschel, 1996). By altering the 
composition of the SEDDs and by the choice of excipients it is possible to modulate 
the rate of digestion by lipase, reduce mucus impediment, enhance epithelial 
absorption and control the rate of release (Leonaviciute & Bernkop-Schnurch, 2015). 
Two other lipid based techniques that have attracted interest are solid lipid 
nanoparticles (SLN) and liposomes. SLN are distinguished by being nano-sized 
particles that are composed of lipids that are solid at room and body temperature; this 
allows greater control over peptide release compared to other lipid systems (Geszke-
Moritz & Moritz, 2016). 
Liposomes are comprised of an aqueous core that is enclosed by a lipid 
bilayer. In their native state they have low stability during gastrointestinal transit 
(Wu, Lu, & Qi, 2015) and recent studies using them for oral peptide delivery have 
examined how their stability and absorption can be improved by incorporating 
excipients. Incorporating biotin into the membrane of nisin containing liposomes 
increased their in vivo intestinal absorption compared to the controls, due to the 
biotin inducing endocytosis in enterocytes (Zhang et al., 2014). Liposomes coated 
with carbopol, chitosan or thiomers had enhanced mucoadhesiveness which 
increased the in vivo or ex vivo absorption of calcitonin containing liposomes 
(Gradauer et al., 2013; Takeuchi, Matsui, Yamamoto, & Kawashima, 2003). 
Incorporating bile salts into liposomes that contained insulin increased their oral 
bioavailability in rats by protecting the liposomes from physiological bile salts (Niu 
et al., 2012). Diasome Pharmaceuticals are currently developing a liposome based 




1.4. Commercial oral peptide delivery systems 
 
 
Fig. 1.4. A selection of commercially available orally delivered bioactive peptides. From left to right and top to 
bottom: ciclosporin (Neoral®, Novartis), pancreatic enzymes (CREON®, Abbott), plecanatide (Trulance™, 
Synergy Pharmaceuticals), lunasin (LunaRich® Reliv), vancomycin (Firvanq™ Cutispharma), desmopressin 
(Minirin®, Ferring Pharmaceuticals), linaclotide (Linzess®, Ironwood Pharmaceuticals in collaboration with 
Allergan) and tyrothricin (Lemocin®, Gebro Pharma). 
 
An overview of orally delivered bioactive peptides that are commercially 
available (Fig. 1.4) or approaching commercialisation are listed in Table 1.1. In cases 
where several manufactures produce the same peptide with the same delivery 
approach, only one manufacturer is listed for brevity. 
Many systems depend on peptides that have structural properties that make 
them suitable for colonic delivery such as being cyclic and/or containing D amino 




The approaches that do not depend on the structural properties of the peptide 
tend to use complex delivery systems which combine several strategies such as an 
outer coating with controlled release, protease inhibitors and absorbance enhancers 
into a single system. This complexity may make such a system only suitable for a 
high value product, such as pharmaceutical products or supplements. 
Despite the structural similarity of many peptides in Table 1.1 and the 
frequent goal of absorption in the small intestine, a different delivery approach is 
used for each peptide; even the Eligen
®
 system which is used for both calcitonin and 
semaglutide uses a different absorbance enhancer for each peptide (5-CNAC for 
calcitonin and SNAC for semaglutide (Davies et al., 2017; Karsdal et al., 2011). The 
range of approaches being investigated, even at a commercial stage, shows that the 
field is highly dynamic, constantly developing and there is still much research 
required before standard delivery systems suitable for a range of peptides are be 
achieved. 
Finally it is notable that there is apparently only one colonic targeting system 
being commercially developed (SmPill
®
 (Keohane et al., 2016)); thus it is an area 
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The lack of systems for the oral delivery of bioactive peptides limits the 
potential health benefits of these peptides, particularly those that could be applied 
locally in the GIT. There is a large range of tools that can aid oral delivery of 
bioactive peptides, however very few delivery systems, especially colon targeted 
systems, that reach commercial development. There exists a need to develop oral 
delivery systems, particularly ones that are simple to produce yet suitable for a range 
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Nisin, an antimicrobial peptide showing activity against a broad range of 
Gram positive bacteria is widely used as a food preservative and has potential as a 
therapeutic for a range of infectious diseases. Here, we present a simple purification 
method, based on a salting-out approach, which can produce a powder containing 
~33% nisin, from a nisin-producing culture in a whey permeate-based medium. This 
process removes over 99% of the lactic acid, NaCl, lactose and non-nisin proteins 
from the cell-free culture supernatant. The approach can also enrich a commonly 
used commercial nisin preparation over 30-fold to a purity of ~58%. These are 
higher purities than comparable published methods. The simplicity of this approach 




Nisin is an antimicrobial peptide produced by strains of Lactococcus lactis 
subsp. lactis (Abee & Delves-Broughton, 2003). Nisin has been granted Generally 
Recognized As Safe (GRAS) status by the US Food and Drug Administration (FDA) 
(US Food and Drug Administration, 1988) and is widely used as a food preservative 
(Abee & Delves-Broughton, 2003) in foodstuffs ranging from cheese and soups to 
beer and sausages (Delves-Broughton, 2005). It is produced by a range of companies 
including DuPont under the brand name Nisaplin
®
, DSM under the brand name 
Delvo
®
Nis and Chr. Hansen under the brand name Chrisin
™
. Nisin has been 
investigated as a treatment for a range of infections (De Kwaadsteniet, Doeschate, & 




(Kamarajan et al., 2015) and proposed as a growth supplement for poultry (Józefiak 
et al., 2013). Nisin has the greatest solubility and stability at pH 3-3.5, with solubility 
and stability decreasing with increasing pH (Davies et al., 1998; Rollema et al., 
1995). Heating nisin to 115 °C for 20 min at pH 3 results in less than 5% loss in 
activity (Davies et al., 1998) and this makes it suitable for high-heat processing such 
as spray drying. Due to the level of interest in nisin, many approaches for the 
production and purification of nisin have been developed, a selection of which are 
described in Table 2.1. 
Nisin producing strains are commonly grown in standard growth media such 
as M17 (Abts et al., 2011), and MRS medium (Meghrous et al., 1997; Prioult et al., 
2000), with glucose as the carbon source to produce nisin. In this study, L. lactis 
NZ9800 pLP712 (nisin A producing strain) was grown in a medium consisting of 
whey permeate supplemented with yeast extract as previously described (Bouksaim 
et al., 1998; Desjardins, Meghrous, & Lacroix, 2001; Xia, Chung, Yang, & Yousef, 
2005). Whey permeate is primarily water, lactose and minerals and is what remains 
after the whey proteins have been harvested from whey (Song, Kim, Lee, & Hwang, 
2007). 
Due to differences in the methods of reporting results in the publications 
listed in Table 2.1, for example describing nisin purity in terms of total protein (Xiao 
et al., 2010) or in terms of total solids (Slootweg, Liskamp, & Rijkers, 2013), direct 
comparisons are difficult. However some clear trends are apparent. Purifications that 
used a commercial preparation as their starting material achieved greater yields and 
purity than those performed on the products of a nisin-producing culture when the 
same purification method was applied to both (Abts et al., 2011; Jozala et al., 2013). 




(Abts et al., 2011; Jozala et al., 2015; Meghrous et al., 1997; Prioult et al., 2000) 
however, these approaches also gave the lowest yields. Non-
chromatographic/antibody based approaches (Gonzalez-Toledo et al., 2010; Jozala et 
al., 2013; Kelly, Reuben, Rhoades, & Roller, 2000; Slootweg et al., 2013; Xiao et al., 
2010), many of which were phase separation, achieved higher yields and would be 
easier to scale up, however they had a relatively lower purity. Of the published high 
yield approaches toluene (Kelly et al., 2000), dichloromethane (Slootweg et al., 2013) 
and ethanol (Xiao et al., 2010) gave the highest purity, however the use of toluene or 
dichloromethane is not ideal from a safety perspective. 
Salting-out is a method commonly used for protein purification and works by 
salts drawing water molecules away from the hydrophobic regions in proteins and 
peptides. These hydrophobic regions then interact with each other, resulting in 
aggregates that precipitate out of solution (Scopes, 1994). However, pH, temperature, 
salt concentration and the concentration of the protein or peptide of interest in the 
solution all affect the effectiveness of the salting-out (Scopes, 1994). 
While salting-out has been used in extracting nisin from culture broth, to the 
authors knowledge this has only been used as an initial stage of a longer purification 
process, with ammonium sulphate being the salt commonly used (Gujarathi, Bankar, 
& Ananthanarayan, 2008; Meghrous et al., 1997). In the method described here, the 
effectiveness of a simple salting-out procedure using sodium chloride to extract nisin 
from the cell-free supernatant (CFS) of a nisin producing culture and a commercial 










Table 2.1. Published purification approaches for nisin. 










factor (on total 
protein basis) 
Ammonium sulphate 
precipitation followed by a 
series of reversed phase 
chromatographies culminating 
in reversed phase HPLC 
Nisin producing 
culture 
Solution µg Pure ~1600 
(Bouksaim 




precipitation followed by 










preparationa,b    













Solution mg >98% n/a 





Solution mg n/a n/a 






Solution µg 63%c ~1100 
(Prioult et 
al., 2000) 




Solution mg ~4.6%d 31 
(Cheigh et 
al., 2004) 




Solution mg/mL ~0.2%e n/a 
(Jozala et 
al., 2013) 












n/a ~53%c 4.4 








mg ~51%d n/a 





















                                                 
a Powder is 2.5 % nisin (w/w) on a total solids basis 
b From Sigma-Aldrich (St. Louis, Missouri, US) 
c % w/w on a total protein basis 
d % w/w on a total solids basis 
e % w/w on a total mass basis 
f From MP Biomedicals (Solon, Ohio, US) 
g From DuPont (Beaminster, UK) 




2.3. Materials and methods 
 
2.3.1. Production of nisin from a culture 
 
For the preparation of the supplemented whey permeate (SWP) medium, 
dried whey permeate (WP, Kerry Group, Naas, Ireland) and yeast extract (YE, 
Merck Millipore, Darmstadt, Germany) were reconstituted in distilled water to a 
final concentration of 6% (w/v) WP and 2% (w/v) YE. 
Fermentations were carried out in a FerMac 310/60 Bioreactor Fermenter 
(Electrolab Biotech, Tewkesbury, Gloucestershire, UK). The 5 L vessel was 
autoclaved twice at 121 °C for 15 min, with a one day waiting period between 
autoclaving to allow any surviving bacterial spores to germinate. The vessel was 
then filled with 4 L of SWP medium and autoclaved as described above. 
L. lactis NZ9800 pLP712 which had been stocked in 20% glycerol (v/v) at -
80 °C, was propagated twice in M17 (Terzaghi & Sandine, 1975) broth (Oxoid, 
Basingstoke, UK) supplemented with 0.5% lactose (VWR, Dublin, Ireland) (LM17), 
before 2 mL was used to inoculate 100 mL of SWP medium. The inoculum was 
grown overnight in 100 mL of SWP medium at 30 °C and the fermenter was then 
inoculated with 80 mL of the overnight culture. 
The bioreactor was run at 30 °C and pH 6.0 (controlled by addition of 6 M 
NaOH) for 16 h. Mixing was performed by an impeller with four inclined flat blades 
at 2×g. The cells were removed by centrifugation at 11,270×g for 20 min at 4 °C and 






2.3.2. Purification of nisin from a culture fermentate 
 
Starting with 760 mL aliquots of the CFS, the pH was adjusted to 7 and the 
NaCl concentration was determined by conductivity. Each CFS aliquot was adjusted 
to a final NaCl concentration of 2.27 M, volume of 800 mL and pH of 7. This was 
centrifuged for 2 h at 4 °C and 16,900×g. The supernatant was discarded. For each 
800 mL of volume before centrifugation, the pellet was suspended in water in a final 
volume of 30 mL. The pH of the suspended pellet was adjusted to 7. The suspended 
pellet was centrifuged for 2 h at 4 °C and 16,900×g. The supernatant was discarded 
and the pellet was collected. 
Freeze-drying was performed on a Virtis Advantage (SP Scientific, Gardiner, 
New York, US), with the sample adjusted to a pH of 3 using HCl. 
 




 (DuPont, Beaminster, UK) (720 g) was suspended in water to a 
total volume of 2580 mL and centrifuged at 16,900g for 15 min; the supernatant 
was discarded and the pellet was suspended in water to give a total volume of 860 
mL. This was centrifuged at 16,900×g for 15 min, the supernatant was discarded and 
the pellet was suspended in 400 mL of water. The pH was adjusted to and 
maintained between 3 and 3.5 using HCl at all stages of the process. 
The solution was spray dried on a B-191 spray dryer (Buchi, Flawil, 
Switzerland) using an inlet temperature of 180 °C and the flow rate adjusted to 





2.3.4. Cell counts 
 
Viable cell counts were determined in culture samples by serially diluting the 
culture in maximum recovery diluent (MRD, Oxoid Ltd., Basingstoke, UK) and 
dilution plating on MRS agar (Oxoid Ltd., Basingstoke, UK) and LM17 agar (Merck 
Millipore, Darmstadt, Germany). The plates were incubated at 30 °C for 48 h and 
results expressed as colony forming units/mL (cfu/mL). 
 
2.3.5. Lactose and lactic acid quantification 
 
Lactose and lactic acid concentrations were determined using high 
performance liquid chromatography (HPLC) based on published methods 
(Desjardins et al., 2001; Xia et al., 2005). A Waters 2695 separation module with a 
Waters 2487 dual λ absorbance detector and a Waters 2414 refractive index detector, 
running on Waters Empower software (Waters, Dublin, Ireland) was used in 
conjunction with a Rezex™, RHM-Monosaccharide, 8% cross linked H+, 300 × 7.80 
mm column from Phenomenex (Macclesfield, UK). The mobile phase, 0.0032 M 
H2SO4, was run at a flow rate of 0.5 mL/min and at 60 °C. Lactose was detected by 
refractive index and lactic acid by absorbance at 210 nm. The samples were 








2.3.6. Nisin quantification by reversed phase - high performance liquid 
chromatography (RP-HPLC) 
 
The concentration of nisin was determined using RP-HPLC based on 
published methods (Buonocore et al., 2003; Chollet, Sebti, Martial-Gros, & 
Degraeve, 2008). RP-HPLC was carried out using a Waters e2695 separation module 
with a Waters 2489 UV/visible detector, running on Waters Empower software 
(Waters, Dublin, Ireland) and a reversed phase Jupiter, 5 µm, C18, 300 A, 250 mm × 
4.6 mm column from Phenomenex (Macclesfield, UK). Solvent A was 0.1% (v/v) 
trifluoroacetic acid (TFA) (Sigma-Aldrich, Arklow, Ireland) in Milli-Q
®
 water 
(Merck Millipore, Carrigtwohill, Ireland), and solvent B was 90% (v/v) HPLC-grade 
acetonitrile (Thermo Fisher Scientific, Dublin, Ireland) containing 0.1% TFA (v/v) 
in Milli-Q
®
 water. A linear gradient from 22.2% B to 55.6% B over 30 min was run 
at a flow rate of 1.0 mL/min. Nisin was detected by absorbance at 214 nm and its 
peak corresponded to approximately 36% acetonitrile. Nisaplin
®
 was used to 
generate a standard curve and the amount of nisin was calculated from the area of the 
peak at 214 nm. The concentration of nisin in Nisaplin
®
 was 1.82% nisin (w/w) 
(DuPont, personal communication, 2016). 
 
2.3.7. Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI TOF MS) 
 
The molecular mass of the RP-HPLC fraction corresponding to the nisin peak 
was determined using MALDI TOF MS using an Axima TOF
2
 (Shimadzu Biotech, 





2.3.8. Nisin quantification by activity assay 
 
The biological activity of nisin was estimated by agar diffusion activity 
assays (Ryan, Rea, Hill, & Ross, 1996). L. lactis subsp. cremoris HP (Lambie, 
Altermann, Leahy, & Kelly, 2014), the indicator strain, was grown overnight in M17 
broth (Oxoid, Basingstoke, UK) containing 0.5% lactose (VWR, Dublin, Ireland) 
(LM17). LM17 agar was tempered to 45 °C and seeded with 0.5% of the indicator 
strain. Twenty millilitre aliquots of the seeded agar were dispensed into sterile petri 
dishes, these were allowed to solidify and wells of 5 mm in diameter were bored in 
the agar. Serial two-fold dilutions of the samples were dispensed into the wells in 50 
µL aliquots and the plates were incubated overnight at 30 °C. The activity of the 
nisin resulted in zones of inhibition surrounding the wells. Nisin was quantified 
based on a published method (Bernbom et al., 2006) by plotting the area of the zone 
of inhibition against the log of the nisin concentration of a serial dilution of 
Nisaplin
®
 to generate a linear standard curve. Nisin activity was also expressed as 
arbitrary units (AU) in terms of AU/mg (Ryan et al., 1996), which was calculated as 




The concentration of NaCl in the sample was determined using a MultiLine
®
 






2.3.10. Quantification of total protein 
 
Total protein was quantified using the Kjeldahl method (ISO, 2004) using a 
Kjeltec™ 8400 Analyser in conjunction with a Kjeltec™ 8460 sampler (FOSS, 
Warrington, Cheshire, UK) with 6.25 used as the conversion factor. 
 
2.4. Results and discussion 
 
Two purification methods were developed to produce an enriched nisin 
powder using either a culture supernatant or a commercially available nisin 
preparation as the source of nisin (Fig. 2.1). In the case of the culture supernatant, 
nisin was produced by growing L. lactis NZ9800 pLP712 in a supplemented WP 
medium under controlled conditions of pH (6.0) and temperature (30 °C) for 16 h. At 
the end of the fermentation the viable cell count was 2.86 × 10
9
 (± 0.23 × 10
9
) 
cfu/mL. Both purification methods involved using NaCl to precipitate the nisin 
peptides. In the case of the commercial preparation there was sufficient NaCl present 
in the Nisaplin
® 
(~93% w/w) such that additional salt was not required to salt-out the 
nisin. As nisin is most stable at pH 3-3.5, it was preferable to perform the salting-out 
at this pH. The concentration of nisin in the commercial sample (Table 2.2) was 
sufficient for precipitation by salting-out at a pH of 3-3.5. The lower initial 
concentration of the nisin from the nisin producing culture (Table 2.2) required a 
higher pH (7.0) for efficient precipitation using the salting-out method. During the 
purification procedure the concentration of nisin was measured using RP-HPLC. The 




TOF mass spectrometry, which showed a mass of 3354.09 Da (Fig. 2.2), correlating 




























Freeze dried  Spray dried 
Fig 2.1. Flow chart of purification from the cell-free supernatant of a nisin producing culture (on left) and 





Table 2.2. Purification of nisin using the salting-out approach from the CFS of a nisin producing culture (L. 
lactis NZ9800 pLP712) and a commercial preparation (Nisaplin®)  
















Volume (mL) 760 n/a     
Total solids (mg) 62,500 (± 2,200) 64.2 (± 5.6)  Total solids (g) 720 10.9 (± 0.5) 
Lactic acid (mg) 37,200 (± 450) 11.4 (± 0.5)     
NaCl (mg) 12,400 (± 130) 2.85 (± 0.30)  NaCl (g) 669 (± 6.0) 1.60 (± 0.08) 
Total protein (mg) 8,350 (± 120) 46.7 (± 11.0)  Total protein (g) 27.7 (± 0.6) 7.83 (± 0.07) 
Lactose (mg) 4,520 (± 110) 1.10 (± 0.14)     
Nisin  (mg) 25.9 (± 0.7) 21.3 (± 4.7)  Nisin (g) 13.1 6.29 (± 0.44) 
Mean ± SD, n ≥ 3 except for lactose and lactic acid n = 2; the difference between before and after purification 












Fig. 2.2. RP-HPLC chromatograms of the purification products from a nisin producing culture (A) and a 
commercial nisin preparation (B). Nisin eluted at 24.7 min corresponding to approximately 36% acetonitrile. RP-





Table 2.3. Summary of the properties of the products of purification using the salting-out approach. 
















On total solids basis 33.3% 
148 







On total solids basis 57.7% 
1.70 
On total protein basis 80.3% 
 
 
                                                 
i From DuPont (Beaminster, UK) 

















































Prior to purification, the major non-nisin components of the CFS, other than 
water, were lactic acid, NaCl, lactose, proteins and peptides. The purification process 
removed over 99% of each of these non-nisin components resulting in a powder 
containing approximately 33% nisin (Table 2.2). Using the same principle, a 
commercial nisin preparation was enriched from 1.82% nisin to approximately 58% 
nisin. The major non-nisin component in Nisaplin
®
 is NaCl and this approach 
removes over 99% of the NaCl (Table 2.2). The nisin concentration of the product 
purified from Nisaplin
®
 on a % w/w basis was 57.06 (± 0.51) when measured by RP-
HPLC and 58.04 (± 0.05) when measured by the biological activity assay. The 
similarity of these results validates both assay methods. This also shows that nisin 
activity is not lost during processing. Table 2.3 presents the salting-out approach in 
the format used in Table 2.1 for the published purification approaches. When the 
activities of the purified products are expressed as AU/mg nisin, the purified product 
from a nisin producing culture had 1,296 (± 173, n = 3) AU/mg, whereas the purified 
product from a commercial preparation had 2,272 (± 812, n = 4) AU/mg. 
As spray-drying is the most common method used to dry solutions or 
suspensions in the food industry (Jangam, 2011), it was used in the case of the 
commercial nisin powder; however due to the small volume of the nisin purified 
from a culture, this was freeze-dried (Fig. 2.1). Purification yield was calculated by 
expressing the amount of nisin in the purified product as a percentage of the total 
amount of nisin before purification and thus expressing how much of the original 
nisin was retained throughout the process. Purifying nisin from a culture gave a yield 
of 82%, whereas in the case of the commercial nisin powder the yield was 48% 
(Table 2.2). The lower yield for nisin purified from a commercial powder can be 




original nisin. Laboratory scale spray drying is noted for its high sample losses 
(Maury et al., 2005; Soares e Silva et al., 2012), however larger spray dryers have 
much higher yields than laboratory scale dryers (Imtiaz-Ul Islam, Edrisi, & Langrish, 
2013); for example, the industrial spray drying of milk is normally performed with 
yields in excess of 95% (Imtiaz-Ul Islam et al., 2013). Therefore it is likely the 
yields would be much greater if the process was scaled up. 
 
2.5. Conclusion  
 
The salting-out approach presented here produces powders containing 33 or 
58% nisin, from a culture supernatant or a commercial nisin preparation, respectively. 
When compared to other high yield approaches that have equivalent starting 
materials, the salting-out approach gives higher purity; in addition it does not require 
organic solvents such as toluene or dichloromethane and the simplicity of the 
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Due to the presence of a non nisin bacterial peptide (European Food Safety 
Authority, 2006) in the commercial nisin preparation (Nisaplin
®
), it was attempted to 
purify the nisin from the other protein components of the commercial nisin 
preparation using cation exchange fast protein liquid chromatography (FPLC). 
 
S2.2. Materials and methods 
 
The cation exchange FPLC procedure was developed based on Abts et al. 
(2011) with several modifications including using 8 times the column volume in 
order to upscale the procedure.  
FPLC was carried out using an ÄKTA purifier and a XK26/20 column (40 
mL column volume) containing a SP Sepharose® Fast Flow cation exchange 
chromatography resin (all FPLC components from GE Healthcare, Little Chalfont, 
UK). The flow rate was 5 mL/min and the peptides were detected by absorbance at 
214 nm. 
To prepare the sample for FPLC, 6.5 g of Nisaplin
®
 was desalted overnight 
using benzoylated dialysis tubing (2,000 dalton molecular weight cut off, D7884, 
Sigma-Aldrich, Arklow, Ireland) in 50 mM acetic acid, pH 3.5. The desalted 
Nisaplin
®
 solution had its total volume brought to 100 mL using 50 mM acetic acid 
pH 4.0 and was loaded onto the FPLC column. Unbound material was eluted with 6 
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column volumes of 200 mM NaCl, 50 mM acetic acid, pH 4.0. The nisin was eluted 
with 13 column volumes of 400 mM NaCl, 50 mM acetic acid, pH 4.0. Finally the 
column was washed with 6 column volumes of 50 mM acetic acid 1 M NaCl pH 4.0. 
The elution products were analysed by RP-HPLC which was performed as described 
in section 2.2.6. with the single modification that the linear gradient from 22.2% B to 
55.6% was run over 15 min. 
To remove the salt from the purified nisin in the 400 mM NaCl elute, it was 
precipitated with 20% (v/v) trichloroacetic acid (TCA) overnight at 4 °C. To remove 
the TCA, the purified nisin was washed twice with 4 °C acetone. To obtain the dry 
mass of the pellet it was freeze dried. The nisin content was quantified by RP-HPLC 
as described in section 2.2.6. The molecular mass of the non-nisin peptide was 
determined by MALDI TOF MS analysis of its RP-HPLC peak as described in 
section 2.2.7. 
 
S2.3. Results  
 The non-nisin bacterial peptide was determined to have a molecular mass of 
2351 Da. by MALDI TOF MS. In the chromatogram of Nisaplin
®
 sample (Fig. 
S2.1A) the non-nisin bacterial peptide eluted at 11.4 min (26% acetonitrile) and the 
nisin eluted at 18.6 min (40.4% acetonitrile). The developed FPLC procedure 
successfully separated these 2 peptides with the non-nisin peptide eluting in 200 mM 
NaCl, 50 mM acetic acid, pH 4.0 and the nisin eluting in 400 mM NaCl, 50 mM 
acetic acid, pH 4.0 (Fig. S2.1). 
The feed stock for this process was 6.5 g of Nisaplin
®
 (118.3 mg of nisin) 
and the end produce after freeze drying had a mass of 83 mg, which was determined 





Fig. S2.1. RP-HPLC chromatograms of Nisalpin® (A), the 200 mM NaCl, 50 mM acetic acid, pH 4.0 FPLC elute 




Although this approach was successfully able to extract nisin from the non-
nisin peptides in Nisaplin
®
, the yields were too low, particularly with regard to the 
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Nisin, an antimicrobial peptide showing activity against many Gram positive 
bacteria, is widely used as a food preservative. The simulated gastrointestinal 
digestion of nisin (variant A) was studied using the in vitro INFOGEST digestion 
method. Following oral, gastric and small intestinal digestion, there was no intact 
nisin in the system and the nisin was primarily digested by pancreatin. After 
digestion, six nisin fragments (1-11, 1-12, 1-20, 1-21, 1-29 and 1-32) were identified 
by reversed phase high performance liquid chromatography and mass spectroscopy 
and four of these nisin fragments (1-20, 1-21, 1-29 and 1-32) demonstrated low 
antibacterial activity against Lactococcus lactis HP in agar diffusion activity assays. 
Additionally, it was observed that bile salts form a complex with nisin. This was 
examined by atomic force microscopy, turbidity and dynamic light scattering, which 
showed that this interaction resulted in significantly larger bile salt micelles. The 
presence of bile salts at physiological levels significantly altered the relative amounts 
of the nisin fragments 1-12, 1-20 and 1-29 produced during an in vitro digestion. 
This study highlights the importance of including bile in simulated digestions of 
antimicrobial peptides in order to obtain a more accurate simulation of the in vivo 




Nisin is a 34 amino acid antimicrobial peptide produced by strains of 
Lactococcus lactis subsp. lactis that is active against many Gram-positive bacteria 
and is widely used as a food preservative (Gharsallaoui, Oulahal, Joly, & Degraeve, 
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2016). Nisin is extremely stable at pH 3 and can be autoclaved at this pH with <5% 
loss of activity (Davies et al., 1998), whereas above pH 6 it is unstable even at room 
temperature (Kelly, Reuben, Rhoades, & Roller, 2000). 
The discovery that nisin is inactivated by pancreatin (Heinemann & 
Williams, 1966), primarily due to its chymotrypsin component (Jarvis & Mahoney, 
1969), was a factor in nisin being awarded Generally Recognized As Safe (GRAS) 
status by the US Food and Drug Administration (FDA) (US Food and Drug 
Administration, 1988) and the European Food Safety Authority (EFSA) declaring 
that nisin is safe for use in food (European Food Safety Authority, 2006) with its 
assigned E number being E 234 (European Commission, 2011). It has been 
demonstrated more recently that nisin is also cleaved by the trypsin component of 
pancreatin (Chan et al., 1996). However these studies focused on pancreatic enzymes 
and did not take into account the other components of the digestive system such as 
bile. 
Bile salts, the major functional component of bile, are biological surfactants 
which are involved in the digestion and absorption of lipids in the small intestine; in 
particular they transport the products of lipolysis in bile salt micelles to the sites of 
absorption (Bauer, Jakob, & Mosenthin, 2005). For the most common human and 
porcine bile salts, micelle formation takes place in two stages; hydrophobic 
interactions between bile salts results in primary micelles, which then interact via 
hydrogen bonding to form secondary micelles (Kandrac et al., 2006; Partay, 
Jedlovszky, & Sega, 2007; Small, 1968). The minimum bile salt concentration 
required for micelle formation is termed the critical micelle concentration (CMC). 
As the concentration of sodium ions affects the CMC, experiments with bile salts are 
commonly performed in 0.15 M Na
+
 solutions to simulate physiological conditions 
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(Hofmann & Hagey, 2008). In a 0.15 M Na
+
 solution, most bile salts have a CMC 
below 10 mM (Hofmann & Roda, 1984); 10 mM is also the bile salt concentration 
recommended for simulating physiological conditions during in vitro digestion 
(Minekus et al., 2014). 
Previous digestion studies on nisin have focussed on pancreatic enzymes 
from the small intestine and those that investigated the nisin fragments produced by 
digestion used enzymes individually and often used digestions in excess of 20 h 
(Chan et al., 1996; Heinemann & Williams, 1966; Jarvis & Mahoney, 1969; 
Slootweg, Liskamp, & Rijkers, 2013). In order to study how nisin is digested under 
more physiologically relevant conditions, the INFOGEST method, a recently 
developed standardized static method for the digestion of food (Minekus et al., 2014) 
was utilised. This method is the consensus of an international network of scientists 
and is based on physiological conditions with each digestion comprising an oral, 
gastric and intestinal stage (Minekus et al., 2014). This approach would establish 
which nisin fragments are produced under physiological conditions and also their 
biological activity. In addition, by performing versions of the digestion without 
individual digestion components, the importance of non-proteolytic components 
such as bile on the digestion profile of nisin could be established. 
 




All reagents were obtained from Sigma-Aldrich (Arklow, Ireland) unless 
otherwise stated. For the simulated digestions the specific Sigma-Aldrich products 
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used were: salivary amylase (A1031), pepsin (P6887), bile (B8631) and pancreatin 
(P7545). Tween
®
 80 was obtained from Merck Millipore (Darmstadt, Germany). The 
nisin preparation used was Nisaplin
®
 (DuPont, Beaminster, UK) (nisin variant A; 
referred to as ‘nisin’ throughout this text). This was enriched by salting out as 
previously described (Gough et al., 2017). 
 
3.3.2. Simulated digestion 
 
Simulated oral, gastric and small intestinal digestions were performed as 
described in the INFOGEST method (Minekus et al., 2014). Five variations of the 
digestion were performed: (i) nisin with all digestion components, (ii) nisin with all 
digestion components except bile, (iii) nisin with all digestion components except 
pancreatin, (iv) nisin with all digestion components except pepsin, bile and 
pancreatin, (v) all digestion components but no nisin. At least three replicates were 
performed for each of these five digestion setups. The initial nisin concentration was 
chosen so that the nisin concentration in the digestion product would be sufficient for 
quantification by reversed phase - high performance liquid chromatography (RP-
HPLC). The digestion containing nisin and all digestion components was performed 
as follows: for the oral stage 5 mL of an 8.7 mg/mL nisin solution was combined 
with simulated salivary fluid (SSF) and salivary amylase (75 U/mL in final oral 
solution) to a final total volume of 10 mL; this was incubated at 37 °C for 2 minutes. 
For the gastric stage, the sample pH was adjusted to 3 using dilute HCl and 
combined with simulated gastric fluid (SGF) and pepsin (2,000 U/mL in final gastric 
solution) to a final total volume of 20 mL; this was incubated at 37 °C for 2 hours. 
For the small intestinal stage the pH was adjusted to 7 using dilute NaOH and 
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combined with simulated intestinal fluid (SIF) and bile (10 mM bile salts in final 
intestinal solution) and pancreatin (100 TAME U/mL in final intestinal volume) to a 
final total volume of 40 mL, this was incubated at 37 °C for 2 hours. The digestion 
products were snap-frozen in liquid nitrogen. 
 
3.3.3. Determination of the effect of the presence of bile during digestion 
on the activity of the digestion products 
 
To determine the effect of the presence of bile during digestion on the 
activity of the digestion products a simplified digestion method based on Minekus et 
al. (2014) was used; nisin was incubated with pancreatin in a MOPS buffer at pH 7 
and 37 °C for 2 h with bile added either before or after digestion, with an equivalent 
volume of water added to samples that did not receive bile. The final constituents in 
each sample, in a total volume of 0.5 mL, were 100 µg/mL nisin, bile at a bile salt 
concentration of 0.3 mM, pancreatin at a concentration such that its trypsin activity 
was 100 TAME units per mL, 50 mM MOPS, 0.15 M NaCl and the pH was 7. The 
digestion products were analysed by activity assay as described in section 2.6. 
 
3.3.4. Reversed phase - high performance liquid chromatography (RP-
HPLC) 
 
RP-HPLC was carried out on a Jupiter, 5 µm, C18, 300 Å, 250 mm × 4.6 mm 
column from Phenomenex (Macclesfield, UK) with an acetonitrile (Thermo Fisher 
Scientific, Dublin, Ireland) gradient as described previously (Gough et al., 2017). In 
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the case of digested nisin, fractions were collected throughout the gradient to 
determine the nisin fragments produced by digestion. 
 
3.3.5. Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI TOF MS) 
 
The molecular mass of the RP-HPLC peaks were determined using MALDI 
TOF MS using an Axima TOF
2
 mass spectrometer (Shimadzu Biotech, Kyoto, Japan) 
as previously described (Field et al., 2012). 
 
3.3.6. Activity assay 
 
Biological activity was estimated by agar diffusion activity assays (Ryan, 
Rea, Hill, & Ross, 1996) in agar plates seeded with Lactococcus lactis subsp. 
cremoris HP which were prepared as described previously (Gough et al., 2017). 
Serial two-fold dilutions of the samples were performed in 0.15 M NaCl, 50 mM 
MOPS, pH 7. In specific cases a surfactant (0.3 mM bile salts, 8 mM Tween
®
 80 or 
0.2 mM Triton™ X-100) was included in the diluent. The samples (50 μL) were 
dispensed into the wells and the plates incubated overnight at 30 °C. The activity of 
nisin resulted in zones of inhibition surrounding the wells. Activity is expressed as 
the minimum inhibitory concentration (MIC) in terms of μg/mL (Chan et al., 1996). 
MIC was calculated by plotting the area of the zone of inhibition at each dilution 
stage against the log of the nisin concentration (Bernbom et al., 2006); these had a 




3.3.7. Atomic force microscopy (AFM) 
 
For AFM, samples comprised 10 mM bile salts, 0.15 M NaCl, and 50 mM 
MOPS at pH 7, with or without 0.5 μg/mL nisin. The nisin concentration of 0.5 
μg/mL was chosen as this is within the range that could occur in the small intestine 
after consumption of a nisin containing foodstuff (Delves-Broughton, 2005; Minekus 
et al., 2014). Aliquots (5 μL) were deposited onto freshly cleaved mica surfaces, 
dried in a desiccator and subsequently stored at ambient conditions to ensure 
equilibrated hydration. AFM images were obtained with an Asylum Research MFP-
3D-AFM (Asylum Research UK Ltd., Oxford, UK) using AC-mode in ambient air. 
An aluminium reflex coated cantilever with a tetrahedral tip (AC 240), spring 
constant of 1.8 N/m (Olympus Optical Co. Ltd., Tokyo Japan), working frequency of 
50-90 kHz, and scan rate of 0.5-1 Hz was used at a 512 × 512 resolution. The radius 




Turbidity was measured at 600 nm as per (Dahmane, Lasia, & Zhao, 2008) 
using a Cary 100 Bio Spectrophotometer with temperature control (Agilent 
Technologies Ireland Ltd., Little Island, Ireland). The samples were prepared at pH 7 







3.3.9. Dynamic light scattering 
 
Z-average was measured by dynamic light scattering (DLS) using a Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK). The samples were prepared in 0.15 
M NaCl, adjusted to pH 7 using NaOH, filtered through a 0.22 µM PVDF filter 
(Gilson Scientific, Luton, UK) and analysed at 20 °C. 
 
3.4. Results and discussion 
 
3.4.1. Simulated digestion 
 
Oral and gastric digestion of nisin without pepsin resulted in a 6% (± 0.6, n = 
3) reduction in intact nisin when measured by RP-HPLC and the inclusion of pepsin 
brought the total reduction to 16% (± 2.2, n = 5); this limited digestion in the oral 
and gastric stages correlates with published results which show that nisin is primarily 
digested in the small intestine (Jarvis & Mahoney, 1969). 
Gastrointestinal digestion without proteases or bile resulted in >50% loss in 
intact nisin (Table 3.1). As the oral and gastric stages caused limited reduction in 
nisin, this reduction can primarily be attributed to the small intestinal pH of 7 and 
temperature of 37 °C, as above pH 6 nisin is unstable with a temperature dependent 
decomposition rate (Kelly et al., 2000). It was noted that pH and temperature were 
not entirely responsible for the reduction in detectable nisin and that the simulated 
intestinal fluid, in particular its sodium bicarbonate component, played a minor role 
(data not shown). 
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Performing the small intestinal stage of digestion with bile and/or pancreatin 
resulted in no intact nisin being detectable by RP-HPLC (Table 3.1) and the products 
of digestions that included bile had greater antibacterial activity than similar 
digestions without bile. 
 
Table 3.1. Products of in vitro gastrointestinal digestions of nisin. 
Starting material Oral, gastric and small intestinal digestion Analysis of digestion products 
% nisin (RP-HPLC) 
MIC (or MIC 
equivalent) 
Nisin solution All components 0% (± 0) 22 µg/mL (± 5) 
Nisin solution All components except bile 0% (± 0) 41 µg/mL (± 2) 
Nisin solution All components except pancreatin 0% (± 0) 0.9 µg/mL (± 0.2) 
Nisin solution 
All components except pepsin, bile and 
pancreatin 
48% (± 2) 2.9 µg/mL (± 0.5) 
H2O (no nisin) All components n/a 82 µg/mL (± 21) 
Nisin solution Not digested 100% 1.8 µg/mL (± 0.1) 
The digestion products were analysed by RP-HPLC and agar diffusion activity assay. The amount of nisin 
detected by RP-HPLC is expressed as a % of the total initial nisin. Activity is expressed as the minimum 
inhibitory concentration (MIC, μg/mL). An equivalent MIC is given for the products of digestions without nisin; 
SD in brackets, n ≥ 3. 
 
The highest antibacterial activity was in digestions without pancreatin; this 
correlates with previous reports that pancreatin is primarily responsible for nisin 
digestion (Heinemann & Williams, 1966). However in digestions with all 
components except pancreatin, there was no intact nisin detected by RP-HPLC. The 
high antibacterial activity implies that intact nisin was present and suggests another 
digestion component may be affecting the behaviour of nisin on the RP-HPLC 
column, thus interfering with its detection. This component appeared to be bile, as 
digestions without bile or proteases had detectable nisin in their products. 
 
3.4.2. Analysis of nisin fragments 
 
As the products of digestions involving pancreatin demonstrated antibacterial 
activity that could not be accounted for by the bile or digestive enzymes, the activity 
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was likely due to fragments of nisin. To determine which nisin fragments were 
produced and which of these were bioactive, the digestion products were separated 
by RP-HPLC and the fractions collected (Fig. 3.1B). The fractions were analysed 
using MALDI-TOF mass spectrometry and by activity assay (Fig. 3.2). Digestions 
with pancreatin produced peptides with molecular masses corresponding to the 
theoretical and published molecular masses of nisin fragments 1-12, 1-20, 1-21, 1-29 
and 1-32 and also a peptide with a molecular mass within two daltons of the 























Fig. 3.1. RP-HPLC chromatograms of (A) undigested nisin and (B) the products of nisin digestion without bile 
(―) and with bile included (‐‐‐‐). Regions where nisin fragments and intact nisin eluted are highlighted. The 
effect of including or excluding bile from a digestion with respect to the amount of nisin fragments 1-12, 1-29 
and 1-20 produced is highlighted. 
 
 
Table 3.2. Nisin fragments detected in the products of digestion. 
Nisin fragment 
Observed / predicted 
molecular mass (Da) 
Antibacterial 
activity 
Effect of inclusion of bile in digestion on height of 
corresponding peak in RP-HPLC chromatogram 
1-11 1023 / 1021 None detected 
Peak height not determinable due to background interference 
from co-eluting bile and pancreatin 
1-12 1151 / 1150b None detected 1.9 (± 0.3) fold decrease (p = 0.0009) 
1-20 1881 / 1881a Yes 1.4 (± 0.1) fold increase (p = 0.02) 
1-21 2013 / 2012b Yes Not significant (p = 0.06) 
1-29 2810 / 2809a Yes 3.5 (± 0.3) fold increase (p < 0.0001) 
1-32 3159 / 3157a Yes 
Peak height not determinable due to background interference 
from co-eluting pancreatin 
Mean fold increases and SD are derived from three sets of replicates; p values are in brackets. 
aChan et al. (1996). 










































Nisin fragment 1-11 Nisin fragment 1-12 
  
  
Nisin fragment 1-20 Nisin fragment 1-21 
  
  
Nisin fragment 1-29 Nisin fragment 1-32 
  
  
Intact nisin (1-34) from control digestion 
 
Fig. 3.2. Mass spectrometry analysis and agar diffusion activity assay (inserts) of nisin fragments produced by 
the digestion of nisin. Analysis of intact nisin from the products of the control digestion is included for 
comparison in which 3354.70 Da correlates with the predicted molecular mass of intact nisin (3355.12 Da) (Chan 



































































































































































































Major peaks on the RP-HPLC traces (Fig. 3.1A and B) corresponded to nisin 
1-12, 1-20, 1-29 and intact nisin, whereas nisin 1-21 gave a minor peak. Intact nisin 
had a shoulder region corresponding to the nisin variant [Ser
33
]-nisin in which the 
serine residue at position 33 did not undergo post-translational modification to 
dehydroalanine (Chan et al., 1996). The peaks corresponding to nisin fragments 1-11 
and nisin 1-32 were obscured by the co-eluting bile and pancreatic components. 
Although the RP-HPLC peak of nisin 1-32 was completely obscured by the 
background, its elution point was identified by activity assay. 
Nisin 1-29 eluted at slightly different time points depending on whether the 
digestion was performed without bile (25.1 min) or with bile included (25.4 min). 
The peaks at 22.8 min and 26.9 min and the four major peaks between 25.5 min and 
26.1 min were primarily due to bile and pancreatin and occurred in the control 
digestions that did not have nisin. The presence of bile in the digestion affected the 
peak heights of nisin fragments 1-12, 1-20 and 1-29 (Fig. 3.1B). 
RP-HPLC fractionation did not lead to pure peptide fractions due to overlap 
between the elution of the fragments, for example in Fig. 3.2 nisin fragment 1-29 
was detected in the mass spectrometry analysis of the elution peak of nisin fragment 
1-11 and was most likely the source of the antimicrobial activity in the activity assay 
of nisin fragment 1-11, also nisin fragment 1-20 was visible in the mass 
spectrometry analysis of the elution peak of nisin fragment 1-32. 
Nisin fragment 1-32 was not detected in the products of digestion in the 
presence of bile; as bile interfered with the detection of intact nisin (1-34) by RP-
HPLC, it is proposed this also occurs with nisin fragment 1-32. 
74 
 
Nisin fragments 1-12, 1-20 and 1-21 have previously been produced by 
digests with trypsin or chymotrypsin for a minimum of 16 hours (Chan et al., 1996; 
Slootweg et al., 2013). Nisin fragment 1-29 has been produced by an 8 hour 
digestion with the bacterial protease thermolysin and by a 4 hour digestion of the 
nisin variant ([Ser
33
]-nisin) with carboxypeptidase Y (Chan et al., 1996). Nisin 
fragment 1-32 has been produced by a 6 day acid treatment (Chan, Bycroft, Lian, & 
Roberts, 1989; Chan et al., 1996). To the authors knowledge it has not been 
previously demonstrated that these fragments can be produced under physiological 
conditions. 
In Table 3.2 it is shown that the molecular masses observed in Fig. 3.2 are 
within two daltons of the predicted masses and that the inclusion of bile in a 
digestion altered the proportions of the nisin fragments produced when compared by 
peak height in a RP-HPLC chromatogram. In this study all the nisin fragments 
corresponding to amino acids 1-20 or longer demonstrated antibacterial activity 
against Lactococcus lactis (Fig. 3.2), which is in agreement with Chan et al. (1996). 
The decrease in nisin 1-12 and an increase in nisin 1-20 and 1-29, which are 
observed in Fig. 3.1B are shown to be significant (Table 3.2). This implies that the 
bile reduces the cleavage of nisin during digestion. 
 
3.4.3. Nisin interaction with bile and other surfactants 
 
As bile had been shown to increase nisin activity (Table 3.1) and alter its 
digestion (Table 3.2) the bile-nisin interaction was further examined and compared 
to nisin’s interaction with other surfactants. The surfactants Tween
®
 80 and Triton™ 
X-114 were chosen for comparison as they increase the activity of nisin (Joosten & 
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Nunez, 1995; Jozala et al., 2008). Triton™ X-100 was substituted for Triton™ X-
114, as Triton™ X-114 phase separates at the incubation temperature of the activity 
assay (30 °C) (Bordier, 1981). Regarding the concentrations used; 10 mM bile salts 
is physiological concentration (Minekus et al., 2014), while 0.3 mM bile salts and 
0.2 mM Triton™ X-100 were the highest concentrations that did not cause 
antibacterial activity in activity assays. While Tween
®
 80 did not have an 
antibacterial affect at concentrations >8 mM, 8 mM was chosen because higher 
concentrations had a noticeable effect on viscosity. All these surfactants were at a 
molar excess over the nisin component (100 µg/mL nisin ≈ 0.03 mM nisin). 
To investigate how surfactants affected the MIC of nisin when determined by 
activity assays; serial dilutions were performed in a MOPS/NaCl diluent on its own 
and with each of the surfactants, with a starting nisin concentration of 100 μg/mL 
(Table 3.3). Bile caused a reduction in MIC compared to the control, however a 
greater reduction was caused by Tween
®
 80 and Triton™ X-100 and both of these 
reduced the MIC by the same amount (Table 3.3). This implies that nisin interacts 
differently with bile compared to the other surfactants. 
 
Table 3.3. Effect of surfactants on the minimum inhibitory concentration (MIC, μg/mL) of nisin in agar diffusion 
activity assays (SD in brackets, n = 3). 
Surfactant MIC (μg/mL) 
No surfactant  1.81 (± 0.11) 
0.3 mM bile salts 0.05 (± 0.01) 
8 mM Tween® 80 0.008 (± 0.001) 
0.2 mM Triton™ X-100 0.008 (± 0.001) 
 
Surfactants can increase the activity of bioactive peptides in activity assays 
by reducing or preventing binding to glass or polypropylene assay containers 
through competition with the peptides for binding sites on the container or 
interacting with the binding sites on the peptides, primarily through hydrophobic 
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interactions (Duncan, Lee, & Warchol, 1995; Joosten & Nunez, 1995). If nisin 
activity was increased by bile, through the formation of a peptide-surfactant 
complex, there would also be an increase in the particle size of the bile salt micelle. 
The effect of nisin-surfactant interaction on particle size was examined by 
AFM, turbidity and DLS. AFM analysis of bile with and without nisin (Fig. 3.3A 
and B) showed individual particles whose cross-sections had z-heights ranging from 
20 to 190 nm, which was similar to the z-average means obtained by DLS for bile 
(100 nm ± 5) and bile with nisin (118 nm ± 9) (Fig. 3.3D) and similar to the 
published values for bile salt secondary micelles (50 to 200 nm) (Hildebrand, 
Garidel, Neubert, & Blume, 2004). 
The turbidity of a system relates to both the size and density of particles that 
scatter light. In Fig. 3.3C, nisin was solubilised in a range of surfactants and turbidity 
increased with increasing nisin concentration, with the greatest turbidity increases 
occurring in the presence of bile. DLS (Fig. 3.3D) found that the z-average diameter 
of 10 mM bile salts with 100 μg/mL nisin was significantly larger than that without 
nisin (p = 0.0123, n = 4). There was no significant change in particle size when nisin 
was in solution with Triton™ X-100 or Tween
®
 80 (data not shown). To produce 
results of suitable quality by DLS, the samples were filtered and measured at 20 °C 
and pH 7 without a buffer. 
The particle size analysis (Fig. 3.3) suggests that nisin formed a complex 
with bile and this was different to its interaction with other surfactants. In the activity 
analysis (Table 3.3) bile caused less of an increase in nisin activity than the other 
surfactants; this could  be explained by bile forming a complex with nisin whereas 
the other surfactants bound to the assay container and thus reduced non-specific nisin 
binding in a different way. In the products of digestions which contained all 
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digestion components except pancreatin (Table 3.1), nisin was detected by activity 
assay but not detected by RP-HPLC; nisin could be favouring hydrophobic 
interaction with bile over hydrophobic interactions with the RP-HPLC column. 
 
Fig. 3.3. Effect of nisin-surfactant interaction on particle size as examined by atomic force microscopy (AFM) (A 
and B), turbidity (C) and dynamic light scattering (DLS) (D). AFM: AFM of bile (A) and AFM of bile with nisin 
(B). Turbidity (C):  10 mM bile salts,  0.3 mM bile salts, ▲ 0.2 mM Triton™ X-100,  8 mM Tween® 80 
and ▬ No surfactant (± SD, n = 4). DLS (D): ≡ 10 mM bile salts and ||| 10 mM bile salts with 100 μg/mL nisin (± 
SD, n = 4). Difference in particle size determined by DLS (D) is significant (p = 0.0123, n = 4). 
 
With respect to the mechanism for bile-nisin interaction, both hydrophobic 
and ionic interactions are possible. Bile salts are anionic with a negative charge on 
an amino acid that is attached to one end of the main body of the bile salt via a short 
hydrocarbon chain (Fig. 3.4) (Hofmann & Hagey, 2008; Small, 1968). Nisin has a pI 
of 8.5 and thus is cationic under physiological conditions with the bulk of the 
positive charge being in the C-terminal domain (Fig. 3.4) and this is responsible for 
its initial interaction with its negatively charged targets (Breukink et al., 1997). The 
oppositely charged terminal regions of bile salts and nisin make ionic interactions 
likely. Bile salts are planar amphipathic molecules and thus have a hydrophobic and 
a hydrophilic side (Fig. 3.4); when forming a primary micelle they orientate their 
hydrophobic sides towards each other, giving the micelle a hydrophobic core (Fig. 
 

















































3.4) (Hofmann & Hagey, 2008). Nisin is also amphipathic with the C-terminal being 
hydrophilic while the N-terminal is hydrophobic (Fig. 3.4) (Gharsallaoui et al., 2016). 
The hydrophobic N-terminal region of nisin has been reported to interact with the 
hydrophobic cores of surfactants such as dodecylphosphocholine and sodium 
dodecyl sulphate micelles (van den Hooven et al., 1996). It is therefore possible that 
the hydrophobic N-terminal region of nisin also interacts with the hydrophobic core 
of bile salt micelles. The reduced cleavage in the N-terminal region of nisin when a 
simulated gastrointestinal digestion is performed in the presence of bile (Table 3.2) 
may be due to the bile salts interacting with and surrounding the N-terminal region 




Fig. 3.4. Schematics of a bile salt, a bile salt primary micelle and a nisin peptide. A bile salt molecule is ~2 nm 
long (Small, 1971) and a nisin peptide is ~5 nm long (Sahl, 1994). Drawings of a bile salt and primary micelle 
are based on those of Small (1968). Bile salt primary micelles can consist of 2 to 10 bile salts (Li et al., 2009).  
The image of nisin was produced using Protein Database entry 1WCO (Hsu et al., 2004) in conjunction with the 
NGL Viewer (Rose & Hildebrand, 2015). 
 
Having shown that nisin formed a complex with bile salts, which altered its 
digestion products, it was investigated how much this affected its antibacterial 
activity after digestion. The loss of nisin activity during digestion is primarily due to 
pancreatic enzymes (Section 3.1). To look specifically at whether bile could 
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performed with pancreatin in buffer and bile added at the beginning or end of the 
digestion and the activity of the product determined by activity assay. The final 
concentration of bile salts was 0.3 mM so that the antibacterial activity of bile salts 
would not distort the results of the activity assay. The MOPS/NaCl buffer (pH 7) that 
was used as a diluent for the activity assay contained 0.3 mM bile salts, so that the 
surfactant effect would be consistent at all stages of the assay. The addition of bile 
before or after a 2 h digestion resulted in MICs of 11.8 μg/mL (± 0.3, n = 3) and 12.7 
μg/mL (± 0.2, n = 3) respectively. Although statistically significant (p = 0.01), the 
difference in activity was slight. 
Although the presences or absence of bile in a static in vitro digestion had a 
significant effect on the nisin fragments produced, this in turn had a negligible effect 
on antibacterial activity. As nisin fragments 1-12, 1-20 and 1-29 have low 
antibacterial activity (<6% the activity of intact nisin against L. lactis (Chan et al., 
1996)) it is assumed that increases or decreases in their amount had a minimal effect 




Nisin was digested by intestinal proteases as has been previously highlighted 
(Heinemann & Williams, 1966; Jarvis & Mahoney, 1969) although intestinal pH and 
temperature by themselves also caused significant loss in nisin. The digestion 
products include six nisin fragments, four of which have limited antibacterial 
activity. Although nisin fragments have been previously identified (Chan et al., 
1996; Slootweg et al., 2013), this is the first time that fragments generated during an 
in vitro digestion under physiological conditions have been identified. Nisin interacts 
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with bile, forming a complex that alters the relative amounts of the nisin fragments 
produced by digestion. This study highlights the importance of including bile in 
simulated digestions of antimicrobial peptides regardless of the presence or absence 
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Entrapment of nisin in starch for colonic 

















Bioactive proteins and peptides have numerous health benefits; however they 
can be digested during gastrointestinal transit if taken orally. Entrapment is an 
established method for oral delivery of bioactives, particularly to the colon; however 
the majority of current approaches come from a pharmaceutical direction and thus 
have aspects that would be less than ideal for a food product such as relatively large 
particles and ingredients that are not clean-label. A potential clean-label entrapment 
material is resistant starch, which is the portion of starch that resists digestion in the 
upper gastrointestinal tract but can be digested by bacteria in the colon; high amylose 
corn starch (HACS) is particularly high in resistant starch. Therefore HACS 
entrapment systems based on producing particles <100 μm in diameter were 
investigated. As a model bioactive peptide, the well characterised antimicrobial 
peptide nisin was used. Two approaches were used to apply this HACS coating, 
spray coating and co-spray drying. As spray coating is normally performed with 
particles >100 μm in diameter, particularly tablets, a carrier was needed to achieve 
suitable flowability for coating and a whey protein isolate (WPI) was found to be 
suitable. The nisin was successfully entrapped in HACS by spray coating; however 
this HACS coating was not resistant to treatment with pancreatic α-amylase at 
physiological concentration. Co-spray drying of nisin and HACS resulted in solid 
gels that had the capacity to resist digestion; however the nisin was not bound by the 
HACS gel. Although nisin was successively entrapped in HACS using both 







Bioactive proteins and peptides have numerous health benefits, such as 
anticarcinogenic and antimicrobial properties, however if taken orally they can be 
inactivated during gastrointestinal transit, particularly due to the low pH and pepsin 
in the stomach, and the trypsin, chymotrypsin and carboxypeptidase in the small 
intestine (Goodman, 2010; Segura-Campos, Chel-Guerrero, Betancur-Ancona, & 
Hernandez-Escalante, 2011). 
Although this makes delivering peptides to the colon particularly 
challenging, lower levels of proteases and higher responsiveness to permeation 
enhancers has made it a site of interest for the delivery of peptides such as insulin 
and calcitonin (Chen et al., 2017; Fetih et al., 2006; Maroni et al., 2012; Petersen et 
al., 2013). Additionally colonic delivery is essential for bioactive peptides that have 
a local effect in the colon, particularly antibacterial peptides that can be used to 
modulate the colonic microbiota. 
Antimicrobial peptides (AMPs) are continually gaining interest as an 
alternative to antibiotics due to the rise in antibiotic resistance; in particular the 
bacteriocins, which are bacterially produced and do not exhibit significant toxicity 
towards mammalian cells unlike other AMP classes (Allen, Trachsel, Looft, & 
Casey, 2014). The narrow spectrum of the majority of these bacteriocins allows 
treatment of gastrointestinal infections without disrupting the native bacteria (Cotter, 
Ross, & Hill, 2013). An example of which is thuricin CD, which has a narrow 
spectrum of activity against the antibiotic resistant bacteria Clostridium difficile (Rea 
et al., 2010), however like most bioactive peptides, it is digested during 
gastrointestinal transit when taken orally (Rea et al., 2014). 
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Nisin is a bioactive peptide that has activity against a wide range of Gram 
positive bacteria and is widely used as a food preservative (Abee & Delves-
Broughton, 2003). When taken orally, nisin is digested during gastrointestinal transit 
(Younes et al., 2017). Due to its commercial availability and thorough 
characterisation, nisin is considered suitable as a model bioactive peptide for colonic 
delivery systems (Habib & Sakr, 1999; Mallen, 2017; Ugurlu, Turkoglu, Gurer, & 
Akarsu, 2007). 
As described in Chapter 1, the primary approaches for protecting a peptide 
during gastric transit to the colon are protease inhibitors, structural modification of 
the peptide and encapsulating the peptide in a protective coating. Protease inhibitors 
interfere with normal nutrient absorption and are carcinogenic with frequent use 
(Bernkop-Schnurch, 1998), whereas structural modification would require a specific 
system for each peptide to ensure the modifications that did not interfere with the 
activity of the peptide, making these options less than ideal. 
As described in Chapter 1, release from a protective coating for colonic 
delivery can be based on pH, time or digestion by colonic bacteria. Due to the 
relative pHs of the small and large intestine, pH based release in the colon is not 
possible and colon targeted pH release systems normally begin releasing in the ileum 
of the small intestine (McConnell, Short, & Basit, 2008) whereas time based system 
are based on a controlled continual release, which is normally controlled by 
adjusting the rate of swelling (Del Curto et al., 2014; Maroni et al., 2016; Yuan, 
Jacquier, & O'Riordan, 2018). Protective coatings that are designed to be digested by 
colonic bacteria are generally based on carbohydrate polymers such as chitosan, 
pectin and starch (and its components such as amylose). These polymers are 
normally used in conjunction with a binder such as ethyl cellulose (EC) or 
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hydroxypropyl methylcellulose (HPMC) or a crosslinking agent such glutaraldehyde 
(Shukla & Tiwari, 2012; Sinha & Kumria, 2001). 
 Starch which is comprised of the carbohydrate polymers amylose and 
amylopectin, is of particular interest as a protective coating material as it can self-
crosslink; by heating and cooling starch in the presence of water it can form solid 
gels, this process is known as gelatinisation and retrogradation (Liu, 2005). Resistant 
starch, is starch that is resistant to digestion in the upper gastrointestinal tract, but 
can be digested by bacteria in the colon, making it suitable for use as a protective 
coating that could provide colonic delivery (Basit, 2005). The portion of starch that 
resists digestion varies between starch source and type; high amylose corn starch 
(HACS, 70% amylose starch from maize) contains 46% resistant starch on a w/w 
basis (McCleary, McNally, & Rossiter, 2002). 
When starch (or its component polymers) are used as a protective coating for 
colonic delivery, they are normally combined with a binder/plasticizer to control 
swelling in aqueous solution and increase structural integrity such as ethyl cellulose 
(Freire et al., 2010; McConnell et al., 2007; Wilson & Basit, 2005), triacetin (Pu et 
al., 2011) and acrylate polymers (Milojevic et al., 1996). 
Two of the most common techniques for the entrapment of bioactives in a 
protective coating are co-spray drying and fluidised bed spray coating (de Vos, Faas, 
Spasojevic, & Sikkema, 2010), with the Wurster process being one of the most 
common for spray coating (Asija, 2012; Saleh & Guigon, 2007). Spray coating is 
normally performed with cores of diameter significantly greater than >0.1 mm, as 
smaller cores have a tendency to agglomerate and are difficult to fluidize (Gupta & 
Sathiyamoorthy, 1998; To & Dave, 2016). 
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Co-spray drying and spray coating have been used in many colonic delivery 
systems based on starch and its component polymers components (Desai, 2007; 
Desai, 2005; Dimantov, Greenberg, Kesselman, & Shimoni, 2004; Freire et al., 
2010; Krogars et al., 2003; McConnell et al., 2007; Milojevic et al., 1996; Palviainen 
et al., 2001; Pu et al., 2011; Wilson & Basit, 2005). Very few of these studies 
(McConnell et al., 2007; Milojevic et al., 1996; Palviainen et al., 2001) applied the 
starch/amylose such that it would retrograded (crosslinking) into a solid gel during 
coating, this is likely due to the technical challenge of such an approach. 
The cores produced in studies involving spray coating with starch/amylose 
have ranged in diameter from 0.3 to 8 mm (Pu et al., 2011; Wilson & Basit, 2005), 
however in the majority of studies where the core diameter was stated, this diameter 
was ≥1 mm (Freire et al., 2010; McConnell et al., 2007; Milojevic et al., 1996; 
Wilson & Basit, 2005). 
In this study, nisin was entrapped in HACS using Wurster spray coating and 
co-spray drying, to protect it from digestion during gastrointestinal transit and enable 
it to be delivered to the colon. Spray coating was performed in two stages; firstly the 
nisin was combined with a carrier to produce a core and then the core was coated 
with HACS, whereas in co-spray drying the nisin and HACS were combined directly 
(Fig. 4.1). 
 There were two major differences with previous starch/amylose based 
approaches to create a product more suitable for inclusion in foodstuffs: the coatings 
had a clean-label composition (Asioli et al., 2017) comprising of only water and 




 As mentioned earlier, small particles have poor flowability in spray coating, 
so in order to achieve suitable flowability in the spray coater with a <0.1 mm core, a 
carrier was required. Lactose is well established as carrier (Hamishehkar, 
Rahimpour, & Javadzadeh, 2012) and maltodextrin and trehalose are also used as 
carriers (Adler & Lee, 1999; Shrestha et al., 2007; Wang & Zhou, 2012) and thus 
they were investigated first. In order to achieve a cohesive coating using only water 
and starch it was necessary that the coating was applied in gelatinised state so that it 
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All reagents and chemicals were procured from Sigma Aldrich (Arklow, 
Ireland) unless otherwise stated. The specific starch from Sigma Aldrich that was 
used was native high amylose corn starch (S4180). The specific enzymes from 
Sigma Aldrich that were used were porcine pancreatic α-amylase (A3176), bovine α-
chymotrypsin (C4129), α-amylase from the bacterium Bacillus subtilis (10070) and 
β-amylase from barley (A7130). 
 
4.3.2. Preparation of nisin 
 
Nisin was enriched from a commercial nisin preparation (Nisaplin
®
, DuPont, 
Beaminster, UK) by salting out (Gough et al., 2017) as described in Chapter 2. This 
is referred to in the text as enriched nisin. 
 
4.3.3. Preparation of gelatinised starch 
 
Gelatinisation was attempted on high amylose corn starch (HACS) by heat, 
pH and shear treatments. All samples were prepared at 5% solids with the exception 
of the samples that underwent pressure cooker treatment; these samples were 
prepared to ensure the percentage solids were below 5% for the duration of 
the heat treatment. All heat treatments performed at 121 °C were for 40 min, 
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these were performed with the samples at pHs ranging from 1 to 12. Shear 
treatments were performed using a T25 Ultra-Turrax
®
 (IKA, Staufen, Germany) 
at up to 15 min at maximum speed (25,000 rpm). Pressure cooker (Presto 
1755, National Presto Industries, Eau Claire, US) treatments were performed at 
120 °C for up to 74 cumulative h at that temperature, with periodic shutdowns to 
allow sampling and replacement of evaporated water. High heat treatment was 
performed in an Elbanton oil bath (Hettich Benelux B.V., Geldermalsen, 
Netherlands) at 140 °C for up to 2 h. 
 
4.3.4. Production of cores for spray coating 
 
Two spray dryers were used. A bench scale spray dryer (B-191, Buchi, 
Flawil, Switzerland) was used to produce cores with a range of compositions in order 
to ascertain optimal flowability. The optimised blend was then produced on a pilot 
scale spray dryer (Anhydro Laboratory Spray Dryer Size 3, SPX Flow Technology 
A/S, Soeborg, Denmark) in order to produce in a single batch a sufficient quantity of 
cores for all subsequent coating trials.  
The standard conditions for producing the cores in the bench scale spray 
dryer were an air inlet temperature of 180 °C, and an outlet temperature of 92 °C and 
an airflow rate of 600 L/h. The range of inlet temperature, outlet temperature and 
total solids used were 120 to 180 °C, 80 to 99 °C and 5 to 40%, respectively. Cores 
were produced containing lactose and lactose blended with trehalose (Treha™, 
Cargill, Manchester, UK) or maltodextrin (dextrose equivalent (DE) 6 and DE 12) 
(Roquette, Corby, UK) at up to 50% w/w. Cores were also produced containing 
whey protein isolate (WPI) (Isolac
®
, Carbery, Cork, Ireland) blended with a 
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commercial nisin preparation and enriched nisin perpetration at up to 95% (w/w) 
WPI. Cores containing only WPI, skimmed milk powder and Nisaplin
®
 were 
produced for comparison. The optimised cores comprised a WPI/enriched nisin 
blend of which 0.5% w/w was pure nisin; this was suspended at 15% w/w total 
solids and spray dried using a pilot scale spray dryer (Anhydro Laboratory Spray 
Dryer Size 3, SPX Flow Technology A/S, Soeborg, Denmark) with an air inlet and 
outlet temperature of 180 °C and 90 °C respectively. 
 
4.3.5. Spray coating 
 
To spray-coat the WPI/enriched-nisin cores with the coating solution a VFC-
LAB Micro Flo-Coater (Freund-Vector, Iowa, US) was used. Spray coating was 
performed using the Wuster process. The optimised conditions were as follow: a 17 
cm inner partition and the type 5 air distribution plate were used, the inlet air 
temperature was 95 °C, the nozzle airflow temperature was 90 °C and the coating 
solution was kept at 80 °C before being sprayed on the sample to prevent premature 
retrogradation, the coating feed rate was 1.1 mL/min, the main airflow was initially 
40 LPM and the atomising air pressure was initially 400 mBar which were increased 
over the course of the coating run to 50 LPM and 500 mBar respectively in order to 
maintain good particle flow and 10 g of the WPI/enriched nisin cores was loaded 
into the machine. The cores were coated in 15 coating cycles. Each of these coating 
cycles consisted of 2 min of coating and 30 s without coating (to allow the 
turbulence break up agglomerates and ensure the coating layers were dried). Every 5 
cycles the coating was pumped back to its heated source bottle to maintain its 




4.3.6. Co-spray drying 
 
For entrapment by co-spray drying, enriched nisin was blended with 
gelatinised starch such that the total solids were 5% and the pH of the solution was 
4.75. The solution was kept at 80 °C before spray drying to prevent retrogradation. 
This was spray dried on a B-191 spray dyer (Buchi, Flawil, Switzerland) with an air 
inlet temperature of 180 °C, and an outlet temperature of 92 °C and an airflow rate of 
600 L/h. 
 
4.3.7. Simulated digestion 
 
To determine the resistance of the HACS based delivery systems to digestion 
during gastrointestinal transit two simulated digestion approaches based on 
simplified versions of the INFOGEST method (Minekus et al., 2014) were used. 
Digestion of spray coated and co-spray dried particles for microscopy and particle 
sizing was based on the small intestine stage and involved a digestion with 
pancreatic α-amylase at a concentration of 200 U per mL in a solution comprising 
55.5 mM Cl
-
, 0.6 mM Ca
2+
 and 20 mM KH2PO4, at pH 7 which was incubated at 37 
°C for 2 h and the digesta comprised 6% w/w of the total mass (0.6 g in a final 
volume of 10 mL). Digestion for insoluble solids, which was performed on the co-
spray dried particles, comprised an additional initial incubation at pH 3 for 2 h 
(gastric stage) and at the small intestine stage the inclusion of α-chymotrypsin at 25 





4.3.8. Breakup of retrograded HACS by enzymatic and chemical 
approaches 
 
To quantify the nisin entrapped within the HACS based delivery systems it 
was necessary to break up the retrograded HACS matrixes. Enzymatic digestions 
utilising α-amylase from the bacterium B. subtilis and β-amylase from barley 
(separately and sequentially) were performed at a ratio of 0.25 mg of enzyme per mg 
of substrate and at a pH appropriate to the enzymes at 37 °C for up to 72 h, 
additionally pancreatic α-amylase was utilised under the same conditions for 
comparison purposes. Dimethyl sulfoxide (DMSO) was used to solubilise 
retrograded HACS as per the method of (Han & Lim, 2004) and the solubilised nisin 
and HACS were separated as per the method of (Xiao et al., 2010). 
 
4.3.9. Reversed-phase high performance liquid chromatography 
 
The concentration of nisin was determined using reversed-phase high 
performance liquid chromatography (RP-HPLC). RP-HPLC was carried out using a 
Waters e2695 separation module with a Waters 2489 UV/visible detector, running on 
Waters Empower software (Waters, Dublin, Ireland) and a Jupiter 5 µm C18 300A 
250 mm × 4.6 mm from Phenomenex (Macclesfield, UK). Solvent A was 0.1% (v/v) 
trifluoroacetic acid (TFA) in Milli-Q water (Merck Millipore, Carrigtwohill, 
Ireland), and solvent B was 90% (v/v) HPLC-grade acetonitrile (Thermo Fisher 
Scientific, Dublin, Ireland) containing 0.1% TFA (v/v) in Milli-Q water. Flow rate 
was 1.0 mL/min. Each sample was run as follows: 22.2% solvent B for 5 min, a 
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gradient increase from 22.2% B to 55.6% B over 30 min, a 2 min gradient increase 
from 55.6% B to 100% B, 5 min at 100% B, 2 min gradient decrease to 22.2% B, 5 
min at 22.2% B. Nisin was detected by absorbance at 214 nm. The nisin peak 
appeared between 24 and 25 min which corresponded to approximately 36% 
acetonitrile. Nisaplin
®
 was used to generate a standard curve and the amount of nisin 
was calculated from the area of the peaks at 214 nm. 
 
4.3.10. Physical characterisation 
 
Moisture content was measured using dry weight differences according to 
published methods (GEA Niro, 2006b). Flowability was measured using the time 
taken for a defined volume of powder to leave a rotating drum, in accordance with a 
published method (GEA Niro, 2006a). 
Visual structural and coating analysis was performed using an Olympus 
BX51 light microscope (Olympus BX-51, Olympus Corporation, Tokyo, Japan) 
under a 20× dry objective lens using both differential interference contrast (DIC) and 
bright field setup. Images were taken using a ProgRes
®
 CT3 camera in conjunction 
with ProgRes
®
 CapturePro version 2.10.0.0 software (Jenoptik, Jena, Germany). To 
identify the starch component of samples, iodine stain (1% iodine and 2% potassium 
iodine) was added such that it made up 10% of the total volume of the samples. To 
inhibit agglomeration of sample components, glycerol was added such that it made 
up 10% of the total volume of the samples. 
Particle size was determined using a Mastersizer 3000™ and a Morphologi
®
 
G3 (Malvern Instruments, Malvern, Worcestershire, UK). For the Mastersizer 
3000™ a Hydro SV (Malvern Instruments, Malvern, Worcestershire, UK) wet 
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sample dispersion unit was used and the optical settings were a particle refractive 
index of 1.45 and a dispersant refractive index of 1.33. For the Morphologi
®
 G3 
analysis, sample powder volumes of 11 mm
3
 and the 2.5× objective lens were used. 
 
4.3.11. Biological activity assay 
 
Biological activity was estimated by agar diffusion activity assays (Ryan, 
Rea, Hill, & Ross, 1996). Lactococcus lactis subsp. cremoris HP, the indicator 
strain, was grown overnight in M17 broth (Oxoid, Basingstoke, UK) containing 
0.5% lactose (VWR, Dublin, Ireland) (LM17). LM17 agar was tempered to 45 °C 
and seeded with 0.5% of the indicator strain. The seeded agar was dispensed in 20 
mL aliquots into sterile petri dishes, these were allowed to solidify and wells of 5 
mm in diameter were bored in the agar. Serial two-fold dilutions of the samples were 
performed in a 50 mM lactic acid buffer, pH 3.5. The samples (50 μL) were 
dispensed into the wells and the plates incubated overnight at 30 °C. The activity of 
nisin resulted in zones of inhibition surrounding the wells. The minimum inhibitory 
concentration (MIC) (μg/mL) was calculated by plotting the area of the zone of 
inhibition at each dilution stage against the log of the nisin concentration (Bernbom 
et al., 2006); these had a linear relationship and the MIC was calculated from the 
equation of the line. The MICs were tested for significant difference by the Kruskal-







4.3.12. Insoluble solids 
 
Intact retrograded starch is insoluble in water (Kapelko-Żeberska, Zięba, & 
Singh, 2015), however the oligosaccharides produced by α-amylase digestion are 
water soluble (Sundarram & Murthy, 2014) and thus the relative resistance to 
digestion of each of the blends produced by co-spray drying could be inferred from 
their insoluble solids. 
Total insoluble solids were measured in co-spray dried samples that had 
undergone simulated digestion and undigested controls. Each sample was 
centrifuged at 179×g for 5 min and the supernatant was removed. Then the sample 
was suspended in 10 mL H2O and centrifuged at 403×g for 5 min and the 
supernatant was removed. The last step was repeated a further two times to ensure 
the entire soluble component was removed. The insoluble component was 
transferred to preweighed discs and dried in a Gallenkamp OVA031 oven (Weiss 
Technik, Loughborough, UK) overnight. 
 
4.3.13. Entrapment efficiency 
 
The efficiency of the entrapment was tested based on published methods 
(Hong, Lee, Baek, & Choi, 2012; Saboktakin, Tabatabaie, Maharramov, & 
Ramazanov, 2011). Twenty mg of co-spray dried particles were suspended in water 
to a final volume of 10 mL, mixed on a roller for 10 min, centrifuged at 1,000×g for 
5 min and the supernatant containing the non-entrapped nisin was collected. The 
pellet was resuspended in 10 mL and the previous steps were repeated. The nisin was 




4.4. Results and discussion 
 
4.4.1. Preparation of gelatinised starch 
 
Gelatinisation temperature and time used for HACS when it is used as a 
coating materials have ranged from 120 to 160 °C and from 15 to 120 min (Desai, 
2007; Dimantov et al., 2004; Krogars et al., 2003; Recife, Meneguin, Cury, & 
Evangelista, 2017) and the temperature for complete gelatinisation of HACS has 
been reported as 129 °C (Ai & Jane, 2015). It is known that the degree and 
temperature required for gelatinisation can be effected by shear treatments on the 
starch granules and by the pH and the length of time gelatinisation takes place over 
(Alcázar-Alay & Meireles, 2015; Baks, Bruins, Janssen, & Boom, 2008; Wang, 
Truong, & Wang, 2003). Starch was gelatinised by a range of pH, shear and heat 
treatments, a selection of which are shown in Fig. 4.2. The degree of gelatinisation 
was examined by light microscopy. Shear, pH, and long term heat treatments 
resulted in a minor increase in the degree of gelatinisation (Fig. 4.2). It was noted 
that the fastest retrogadation occurred in samples at pH 4.5 and 5. From a production 
point of view it would be preferable to use a lower temperature treatment, however 
only the high heat treatment (140 °C) for 2 h gave complete gelatinisation which 







   
   
   
Fig. 4.2. Selected attempts at gelatinisation of high amylose corn starch (HACS). Untreated HACS (A), HACS 
heat treated (121 °C for 40 min) at pH 1.5, 5 and 12 and in conjunction with shear treatment (B, C, D and E 
respectively), HACS heat treated (120 °C) for 5 h (F), HACS heat treated (120 °C) for 74 h (G), HACS heat 
treated (140 °C) for 1 h and 2 h (H and I respectively). All images were taken at 20X magnification using a 
differential interference contrast (DIC) setup apart from image A, which was taken using bright field to obtain the 
characteristic extinction cross of untreated starch granules. 
 
4.4.2. Production of cores 
 
A range of carriers were used to produce cores of suitable flowability (Fig. 
4.3). The yield when producing the cores, is a reflection of the flowability of the 
cores (Yang, Xu, Qu, & Li, 2015), with the higher the yield, the better the 
flowability. There were distinct differences in yield between carrier type while 










in the blend or the process conditions. The most flowable carrier was the WPI and 
whereas the salt in the commercial nisin preparation likely reduced its flowability 
when blended with the WPI, the lower salt in the enriched nisin preparation allowed 
good flow when combined with the WPI. That no greater yield than ~60% was 
achieved on the bench scale spray dryer is likely due to the limitations of bench scale 
spray drying  (Maury et al., 2005; Soares e Silva et al., 2012). As expected the 
moisture content of the products were directly related to the outlet temperature of the 
spray dryer and by keeping the outlet temperature above 90 °C, a moisture content 
below 5% could be achieved. 
 
 
Fig. 4.3. Yields of potential carrier materials and cores for spray coating when produced on bench scale spray 
dryer. The carrier yields are average by constituents irrespective of constituent blend or process conditions. Mean 
values are ± standard deviation, n ≥ 3. 
 
The feed stock of WPI/enriched nisin cores for spray coating was produced in 
a single batch using a pilot scale spray dryer. The cores contained 0.5% nisin and 
had a mean diameter of 27.6 µm (volume moment mean, D(4,3)). There was no 
significant difference between the antibacterial activity of nisin in the commercial 
product and in the spray dried cores; the activity of nisin was not affected by spray 




















Whey protein isolate (WPI)
Commercial nisin preparation/WPI blends
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components of the WPI co-eluting from the RP-HPLC column. Regarding 
flowability; when tested by GEA Niro analytical method A 23 (GEA Niro, 2006a), 
the WPI before spray drying had a flowability (± SE) of 19.3 s (±0.4, n=3) which 
compares favourably to the WPI/enriched nisin cores after spray drying (19.7 ±0.3 s, 
n=3), indicating that spray drying did not negatively impact on flowability. Although 
these values are poorer than the flowability of SMP (14 ±0.4 s, n=4), the flow 
behaviour of the WPI and the WPI/enriched nisin cores was considerably better in 
the spray coater. This superior aerosolisation is likely due to the air pockets that are 
visible on the surface of the cores (Fig. 4.4) as pores improves the aerosolisation of a 
powder (Vanbever et al., 1999). 
 
 
Fig. 4.4. WPI/enriched nisin cores for spray coating viewed by bright field at 20X magnification. 
 
4.4.3. Spray coating 
 
The spray coating procedure was optimised to produce a product with the 
greatest possible coating thickness. Although the irregular surface of the core was 
critical to the cores obtaining good flowability, this created a challenge to achieve 
complete coating of the core as irregular surfaces are known to inhibit the spread of 
coating solution over the core (Asija, 2012). There were three key areas where a 
coating run could fail: firstly particles could become trapped in the top of the spray 
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coater, secondly the coating solution could dry too slowly on the particle surface 
resulting in agglomerates and thirdly the coating solution could retrograde into a 
solid gel in the tubing and nozzle. 
By adjusting the process parameters to reduce the likelihood of one source of 
failure, could increase the likelihood of another. For example, increasing the pump 
speed to reduce the likelihood of the coating solution gelling in the tubing/nozzle 
also increased the likelihood of agglomerates in the coating chamber whereas 
increasing the solids content of the coating solution allowed for faster drying and 
thus reduced formation of agglomerates but also increased the likelihood of the 
coating solution gelling in the tubing/nozzle. Another example is the main and 
coating nozzle airflow, an increase in which reduced the likelihood of agglomerates 
forming while increasing the likelihood of particles becoming trapped in the top of 
the coating chamber. A detailed overview of the range of process conditions trialled 
and the optimum balance between them is described in Table 4.1. The coated 
product is seen with the HACS coating visible by iodine staining in Fig. 4.5A and B. 
This demonstrates spray coating of <100 μm diameter cores with HACS that 











Table 4.1. Optimisation of spray coating procedure. 
Variable Effect Range tested Optimum 
Preheating of 
equipment 
Reduces stickiness to chamber wall Temperature 
levels off after 30 
min 
30 min 
Mass of cores 
for coating 
Too great resulted in lag in bottom of chamber during 
recirculation 




Recirculation of the particles Full range of 
plates  
Type 5 air 
distribution plate 
Main Airflow ↑ Particles will lodge in the top of chamber 
↓ Risk of particle agglomeration (coating will dry too 
slowly)  
27 to 100 L/min 40 L/min increasing 
towards 50 L/min 




↑ Particles will lodge in the top of chamber 
↓ Risk of particle agglomeration (droplet size will be 
too large) 








Viscosity and rate of retrogradation increase with 
concentration 
1 to 10% (w/w) 5% (w/w) 
Inlet 
temperature 




Drying rate of coated particles 0 to 90 °C 90 °C 
Pump speed ↑ Too much solution enters the chamber causing 
agglomeration 
↓ Coating solution resides too long in tubing and 
nozzle and coating solution retrograding within them 
10 to 100 rpm 20 rpm 
Wurster 
partition 
Recirculation of the particles 6.4 to 17 cm 17 cm 
Filter pulse 
interval 
Dislodging particulates from upper chamber 1 to 5 s 1 s 
Spray cycle Longer spray time: 
↑ Risk of particle agglomeration 
↓ Risk of coating solution retrograding within nozzle 
and tubing 
1 to 8 min 2 min 
Longer interval time: 
↓ Risk of particle agglomeration 
↑ Risk of coating solution retrograding within nozzle 
and tubing 
10 s to 2 min 30 s 
Number of spray cycles before coating solution is 
returned to stock container and number a times this is 
repeated (cycle groups): 
↓ Risk of particle agglomeration 
↓ Risk of coating solution retrograding within nozzle 
and tubing, however each time this procedure is 
performed the risk of nozzle clogging increases 
1 to 21 cycles and 
3 to 5 cycle 
groups 
 





To test their susceptibility to small-intestinal digestion, the products of spray 
coating underwent a 2 h digestion with pancreatic α-amylase. This appears to have 
removed the HACS coating as they were no longer stainable with iodine (Fig. 4.5C 
and D) and the size of the particles reverted to a similar size distribution to that of 
the WPI carrier (Fig. 4.6). The enzymatic resistance of HACS coatings are related to 
their thickness (Dimantov et al., 2004). It was not possible to increase the coating 
thickness without the coating run failing as described previously. Additionally, as 
this approach required that each layer of the coating be solidified before the next 
layer was applied, there was negligible possibility of crosslinking between layers. To 
circumvent these problems a co-spray drying approach was employed so that all the 
HACS in the particle could retrograde simultaneously and thus achieve the thickness 




Fig. 4.5. Images of spray coated samples before (A and B) and after (C and D) digestion with 
pancreatic α-amylase. Samples iodine stained and viewed by differential interference contrast (DIC) 









Fig. 4.6. The effect of digestion with pancreatic α-amylase on the products of spray coating by way of change in 
particle size. The WPI used in production of the cores is shown as a comparison. 
 
4.4.4. Co-spray drying 
 
As the most rapid retrogradation of the HACS had previously occurred at pH 
4.75, spray drying was performed this pH. A total solids of 5% w/w was the greatest 
concentration of HACS that had a viscosity suitable for bench scale spray dryer. The 
resulting powder had a circle equivalent (CE) mean diameter of 10.9 μm, which is 
consistent with the known particle sizes produced by the make and model of spray 
dryer used (Maury et al., 2005). 
A spray dried HACS powder was digested with pancreatic α-amylase in the 
same manner as the spray coated sample. As spray dried HACS successfully 
demonstrated a degree of resistance to digestion (Fig. 4.7), it was attempted to entrap 
the enriched nisin in HACS by co-spray drying. These were then subjected to a more 
thorough simulated digestion comprising a gastric stage of 2 h at pH 3 followed by 
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Fig. 4.7. Spray dried HACS before (A) and after (B) digestion with pancreatic α-amylase. Samples iodine stained 
and viewed by differential interference contrast (DIC) at 20X magnification. 
 
As the change is particle size due to digestion of the co-spray dried 
HACS/nisin blends could not be accurately measured on the Mastersizer 3000™ due 
to the formation of agglomerates, the relative resistance of the different blends were 
inferred from their total insoluble solid, as intact retrograded starch is insoluble in 
water (Kapelko-Żeberska et al., 2015) whereas the oligosaccharides produced by α-
amylase digestion are water soluble (Sundarram & Murthy, 2014). As expected the 
greater proportion of HACS in the blend the greater the resistant to simulated 
digestion of spray dried nisin/starch (Fig. 4.8), however it is noticed that the 100% 
enriched nisin sample increased in insoluble solids after digestion, implying that 






























































In order to quantify the intact nisin within the products of co-spray drying 
after simulated digestion, a way of breaking apart the products of co-spray drying 
that would not denature the nisin was investigated. However amylases from bacterial 
and plant sources had no greater ability to digest retrograded HACS than the porcine 
pancreatic amylase used in the INFOGEST method and although it was possible to 
solubilise retrograded HACS in DMSO and then precipitate it out of solution using 
ethanol, nisin was not detected in the sample in subsequent RP-HPLC analysis. 
 When the entrapment efficiency of the samples were tested, no nisin was 
found to be bound in the samples. Aqueous conditions induce a degree of swelling 
and porosity in starch gels (Chourasia & Jain, 2003; McConnell et al., 2007), this 
was likely how nisin was released and this problem was likely exacerbated by the 
very small size of the particles produced by co-spay drying. Using a much larger 




In this study it was attempted to achieve colonic delivery of nisin in particles 
with a diameter <100 μm through the use of only starch (HACS) and water, by 
protecting the nisin from digestion during gastrointestinal transit. By using a WPI 
carrier it was possible to achieve flowability suitable for spray coating with cores 
<100 μm in diameter, however while the porosity of the carrier increased the 
flowability of the cores it also reduced the coating efficiency. To fully gelatinise 
HACS such that it was a homogenous solution suitable for coating required a heat 
treatment of 140 °C for 2 h. This coating solution was successfully applied to the 
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cores such that the coating retrograded into a solid gel on the particle surface. The 
spray coated HACS coating did not resist digestion, this is likely because it was too 
thin and having each coating layer retrograde separately reduced the crosslinking 
potential of the coating. Co-spray drying resulted in particles in which all the HACS 
could retrograde simultaneously and these particles possessed a capacity to resist 
digestion, however they did not retain nisin. The ability of these particles to resist 
digestion shows the potential of this approach, using a larger particle could address 
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Entrapment of nisin in a starch gel and 

















Oral delivery is the most desirable route of delivery for bioactive proteins and 
peptides; however digestion during gastrointestinal transit can remove the potential 
health benefits of these bioactives. Entrapment is often employed for the oral 
delivery of bioactives, particularly for delivery to the colon. The majority of current 
approaches come from a pharmaceutical perspective and thus, have aspects that 
would be less than ideal for a food product such as complex entrapment procedures 
and ingredients that are not clean-label.  
Starch that resists digestion in the upper gastrointestinal tract but can be 
digested by bacteria in the colon, known as ‘resistant starch’, is a potential 
entrapment material; high amylose corn starch (HACS) is particularly high in 
resistant starch. Heating and cooling starch in water causes the dissociation and 
reassociating of the component amylose and amylopectin chains of starch, in a 
process known as gelatinisation and retrogradation, which can result in a solid starch 
gel. In this study the antimicrobial peptide nisin was used as a model bioactive 
peptide. 
By gelatinising and retrograding HACS in the presence of nisin it was 
possible to entrap nisin in starch. Nisin losses during processing (115 °C for 15 min) 
were 1.59% (± 0.04, n = 3) and of the original nisin 49.64% (± 1.79, n = 3) was not 
bound to the gel; this implies that ~49% of the nisin was entrapped. To quantify the 
entrapped nisin, fermentation of the HACS with the starch digesting bacteria 
Ruminococcus bromii was used as a means of releasing the nisin from the starch. 
Complete fermentation was not achieved although a greater % of the HACS was 
fermented than in previously published work. For simulated in vitro digestion of the 
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HACS/nisin gel a chewing model (mean particle diameter: 1.8 ± 0.2 mm) was 
coupled with a modified version of the in vitro INFOGEST digestion method. After 
simulated digestion there was less nisin detected in solution in the samples with a 
HACS/nisin gel compared to the controls. This implies that a portion of the 
entrapped nisin remained bound in the HACS gels and that the HACS gel would 
allow nisin to reach the colon. However this could not be conclusively stated, as 
nisin is unstable at the pH of the small intestine (pH7), which impairs accurate 




Bioactive proteins and peptides have numerous health benefits, however their 
bioavailability can be limited if taken orally as they can be digested during 
gastrointestinal transit, particularly due to the low pH and pepsin in the stomach, and 
the trypsin, chymotrypsin and carboxypeptidase in the small intestine (Goodman, 
2010; Segura-Campos, Chel-Guerrero, Betancur-Ancona, & Hernandez-Escalante, 
2011). 
Delivering peptides to the colon is of particular interest due its lower levels 
of proteases and higher responsiveness to several permeation enhancers (Chen et al., 
2017; Fetih et al., 2006; Maroni et al., 2012; Petersen et al., 2013). Additionally 
colonic delivery is essential for bioactive peptides that have a local effect in the 
colon such as antimicrobial peptides. 
Antimicrobial peptides, particularly the bacterially produced class known as 
bacteriocins are gaining interest as an alternative to antibiotics due to the rise in 
antibiotic resistance (Allen, Trachsel, Looft, & Casey, 2014). Many bacteriocins 
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have a narrow spectrum of activity that allows treatment of gastrointestinal 
infections without disrupting the native bacteria (Cotter, Ross, & Hill, 2013). Many 
bacteriocins are heat stable (Collado et al., 2005; Deraz et al., 2005; Oh, Kim, & 
Worobo, 2000) which allows the possibility of high heat processing conditions. 
Nisin is a bioactive peptide that has activity against a range of Gram positive 
bacteria and is widely used as a food preservative (Abee & Delves-Broughton, 
2003). Nisin is highly heat stable and when at pH 3 it can be heated to 115 °C for 20 
min with <5% loss in activity (Davies et al., 1998). If taken orally, nisin is digested 
during gastrointestinal transit (Younes et al., 2017), which makes it an ideal 
candidate for testing a colonic delivery system. Nisin has been proposed as a model 
bioactive peptide for colonic delivery systems due to its commercial availability and 
thorough characterisation (Habib & Sakr, 1999; Mallen, 2017; Ugurlu, Turkoglu, 
Gurer, & Akarsu, 2007). 
 Starch that is resistant to digestion in the upper gastrointestinal tract, but can 
be digested by bacteria in the colon is termed ‘resistant starch’ (Sajilata, Singhal, & 
Kulkarni, 2006). Resistant starch has been proposed as a protective coating that 
could provide colonic delivery (Basit, 2005). The portion of starch that resists 
digestion is determined by starch source and type; in this study high amylose corn 
starch (HACS) (70% amylose starch from maize) was used, which contains 46% 
resistant starch on an w/w basis (McCleary, McNally, & Rossiter, 2002).  
 Starch is comprised of the carbohydrate polymers amylose and amylopectin. 
In plants amylose and amylopectin are arranged in a semi-crystalline form known as 
a starch granule. When these granules are heated in the presence of water the 
amylose and amylopectin disassociate, with the granules leaching amylose and 
absorbing water causing them to swell and ultimately dissipate. When the solution is 
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subsequently cooled, the amylose and amylopectin re-associate, turning the solution 
into a starch gel, with the gel strength primarily determined by amylose content. 
These two stages are referred to as gelatinisation and retrogradation (Alcázar-Alay & 
Meireles, 2015; Wang et al., 2015). 
 In Chapter 4 nisin was entrapped in HACS using spray coating and co-spray 
drying, to protect it from digestion during gastrointestinal transit and enable it to be 
delivered to the colon. The products of spray coating approach had negligible 
digestion resistance. The products of the co-spray drying approach possessed 
digestion resistance however they had negligible entrapment efficiency. It was 
suggested in Chapter 4 that the poor entrapment efficiency of the products of co-
spray drying was related to their small particle size (diameter ≈ 10 μm). In this 
Chapter, to entrap nisin in larger particles, nisin’s high heat stability was utilised. To 
entrap the nisin in a HACS gel for colonic delivery, HACS was blended with nisin 
and then the HACS was gelatinised and retrograded forming a solid gel. 
The approach in this study differs from previous studies in two ways. Firstly 
the entrapment material compromises of only starch and water, which makes it 
suitable for a ‘clean-label’ approach; this is in contrast to many of the previous 
studies that have used a starch based coating that incorporate ingredients such as 
ethyl cellulose, triacetin, polymethacrylate and triethyl citrate (Freire et al., 2010; 
McConnell et al., 2007; Milojevic et al., 1996; Pu et al., 2011; Wilson & Basit, 
2005).  
A second way in which the approach in this study is novel is the simplicity of 
the entrapment procedure. Most starch based entrapment procedures use 
compression coating, spray coating or co-spray drying to apply a starch coating 
(Desai, 2007; Desai, 2005; Dimantov, Greenberg, Kesselman, & Shimoni, 2004; 
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Freire et al., 2010; McConnell et al., 2007; Milojevic et al., 1996; Moussa & 
Cartilier, 1997; Palviainen et al., 2001; Pu et al., 2011; Recife, Meneguin, Cury, & 
Evangelista, 2017; Wilson & Basit, 2005). These are in contrast to the approach used 
in this study whose simplicity may make it easier to use in commercial applications. 
 




All reagents and chemicals were procured from Sigma Aldrich (Dublin, 
Ireland) unless otherwise stated. The specific starch from Sigma Aldrich that was 
used was native high amylose corn starch (S4180). The specific enzymes from 
Sigma Aldrich that were used were porcine pancreatic α-amylase (A3176), bovine α-
chymotrypsin (C4129) and salivary amylase (A1031). 
 
5.3.2. Preparation of nisin 
 
Nisin was enriched from a commercial nisin preparation (Nisaplin
®
, DuPont, 
Beaminster, UK) by salting out (Gough et al., 2017) as described in Chapter 2. This 








5.3.3. Reversed-phase high performance liquid chromatography 
 
The concentration of nisin was determined using reversed-phase high 
performance liquid chromatography (RP-HPLC). RP-HPLC was carried out using a 
Waters e2695 separation module with a Waters 2489 UV/visible detector, running on 
Waters Empower software (Waters, Dublin, Ireland) and a Jupiter 5 µm C18 300A 
250 mm × 4.6 mm from Phenomenex (Macclesfield, UK). Solvent A was 0.1% (v/v) 
trifluoroacetic acid (TFA) (Sigma-Aldrich, Arklow, Ireland) in Milli-Q water (Merck 
Millipore, Carrigtwohill, Ireland), and solvent B was 90% (v/v) HPLC-grade 
acetonitrile (Thermo Fisher Scientific, Dublin, Ireland) containing 0.1% TFA (v/v) 
in Milli-Q water. Flow rate was 1.0 mL/min. Each sample was run as follows: 22.2% 
solvent B for 5 min, a gradient increase from 22.2% B to 55.6% B over 30 min, a 2 
min gradient increase from 55.6% B to 100% B, 5 min at 100% B, 2 min gradient 
decrease to 22.2% B, 5 min at 22.2% B. Nisin was detected by absorbance at 214 
nm. The nisin peak appeared between 24 and 25 min which corresponded to 
approximately 36% acetonitrile. Nisaplin
®
 was used to generate a standard curve and 
the amount of nisin was calculated from the area of the peaks at 214 nm. 
 
5.3.4. Matrix-assisted laser desorption/ionization time of flight mass 
spectrometry (MALDI TOF MS) 
 
MALDI TOF MS was performed using an Axima TOF
2
 mass spectrometer 





5.3.5. Production of starch gels 
 
Starch gels were prepared by heating high amylose corn starch (HACS). 
Blends ranged from 50 to 70% dilute HCl (w/w), with the balance made up by 
HACS and enriched nisin with the enriched nisin powder comprising less than 10% 
(w/w) of the total solids and the blends had a final pH of 3. These were heated at 
temperatures ranging from 121 to 115 °C for 15 min and subsequently incubated at 4 
°C for a minimum of 16 h to ensure thorough retrogradation. 
 
5.3.6. Simulated chewing 
 
Two approaches were used to mimic the breakup of the gels due to chewing. 
The first approach was performed using an Eddingtons Mincer Pro (86002, 
Eddingtons, Hungerford, UK) as per the INFOGEST method (Minekus et al., 2014) 
using the ‘fine’ extrusion disk (apertures are ~4 mm in diameter) and in cases where 
a mincer was unsuitable such as when material had to be prepared under sterile 
conditions for use in fermentation vessels, the gel was broken using a sterilised 
spatula to an equivalent size to that of the mincer. 
 To more accurately model the effect of chewing a second approach was 
applied based on a ‘chew and spit’ approach (Wickham, Faulks, & Mills, 2009). The 
size of particles produced by chewing a HACS gel was determined by taking images 
of chewed particles using an Epson V700 scanner (Seiko Epson, Hemel Hempstead, 
UK) and measuring the equivalent spherical diameter of the particles using the 
Image J software (version 1.48) (Schneider, Rasband, & Eliceiri, 2012). 
Subsequently when preparing samples for digestion, they were chopped until they 
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reached the established diameter of 1.8 (± 0.2) mm, which was confirmed using the 




There were two simulated digestion approaches based on the INFOGEST 
method, a recently developed standardized static method for the digestion of food 
(Minekus et al., 2014). 
The first digestion approach was used to determine the resistance of the 
HACS gels to digestion by determining total insoluble solids after digestion (this is 
the same as the final digestion procedure performed in Chapter 4): namely an 





 and 20 mM KH2PO4, at pH 3 for 2 h at 37 °C and then an incubation 
with pancreatic α-amylase at a concentration of 200 U per mL and α-chymotrypsin at 
25 N-benzoyl-L-tyrosine ethyl ester (BTEE) U per mL at pH 7 for 2 h at 37 °C and a 
final volume of 10 mL. 
The second digestion approach was used to determine the amount of nisin 
released through digestion. This was performed as per the INFOGEST method 
(Minekus et al., 2014) without bile or enzymes other than α-amylase. This involved 
an oral, gastric and intestinal stage. The HACS gels contained 1, 2 or 4% enriched 
nisin. An example digestion is as follows: For the oral stage 5 g of HACS gel 
containing 0.1 g (2% w/w) enriched nisin or a control containing 0.1 g of enriched 
nisin that had undergone  the same processing as the test solution (suspended in a pH 
3 dilute HCl solution, heated at 115 °C for 15 min, incubated at 4 °C for 16 h), were 
suspended in simulated salivary fluid (SSF) and salivary amylase (75 U/mL in final 
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oral solution) to a total volume of 10 mL; this was incubated at 37 °C for 2 min. For 
the gastric stage, the sample pH was adjusted to 3 using dilute HCl to a total volume 
of 20 mL; this was incubated at 37 °C for 2 h. For the small intestinal stage the pH 
was adjusted to 7 using dilute NaOH and combined with simulated intestinal fluid 
(SIF) and pancreatic α-amylase at a concentration of 200 U per mL to a total volume 
of 20 mL. Control digestion for the effect of pH were also performed for stages of 
the same duration, temperature and mineral composition but all at a pH of 3 and 
without α-amylase as it would be inactivated at this pH. Samples were taken at the 
end of oral, gastric and small intestine phase and quantified by RP-HPLC. 
 
5.3.8. Insoluble solids 
 
Intact retrograded starch is insoluble in water (Kapelko-Żeberska, Zięba, & 
Singh, 2015), however the oligosaccharides produced by α-amylase digestion are 
water soluble (Sundarram & Murthy, 2014) and thus the relative resistance to 
digestion of each HACS gel could be inferred from their insoluble solids. 
Total insoluble solids were measured in samples that had undergone 
digestion and undigested controls. Water was added to the samples to bring their 
volumes to 50 mL and they were centrifuged at 1,000×g for 5 min. The insoluble 
component was transferred to preweighed discs and dried in a Gallenkamp OVA031 







5.3.9. Entrapment efficiency 
 
The efficiency of the entrapment was tested based on published methods 
(Hong, Lee, Baek, & Choi, 2012; Saboktakin, Tabatabaie, Maharramov, & 
Ramazanov, 2011) by suspending the particles in water with mild agitation on a 
rotor, pelleting them by centrifugation and analysing the supernatant by RP-HPLC. 
The standard conditions were suspension at 10% (w/w) for 5 min and centrifugation 
for 5 min at 200×g. This suspension and pelleting treatment was repeated 5 times 




Samples were examined using an Olympus BX51 light microscope (Olympus 
BX-51, Olympus Corporation, Tokyo, Japan) under a 20× dry objective lens using 
bright field setup. Images were taken using a ProgRes
®
 CT3 camera in conjunction 
with ProgRes
®
 CapturePro version 2.10.0.0 software (Jenoptik, Jena, Germany). 
 
5.3.11. Bacterial fermentation 
 
Bacterial fermentation was performed with R. bromii (ATCC 27255, LGC 
Standards, London, UK) which was grown in M2GSC media (Miyazaki, Martin, 
Marinsek-Logar, & Flint, 1997; Ze, Duncan, Louis, & Flint, 2012) which contained 
per 100 mL: 45 mg K2HPO4, 45 mg KH2PO4, 90 mg (NH4)2SO4 , 90 mg NaCl, 9 mg 
MgSO4·7H2O, 9 mg CaCl2, 1 g bacto casitone (BD, Wokingham, UK), 0.25 g yeast 
extract (Merck, Carrigtwohill, Ireland), 0.4 g NaHCO3, 0.2 g cellobiose, 0.2 g 
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glucose (VWR, Dublin Ireland), 0.2 g soluble starch, 30 mL clarified rumen fluid, 
0.1 mg resazurin and 0.1 g cysteine hydrochloride. The media was sparged with CO2 
to remove the O2. The R. bromii were cultured under strict anaerobic conditions at 37 
°C. All HACS gels were prepared for fermentations by heating at 115 °C for 15 
minutes and retrograded and broken up as described previously. Fermentations were 
performed in 7.5 mL of media with 0.125 to 0.8 g of HACS gel for up to 96 h on a 
tube rotator (444-0502, VWR, Dublin, Ireland). Media was either seeded with 100 
µL of turbid culture the previous evening (stationary phase culture) or on the 
morning of the fermentation (freshly seeded culture). Fermentations were also 
performed with cell free supernatant from a stationary phase culture prepared  by 
centrifugation at 5444×g for 20 min. Fermentations were also performed in Multifor 
bioreactor vessels (Infors, Bottmingen, Switzerland) with 5 g of HACS gel for 20 h 
at a pH of 6.89, the rotor at 100 rpm and with continual sparging with nitrogen. In 
these vessels the fermentation was performed with total volume of 200 mL of which 
0.5, 5 or 100% was stationary phase culture and the balance was M2GSC media. In 
all cases the fermentations were performed at 37 °C under strict anaerobic conditions 
and control fermentations without the HACS gel or with uninoculated media were 
performed. The products of the fermentation were pelleted by centrifugation at 
200×g for 10 min in the case of the 7.5 mL fermentation or 500×g for 2 h in the case 
of the 200 mL fermentation vessels, freeze dried (Virtis Advantage, SP Scientific, 
Gardiner, NY, US) and the change in mass was compared to the controls to calculate 






5.4. Results and discussion 
 
5.4.1. Initial gel entrapment and comparison with previous work 
 
HACS gels prepared by heating a HACS/nisin blend at 121 °C for 15 min, 
retrograding at 4 °C and broken up using a mincer, were tested for their nisin 
entrapment and for the ability to resist digestion. The relative resistance to digestion 
of each HACS gel could be inferred from their insoluble solids as intact retrograded 
starch is insoluble in water (Kapelko-Żeberska et al., 2015), however the 
oligosaccharides produced by α-amylase digestion are water soluble (Sundarram & 
Murthy, 2014). 
The ability of the gels to retain nisin (entrapment efficiency) was increased 
by increasing the % solids (w/w) in the formulation of the gels (Fig. 5.1A) and also 
by reducing % enriched nisin (w/w) in the formulation of the gels (Fig. 5.1B). The 
resistance to digestion, which was inferred from the % insoluble solids remaining 
after digestion, was increased by lowering the % enriched nisin (w/w) and increasing 
the % HACS (w/w) in the formulation of the gels (Fig. 5.1C). It is noted, as in 
Chapter 4, that the digestion products of the enriched nisin contribute to the 
insoluble solids (Fig. 5.1D), so the true difference in digestion resistance in Fig 5.1C 
is even greater than that inferred from the insoluble solids. 
In Chapter 4 the co-spray dried particles had a degree of resistance to 
digestion, however they had negligible entrapment efficiency which was believed to 
be due to their small particle size (diameter ≈ 10 μm). The Eddingtons Mincer Pro 
produces particles of ~4 mm in diameter. As expected, these larger particles had 






Fig. 5.1. Entrapment efficiency and digestion resistance of HACS gels. In section A all the gels were prepared 
with enriched nisin constituting the same % of total solids (10% w/w) and in sections B, C and D the gels were 
prepared with the same % total solids (40, 40 and 50% w/w, respectively). 
 
5.4.2. Optimisation of gel entrapment 
 
Heating nisin at 121 °C and 118 °C for 15 min resulted in a 15.9% and 11.7% 
loss of nisin respectively, whereas there was only 1.59% (± 0.04, n = 3) loss of nisin 
detected in the products when heated at 115 °C for 15 min in a pH 3 solution. This 
low loss at 115 °C is in agreement with published work (Davies et al., 1998). 
A HACS gel comprising 43% (w/w) HACS and 2% (w/w) enriched nisin was 
produced by heating at 115 °C for 15 min, retrograding at 4 °C and broken up using 
a mincer. Analysing the entrapment efficiency of this gel showed only 49.7% (± 1.8, 
n = 3) of the original nisin was unbound. Therefore these parameters became the 
standard process conditions and blend for subsequent HACS gel preparations. Light 

















































































































































min, achieve partial gelatinisation with the granules swelling and losing their 
extinction cross, once cooled these granules are bound together in a retrograded 
HACS gel (Fig. 5.2B). 
 
  
Fig. 5.2. Raw HACS granules (A) and the gel produced by heating HACS at 115 °C for 15 min and subsequently 
retrograded at 4 °C for16 h (B). Viewed by bright field at 20X magnification. 
 
5.4.3. Bacterial fermentation 
 
In order to demonstrate that nisin is retained within the HACS gel after 
digestion a method to detect the release of nisin from the gel was required which 
would not impact on nisin activity. As enzymatic approaches had been ineffective in 
Chapter 4, a bacterial fermentation approach was pursued. R. bromii was chosen as it 
has been identified as keystone species in resistant starch fermentation (Ze et al., 
2012). 
A cell free supernatant from a stationary phase culture of R. bromii had 
negligible ability to ferment HACS indicating that live cells are required for 
fermentation (Fig. 5.3). As the presence of starch is known to induce the production 
of α-amylase in microbes (Gupta et al., 2003) this result is unsurprising. 
A stationary phase R. bromii culture fermented more HACS gel than a 
freshly seeded culture (Fig. 5.3). While having the capability to ferment resistant 




and fructose (Mukhopadhya et al., 2018) and bacteria often show a hierarchical 
preference for carbohydrate fermentation (Tuncil et al., 2017). It is likely that R. 
bromii does not ferment the HACS until other carbohydrate sources in the media 
including those from the rumen fluid have been metabolised, this could explain why 
the stationary phase culture digested more HACS than freshly inoculated culture. 
However, in vivo, as simple sugars are absorbed higher up in the GIT system it is 
likely that the concentration of mono and disaccharides in the colon would be low 
giving R. bromii a competitive advantage in the lower GIT, given its ability to 
ferment resistant starch. 
 
 
Fig. 5.3. Effect of growth stage and presence of R. bromii on amount of HACS gel fermented. Fermentations 
comprised 0.5 g of HACS gel and 7.5 mL of either freshly seeded culture, stationary phase culture or cell free 
supernatant from a stationary phase culture, which were incubated at 37 °C for 22 h under anaerobic conditions. 
The % w/w HACS fermented was calculated with respect to uninoculated controls. 
 
To increase the amount of HACS fermented, the relationship between the 
starting amount of HACS and the proportion and total mass of HACS fermented was 
investigated. The greater the original mass of HACS in a sample, the greater the 
mass of HACS fermented but the lower the proportion of the sample that is 





































Fig. 5.4. Effect of substrate concentration on the amount of HACS gel fermented by R. bromii. The % w/w and 
mass of the HACS gel fermented are indicated by  and  respectively. Fermentations comprised 7.5 mL of 
stationary phase cultures of R. bromii and 0.125, 0.25, 0.5 or 0.8 g of HACS gel and were incubated at 37 °C for 
22 h under anaerobic conditions. The % w/w HACS fermented was calculated with respect to the uninoculated 
controls. 
 
The starch fermentation preferences of colonic bacteria can depend on the 
molecular size of the starch and they can also have a preference for amylose or 
amylopectin (Tuncil et al., 2017). This sequential fermentation of starch components 
could explain how the increase in substrate results in an increase in mass fermented 
but a reduction in the total % w/w fermented. It is noted that the slope of the % gel 
fermented line implies that further reductions in the substrate would not increase the 
% fermented significantly above 50% w/w. 
Using a bioreactor, with anaerobic conditions maintained by continuous 
nitrogen sparging and pH maintained at 6.8, did not cause a noticeable increase in 
the amount of HACS fermented and the stationary phase cultures still gave greater 





























































Fig. 5.5. Effect of anaerobic fermentation at 37 °C for 20 h in bioreactors with pH control and continuous 
nitrogen sparging on the amount of HACS gel fermented by R. bromii. Fermentations comprised .5 g of HACS 
gel and 200 mL of R. bromii culture. The % w/w HACS fermented was calculated with respect to the 
uninoculated controls. 
 
Further attempts to increase the amount of retrograded HACS gel fermented, 
such as longer fermentation periods of up to 96 h did not result in greater than 50% 
of the retrograded HACS being fermented. However, this is comparable to (Ze et al., 
2012) who achieved 43.1% fermentation of retrograde HACS using R. bromii. 
MALDI TOF MS and RP-HPLC was used to detect and quantify the nisin 
released during the fermentation of HACS containing nisin by R. bromii. Although 
nisin was detected in the media by MALDI TOF MS the concentration was 
insufficient for quantification by RP-HPLC. In controls without HACS or bacteria, 
nisin was detectable by HPLC in the media, therefore it was deduced that the 
fermentation of HACS containing nisin by R. bromii did not release the majority of 
nisin from the gels. 
 
5.4.4. Simulated chewing 
 
To look at the importance of particle size in determining nisin release from 
HACS gels simulated digestions (by the second approach described in section 5.2.7) 
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× 1.5 cm. The solution was tested by RP-HPLC to quantify the released nisin. The 
greatest nisin was detected after gastric phase and was 40% and 19% respectively.  
As the particle size of the HACS gels had a major effect on the retention of 
the entrapped nisin during digestion, to accurately model the chewing of nisin a 
‘chew and spit’ (Wickham et al., 2009) approach was employed. Modelling chewing 
time using a single 1 g gel block allowed more consistent chewing times than using 
smaller particles with the same total mass. A 1 g gel had been prepared with 45% 
HACS (w/w) time took 7.1 (± 0.3, n = 4) s to chew to the point of swallowing. 
Further blocks were chewed for this time and images were taken of the products 
which were measured by image analyses software (Fig. 5.6). It was determined that 
for 1 g gel blocks prepared with 45% HACS (w/w), the mean diameter after chewing 
was 1.8 (± 0.1, n = 3) mm. Subsequently, the simulated chewing phase comprised 
manually chopping the gels into particles of 1.8 (± 0.2) mm in diameter. 
 
 
Fig. 5.6. Measurement of particle size of products of chewing. The particles (A) were measured using the Image 
J software (version 1.48) (Schneider et al., 2012) to obtain their equivalent spherical diameter (B). 
 
5.4.5. Simulated digestion 
 
Simulated digestion comprised an oral phase, gastric and intestinal stage. So 
that the nisin released from the HACS gel could be quantified it was necessary to 




















The first approach (approach A) used the native pHs and α-amylase to digest the 
HACS, whereas the second approach (approach B) was to account for the effect of 
pH on nisin and thus all stages were at pH 3 as this is where nisin is most stable 
(Davies et al., 1998) and as porcine pancreatic α-amylase is denatured at pH 3 
(Gopal & Muralikrishna, 2009) this was not included. 
 
Table 5.1. Simulated digestion approaches.  
Phases Approach A Approach B 
Oral phase (2 min) pH 7, salivary α-amylase pH 3 
Gastric phase (2 h) pH 3 pH 3 
Small intestinal phase (2 h) pH 7, pancreatic α-amylase pH 3 
All phases included phase appropriate minerals/electrolytes and were at 37 °C. 
 
The test samples were nisin entrapped in HACS gel and the controls 
comprised nisin without HACS, both of which had undergone the same processing 
including the heat treatment. In approach A (Fig 5.7A) there was less nisin detected 
in solution for the test sample than the control samples after each digestion phase. 
This implies that the HACS gels (test samples) are retaining a portion of the original 
nisin after digestion. 
However, the amount of nisin detected in solution from both the test and 
control samples is lower in the intestinal phase than the gastric phase. This is likely 
due to the nisin degrading at pH 7 and 37 °C as nisin is unstable above pH 6 with a 
temperature dependent decomposition rate (Kelly, Reuben, Rhoades, & Roller, 
2000). 
To test if nisin was being degraded by the neutral pH, a second digestion 
approach (approach B) was implemented. This confirmed the nisin loss was due to 
the neutral pH, although there was still less nisin detected in solution for the test 





Fig. 5.7. Simulated digestions of nisin entrapped in HACS gel (test samples) (black bars) and nisin without 
HACS (control samples) (grey bars). All samples are comprised of 2% enriched nisin (w/w). The samples were 
subject to a simulated digestion with α-amylase and native pH (A) and without α-amylase and all phases at pH 3 
(B). Samples were taken after the oral, gastric and intestinal phase had their nisin quantified by RP-HPLC. 
 
The amount of nisin released during in vitro digestion could not be accurately 
quantified as nisin is unstable at the pH of the small intestine (pH 7) (Kelly et al., 
2000) and while nisin is stable at pH 3 (Davies et al., 1998), porcine pancreatic α-
amylase is inactivated at that pH (Gopal & Muralikrishna, 2009). 
There are many proteinaceous bioactives that have high thermal stability, 
including the bacterially produced antibacterial peptides that are traditionally 
classified as class II bacteriocins (Casteels et al., 1989; Collado et al., 2005; Deraz et 
al., 2005; Klaenhammer, 1993; Oh et al., 2000; Singh & Vij, 2018). Therefore the 
approach taken here using nisin as a prototype peptide could be applied to other 




Nisin can be entrapped in a HACS gel by gelatinising and retrograding the 
HACS in the presence of nisin and nisin is resistant to the heat treatment required to 
generate such a gel. The size of the HACS gel particles affect release of nisin in 























































































release during simulated digestion could be accurately modelled. It appears that a 
portion of the nisin remains entrapped in the HACS gel after a simulated digestion, 
however due to the pH at the small intestine phase (pH 7) degrading the nisin as it is 
released, the amount of nisin remaining within the HACS gel cannot be quantified 
with certainty. To determine the nisin entrapped in the HACS gel and as previous 
enzymatic and chemical methods had been unsuccessful, a fermentation method 
based on the starch digesting bacteria R. bromii was developed. It was deduced that 
R. bromii only ferments HACS gel when other nutrient sources are exhausted and the 
presence of the HACS gel is required to induce production of the necessary 
amylases. Although greater proportion of the HACS was fermented than in 
previously published results, it was insufficient to release the majority of the bound 
nisin. 
Therefore it does not seem possible to conclusively demonstrate the 
efficiency of this delivery system using in vitro models and an in vivo model would 
be required to prove the suitability of this system for bioactive delivery to the colon. 
Therefore an in vivo trial in mice was undertaken to determine the ability of HACS 
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Nisin is an antimicrobial peptide showing activity against a broad range of 
Gram positive bacteria and is widely used as a food preservative. Fluorescent 
labelling of nisin would allow the determination of its localisation and release from a 
product. In the context of oral delivery systems for bioactive peptides, fluorescent 
labelling allows determination of the efficiency of the entrapment, the degree of 
protection and the rate of release. A system for orally delivering bioactive peptides to 
the colon by entrapping them in high amylose corn starch (HACS) gels was 
previously developed using nisin as a model peptide. The entrapment procedure 
required heating to 115 °C for 15 minutes at pH 3. Due to the detrimental effect of 
these processing conditions fluorescein isothiocyanate (FITC) was found to be 
unsuitable as a label. The Alexa Fluor
®
 range of fluorescent labels have greater 
stability than conventional labels. Using an anion exchange approach allowed up-
scaling of a previously reported approach for labelling nisin with and Alexa Fluor
®
 
647. This label was able to remain conjugated to the nisin and maintain its 
fluorescent properties after processing. Although Alexa Fluor
®
 647 has been 
previously shown to bind to nisin without affecting its antibacterial activity, in this 
study nisin lost its antibacterial activity when bound to Alexa Fluor
®
 647. Starch gels 
in which nisin labelled with Alexa Fluor
®
 647 was entrapped, were examined by 









To avail of the health benefits of ingestion of bioactive peptides such as 
insulin or calcitonin, they require a delivery system to protect them from digestion, 
release them at the target site and enable their absorption. The distribution of the 
bioactive peptides in the matrix of the delivery system affects both the degree of 
protection from digestion and the rate of release; thus the efficiency of the system. 
To determine the distribution of the bioactive peptides in the matrix of the delivery 
system and also their release from the matrix, bioactive peptides are often 
fluorescently labelled.  
Fluorescent labels that have been used in previous studies include 5-(6)-
carboxytetramethylrhodamine succinimidylester, which was used to label salmon 
calcitonin that was entrapped in a poly(lactic acid) (PLA) matrix (Brunner, 
Minamitake, & Gopferich, 1998), fluorescein isothiocyanate (FITC), which was used 
to label Lysine-Arginine-Phenylalanine-Lysine that was entrapped in a calcium-
alginate matrix (Hurteaux, Edwards-Levy, Laurent-Maquin, & Levy, 2005) and 
Alexa Fluor® 488, which was used to label insulin that was entrapped in an 
alginate–chitosan matrix (Zhang et al., 2011). 
Fluorescent labelling of proteins and peptides is achieved through both 
genetic approaches and through direct labelling of the native protein. Genetic 
approaches include incorporation of a fluorescent amino-acid sequence fused to the 
protein of interest and incorporation of a genetic encoded tag that can be complexed 
with a fluorochrome, while the primary approaches for direct labelling of the native 
proteins and peptides are antibody based systems (immunolabeling), organic dyes 
and quantum dots, which are a recently developed system (Giepmans, Adams, 
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Ellisman, & Tsien, 2006). The fluorophore-antibody complexes are typically 200 
kDa (Giepmans et al., 2006) and a quantum dot and its linker proteins are 
comparable in size to a protein of 500-750 kDa (Jaiswal & Simon, 2004); this makes 
them likely to interfere with the functionality of any peptide bound to them. Due to 
the small size of organic dyes (for example FITC is 389 Da (Wischke & Borchert, 
2006)), they are less likely to interfere with the activity of a peptide (Resch-Genger 
et al., 2008). 
Nisin is a bioactive peptide that has activity against a wide range of Gram 
positive bacteria and is widely used as a food preservative (Abee & Delves-
Broughton, 2003). When taken orally nisin is digested during gastrointestinal transit 
(Younes et al., 2017). Nisin is highly heat stable and when at pH 3 it can be heated to 
115 °C for 20 min with <5% loss in activity (Davies et al., 1998). In Chapter 5 nisin 
was entrapped in a high amylose corn starch (HACS) gel matrix through a heat 
treatment of 115 °C for 15 minutes at pH 3, in order to enable its colonic delivery. 
Fluorescent labelling of nisin would allow its localisation in the HACS 
matrix to be determined. There are two considerations that inform the choice of label 
for the fluorescent labelling of nisin. Firstly the label must not interfere with the 
activity of the nisin; to do this it must be small enough not to cause steric 
interference and it must be bound on the C-terminal; the addition of a label to other 
locations, particularly the N–terminal, is known to inhibit nisin activity (Guiotto et 
al., 2003; Slootweg et al., 2013). Secondly the label must be able to maintain its 
bond with nisin and not loose fluorescence under the pH and temperature conditions 
required to entrap nisin in a HACS gel. 
The Alexa Fluor
®
 range of fluorescent labels have significantly greater pH 
and heat stability than conventional fluorescent labels (Kapoor et al., 2009; Panchuk-
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Voloshina et al., 1999). Alexa Fluor
®
 647 has been covalently bound to the C-
terminal of nisin and there was no loss in nisin activity as determined by 
carboxyfluorescein leakage assay (Scherer et al., 2013). 
In this chapter nisin was fluorescently labelled to determine its localisation 
when entrapped in a HACS gel. Initially labelling was attempted using conventional 
fluorescent label FITC to confirm that conventional fluorescent labels were 
insufficient for the requirements. Subsequently nisin was labelled using Alexa 
Fluor
®
 647 based on the method of Scherer et al. (2013). The major modification to 
the method of Scherer et al. (2013) was the use of an ion exchange chromatography 
procedure for purification of the product of the labelling reaction, this allowed the 




6.3.1. Preparation of nisin 
 
Nisin was enriched from a commercial nisin preparation (Nisaplin
®
, DuPont, 
Beaminster, UK) by salting out as described in Chapter 2 (Gough et al., 2017). This 
is referred to in the text as enriched nisin. 
To further purify the enriched nisin by removing non-nisin peptides, a 
HiTrap™ CM fast flow (FF) cation exchange column was used (17-6002-33, VWR, 
Dublin, Ireland). The cation exchange column had a column volume of 1 mL and a 
flow rate of 1 mL/min was used. The column was first washed with 5 column 
volumes of 1 M NaCl, 0.1M MES buffer pH 6. Then it was equilibrated with 5 
column volumes of 0.1 M MES buffer pH 6. Ten mL of a 2 mg/mL enriched nisin in 
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0.1M MES buffer pH 6 was loaded on to the column. The column was washed with 
10 column volumes of 0.1M MES buffer pH 6 to remove unbound material 
including non-nisin peptides. The column was then washed with 20 column volumes 
of 1 M NaCl, 0.1M MES buffer pH 6 to elute the nisin. To remove the salt from the 
purified nisin, it was precipitated with 20% (v/v) trichloroacetic acid (TCA) 
overnight at 4 °C. To remove the TCA, the purified nisin was washed twice with 4 
°C acetone. The nisin was quantified by reversed-phase high performance liquid 




Labelling of enriched nisin with fluorescein isothiocyanate (FITC) (F7250, 
Sigma Aldrich, Arklow, Ireland) was performed as per manufacturer’s instructions. 
The labelled samples were brought to a final FITC concentration of 13 μg/mL in 
both a 0.1 M sodium carbonate pH 9 buffer and a 0.1 M citric acid buffer pH 3. 
Enriched nisin and nisin purified by cation exchange were labelled with 
Alexa Fluor
®
 647 Hydrazide (A20502, Fisher Scientific, Dublin, Ireland) using the 
method of Scherer et al. (2013) with some modifications. For each labelling reaction 
46 µL of Alexa Fluor
®
 647 Hydrazide in DMSO (16.5 µg/µL) was added to 0.5 mL 
of nisin in 0.1 M MES pH 5 buffer (5 mg/mL), which corresponds to a 0.8 mol dye 
to 1 mol peptide ratio. Immediately before use a solution of 500 mM N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) in 0.1 M MES 
buffer was prepared and 14 μL of this added to the reaction mixture. This was 
incubated overnight at room temperature. 
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To purify the labelled nisin a HiTrap™ Q Sepharose FF anion exchange 
column was used (17-5156-01, VWR, Dublin, Ireland). The anion exchange column 
had a column volume of 5 mL and a flow rate of 5 mL/min was used. The column 
was first washed with 5 column volumes of 1 M NaCl, 100 mM bis-tris propane 
buffer pH 9 and then it was equilibrated with 5 column volumes of 100 mM bis-tris 
propane buffer pH 9. The products of a single labelling reaction were diluted in 100 
mM bis-tris propane pH 9 buffer to a final volume of 10 mL and loaded on the 
column. The column was washed with 10 column volumes (50 mL) of 100 mM bis-
tris propane pH 9. The column was then washed with 10 column volumes of 100 
mM bis-tris propane pH 7 to elute the Alexa Fluor
®
 647 conjugated nisin. Finally the 
column was washed with 10 column volumes of 1 M NaCl 100 mM bis-tris propane 
pH 9 buffer. 
The elution product (Alexa Fluor
®
 647 conjugated nisin) was condensed by 
freeze drying and then desalted using a Vivaspin
®
 15R ultrafiltration spin columns 
with a 2 kDa molecular weight cut off (MWCO) (VS15RH91, Sartorius, Dublin, 
Ireland), according to the manufacturer’s instructions. The reduction of salt was 
monitored by conductivity using a MultiLine
®
 P3 conductivity meter (WTW, 
Weilheim, Germany). The products of desalting were freeze dried.  
 
6.3.3. Matrix-assisted laser desorption/ionization time of flight mass 
spectroscopy (MALDI TOF MS) 
 
The nisin bound to Alexa Fluor
®
 647 was analysed by MALDI TOF MS 
using an Axima TOF
2
 (Shimadzu Biotech, Kyoto, Japan) as previously described 
148 
 
(Field et al., 2012) to confirm the conjugation had occurred and that a single 
fluorescent label was applied per peptide. 
 
6.3.4. Heat treatments 
 
Heat treatments were performed at 115 °C for 15 minutes to match the 
production conditions for entrapment of nisin in the HACS gel matrix as described in 
Chapter 5. 
 
6.3.5. Spectrophotometry  
 
Fluorescencent and UV/Visible spectrophotometry were performed using a 
Varian Cary Eclipse and a Varian Cary 1 (Agilent Technologies, Little Island, 
Ireland) and a Jenway 6300 (Cole-Parmer, Stone, UK). The quantification of the 
Alexa Fluor
®
 647 conjugated nisin was performed by absorbance at 650 nm 
(excitation maximum of Alexa Fluor
®
 647 (Anderson & Nerurkar, 2002)) with 
respect to its molar extinction coefficient and to a standard curve produced from 
Alexa Fluor
®
 647 of known concentrations. 
 
6.3.6. Reversed-phase high performance liquid chromatography 
 
Free nisin, free Alexa Fluor
®
 647 and nisin bound to Alexa Fluor
®
 647 were 
detected by using reversed-phase high performance liquid chromatography (RP-
HPLC) based on published methods (Buonocore et al., 2003; Chollet, Sebti, Martial-
Gros, & Degraeve, 2008). RP-HPLC was carried out using a Waters e2695 
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separation module with a Waters 2489 UV/visible detector, running on Waters 
Empower software (Waters, Dublin, Ireland) and a Jupiter 5 µm, C18, 300A, 250 
mm × 4.6 mm from Phenomenex (Macclesfield, UK). Solvent A was 0.1 % (v/v) 
trifluoroacetic acid (TFA) (Sigma-Aldrich, Arklow, Ireland) in Milli-Q
®
 water 
(Merck Millipore, Carrigtwohill, Ireland), and solvent B was 90 % (v/v) HPLC-
grade acetonitrile (Thermo Fisher Scientific, Dublin, Ireland) containing 0.1 % TFA 
(v/v) in Milli-Q
®
 water. A linear gradient from 0% B to 55.6% B over 25 min was 
run at a flow rate of 1.0 mL/min. Nisin was detected by absorbance at 214 nm and 
Alexa Fluor
®
 647 and Alexa Fluor
®
 647 conjugated to nisin were detected at 650 
nm. 
 
6.3.7. Activity assay 
 
The biological activity of nisin bound to Alexa Fluor
®
 647 and unbound nisin 
were compared by agar diffusion activity assay (Ryan, Rea, Hill, & Ross, 1996). L. 
lactis subsp. cremoris HP, the indicator strain was grown overnight in M17 broth 
(Oxoid, Basingstoke, UK) containing 0.5% lactose (VWR, Dublin, Ireland) (LM17). 
LM17 agar was tempered to 45 °C and seeded with 0.5 % of the indicator strain. 
Twenty millilitre aliquots of the seeded agar were dispensed into sterile petri dishes, 
these were allowed to solidify and wells of 5 mm in diameter were bored in the agar. 
Serial two-fold dilutions of the samples were dispensed into the wells in 50 μL 
aliquots and the plates were incubated overnight at 30 °C. The activity of the nisin 





6.3.8. Entrapment of nisin in starch gel 
 
Starch gels with nisin were composed of 55% (w/w) dilute HCl, 44% (w/w) 
HACS and 1% (w/w) enriched/labelled nisin (3% (w/w) of nisin was labelled with 
Alexa Fluor
®
 647), with a final pH of 3. The gels were heated to 115 °C for 15 min 
and subsequently incubated at 4 °C for a minimum of 16 h to ensure thorough 
retrogradation. 
 
6.3.9. Confocal microscopy 
 
Confocal microscopy was performed using a Leica TCS SP Confocal Laser 
Scanning Microscope (Leica Microsystems, Heidelberg GmbH, Mannheim, 
Germany). Starch gels containing entrapped nisin of which 3% (w/w) was labelled 
with Alexa Fluor
®
 647, were viewed using a 10× air and 63× oil immersion lens with 
zooms of 1×, 3× and 5×. The labelled nisin was excited with a He–Ne laser with a 
wavelength of 633 nm and the detector was set in the range of 656 to 682 nm. The 
images of the fluorescence were overlaid with images of the gel taken using 
differential interference contrast (DIC). 
 
6.4. Results and discussion 
 
An examination of the pH and heat stability of FITC conjugated to nisin is 
shown in Fig. 6.1A, B and C. FITC has optimum activity at pH 9 (Sherr, Caron, & 
Sherr, 1993) and has an absorbance maximum at 495 nm and an emission maximum 
at 519 nm (Hermanson, 2013). In Fig. 6.1A free FITC at pH 9 had an absorbance 
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maximum at 495 nm; however conjugation to nisin induced a blue shift to an 
absorbance maximum of 418. When this nisin conjugated FITC underwent a heat 
treatment at pH 9 (Fig. 6.1A) the absorbance maximum reverted to that of free FITC; 
this may be due to the heat treatment releasing the FITC from the nisin. 
Examination of the absorbance of FITC conjugated to nisin before and after 
heat treatment at pH 3 and free FITC at pH 3 showed they all had an absorbance 
maximum at 435 nm (Fig. 6.1B). This implies that the pH of 3, blue shifted the 
absorbance from the normal absorbance maximum of 495 nm.  
With respect to fluorescence after heat treatment at pH 3, FITC conjugated to 
nisin had greater fluorescence at 435 nm (the pH 3 absorbance maximum) than 495 
nm (the normal excitation maximum (Er, 2006) (Fig. 6.1C). Irrespective of this, 
FITC conjugated to nisin and heat treated at pH 3 had distinctly lower fluorescence 
than the control (FITC conjugated to nisin at pH 9 and excited at its absorbance 
maximum of 418 nm) (Fig. 6.1C). FITC does not appear to be suitable for labeling 
nisin that will undergo the HACS gel encapsulation process (115 °C for 15 minutes 













Fig. 6.1. Analysis of FITC conjugated to nisin. (A) overlay of absorbance of FITC conjugated to nisin before 
(▬▬) and after (▬▬) heat treatment at pH9 and free FITC at pH9 (▬▬). (B) overlay of absorbance of FITC 
conjugated to nisin before (▬▬) and after (▬▬) heat treatment at pH3 and free FITC at pH3 (▬▬). (C) 
overlay of fluorescence at of FITC conjugated to nisin at pH9 and an excitation of 418 nm (▬▬) and after heat 
treatment at pH3 and an excitation of 435 nm (▬▬) and 495 nm (▬▬). Fluorescence is described in terms of 




 range of fluorescent labels have been demonstrated to have 
much greater temperature (Kapoor et al., 2009) and pH (Panchuk-Voloshina et al., 
1999) stability than conventional fluorescent labels such as FITC. Alexa Fluor
®
 647 
was chosen because it has been used in a published method to label nisin without 
affecting its antibacterial activity (Scherer et al., 2013). 
Initially there was a concern that the Alexa Fluor
®
 dye would label the non-
nisin peptides in the enriched nisin and to avoid this problem the enriched nisin was 
further purified by cation exchange. However the same RP-HPLC profile resulted 
from labelling the enriched nisin and the cation exchange purified nisin. Therefore as 
labelling of non-nisin peptides in the enriched nisin was not an issue, for subsequent 























































Unlike FITC, there was no change in the absorbance spectrum of Alexa 
Fluor
®
 647 after conjugation to nisin, with the absorption maximum remaining at 
650 nm. Due to the quantity of nisin used in the HACS gel entrapment protocol 
(Chapter 5), it was necessary to upscale the Scherer et al. (2013) method to have 
sufficient labelled nisin. Therefore in this study the products of the labelling reaction 
were purified using a scalable ion-exchange approach as opposed to the RP-HPLC 
approach used in Scherer et al. (2013). 
To purify the product of the labelling, initially cation exchange (SP and CM 
Sepharose) was used. However, the nisin conjugated to Alexa Fluor
®
 647 did not 
bind to the columns even when they were run at a pH of 4 (4 is the lowest pH that 
Alexa Fluor
®
 647 is reported to be stable at (Thermo Fisher Scientific, 2018)). 
Because of this anion exchange approaches were tried and it was found that at pH 9 
the nisin conjugated to Alexa Fluor
®
 647 bound to Q Sepharose. 
Using ion-exchange to purify the labelling product allowed >25 times the 
Alexa Fluor
®
 647 conjugated nisin to be purified per run cycle, than was possible 
using the RP-HPLC approach described by Scherer et al. (2013). 
The elution product (Alexa Fluor
®
 647 conjugated to nisin) of the anion 
exchange column gave a single distinctive peak when analysed by RP-HPLC and 
this peak is different to the free nisin or Alexa Fluor
®
 647 controls (Fig. 6.2). This 
shows the purification was successful, however it also shows that the hydrophobicity 
of the Alexa Fluor
®
 647 conjugated to nisin is distinct from that of nisin, which may 







Fig. 6.2. Overlay of RP-HPLC chromatograms of the product of purification by anion exchange column and 
controls. Absorbance of Alexa Fluor® 647 conjugated to nisin after purification by anion exchange at 650 nm 
(▬▬) and 214 nm (▬▬), absorbance of Nisaplin® (nisin control) at 214 nm (▬▬) and absorbance of Alexa 




 647 conjugated to nisin was not detected by MALDI TOF 
MS. This was also reported by Esteban et al. (2011) who were also unable to detect 
Alexa Fluor
®
 647 peptide conjugates by MALDI TOF MS, but were able to detect 
Alexa Fluor
®
 488 peptide conjugates by the same approach. It is possible that the 
conjugates are insufficiently protonated due to the negative charges brought by the 
Alexa Fluor
®
 647 label (Sobek, Aquino, & Schlapbach, 2011). 
Nisin has maximum stability during heat treatment at pH 3 (Davies et al., 
1998) whereas the lowest reported pH that Alexa Fluor
®
 647 is stable at is pH 4 
(Thermo Fisher Scientific, 2018). Comparing Alexa Fluor
®
 647 conjugated nisin that 
underwent the heat treatment at pH 3 to untreated Alexa Fluor
®
 647 conjugated nisin 
at pH4 by RP-HPLC showed that their absorbance was unaffected by processing 
conditions and that they remained conjugated (Fig. 6.3A), while comparing their 



















































Fig. 6.3. Effect of heat treatment (115 °C for 15 min) at pH 3 on Alexa Fluor® 647 conjugated to nisin (─ ─ ─) 
compared to unheated controls at pH 4 (▬▬). (A) overlay of RP-HPLC chromatograms with absorbance at 650 
nm. (B) overlay of fluorescence spectrums using an excitation wavelength of 649 nm. Fluorescence is described 
in terms of arbitrary units (AU). 
 
There was no antibacterial activity detected by agar well diffusion activity 
assay of nisin conjugated to Alexa Fluor
®
 647 despite it having a much greater nisin 
concentration than the positive control (Nisaplin
®
) (Fig. 6.4). Nisin conjugated Alexa 
Fluor
®
 647 was previously deemed to be biologically active due to its capacity to 
release carboxyfluorescein from liposomes composed of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC) with 0.2 mole-percentage lipid II (Scherer et al., 2013); as 
the agar well diffusion activity assay used in this study tests nisin activity against 
live bacteria it can be considered a more accurate assessment of nisin activity. It is 
possible that the negative charge of the Alexa Fluor
®
 647 (-3, (Sobek et al., 2011)) 
reduced the overall charge of the conjugate too much for the nisin to be effective. 
As the nisin component of the conjugate has lost its activity, presumably due 
to a change in overall charge, the behaviour and localisation of the conjugate in the 























































Fig. 6.4. Agar well diffusion activity assay. The first row (green box) is bis-tris propane at pH 7 and has a 
concentration of 100 mM in the first well. The second and third rows (red box) are Nisaplin® with the first well 
in the second row having a nisin concentration of 0.02 μg/μL and this dilution series continues into the third row. 
The fourth row (blue box) is nisin conjugated to Alexa Fluor® 647 and has a nisin concentration of 0.4 μg/μL in 
the first well. 
 
Starch gels containing entrapped nisin of which 3% (w/w) was labelled with 
Alexa Fluor
®
 647, were analysed by confocal microscopy (Fig. 6.5A and B). The 
labelled nisin (red fluorescence) appeared to localise at the surface of the starch 
granules, however it is unclear if it was penetrating into the granule surface. As the 
fluorescence follows the curve of the granular surfaces, it is possible the labelled 
nisin was interacting with the granular surfaces. 
 
  
Fig. 6.5. Confocal microscopy of starch gels containing entrapped nisin of which 3% (w/w) was labelled with 
Alexa Fluor® 647. Images were obtained using a 63× oil immersion lens with a zoom of 3× (image A) and 5× 
(image B). Images of fluorescence obtained by excitation at 633 nm and detection in the range of 656 to 682 nm 
were overlaid with images taken using differential interference contrast (DIC). 
Bis-tris propane 
Nisaplin® 
Nisin conjugated to Alexa Fluor® 647 
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The fluorescent label AlexaFluor
®
 647 remained conjugated to the nisin and 
maintains its fluorescent properties after undergoing the processing conditions 
required for gel entrapment (pH 3, 115 °C, 15 minutes). However, the fluorescent 
label inhibited the antibacterial activity of the nisin. The labelled nisin appears to 
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Oral delivery of nisin in resistant starch based 
matrices alters the gut microbiota in mice 
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delivery of nisin in resistant starch based matrices alters the gut microbiota in mice. 











There is a growing recognition of the role the gastrointestinal microbiota 
plays in health and disease. Ingested antimicrobial proteins and peptides have the 
potential to alter the gastrointestinal microbiota; particularly if protected from 
digestion. Nisin is an antimicrobial peptide that is used as a food preservative. This 
study examined the ability of nisin to affect the murine microbiota when fed to mice 
in two different starch based matrices; a starch dough comprising raw starch granules 
and a starch gel comprising starch that was gelatinized and retrograded. The effects 
of the two starch matrices by themselves on the microbiota were also examined. 
Following 16S rRNA compositional sequencing, beta diversity analysis highlighted 
a significant difference (p = 0.001, n = 10) in the murine microbiota between the four 
diet groups. The differences between the two nisin containing diets were mainly 
attributable to differences in the nisin release from the starch matrices while the 
differences between the carriers were mainly attributable to the type of resistant 
starch they possessed. Indeed, the differences in the relative abundance of several 
genera in the mice consuming the starch dough and starch gel diets, in particular 
Akkermansia, the relative abundance of which was 0.5% and 11.9%, respectively (p 
= 0.0002, n = 10), points to the potential value of resistance starch as a modulator of 
beneficial gut microbes. Intact nisin and nisin digestion products (in particular nisin 
fragment 22-31) were detected in the faeces and the nisin was biologically active. 
However, despite a threefold greater consumption of nisin in the group fed the nisin 
in starch dough diet, twice as much nisin was detected in the faeces of the group 
which consumed the nisin in starch gel diet. In addition, the relative abundance of 
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three times as many genera from the lower gastrointestinal tract (GIT) were 
significantly different (p < 0.001, n = 10) to the control for the group fed the nisin in 
starch gel diet, implying that the starch gel afforded a degree of protection from 




The gastrointestinal microbiota impacts on the health of the host in variety of 
ways, including through its potential to protect against infection, provide nutrients 
and influence on bodyweight (Clarke et al., 2012; Jandhyala et al., 2015; Nicholson 
et al., 2012). The composition of the microbiota, and thus its health effects, can be 
altered by a variety of means, including antimicrobials and diet (Chung et al., 2016; 
Cotter, Stanton, Ross, & Hill, 2012; Martinez et al., 2010). 
Nisin is an antimicrobial peptide with broad activity against Gram positive 
bacteria produced by strains of Lactococcus lactis subsp. lactis (Abee & Delves-
Broughton, 2003). Nisin has been approved for use as a food preservative by both 
US Food and Drug Administration, (FDA) (US Food and Drug Administration, 
1988) and by the European Food Safety Authority (EFSA) with its assigned E 
number being E 234 (Younes et al., 2017). 
Nisin is very stable at low pH and at pH 3 there is <5% loss of activity when 
heated to 115 °C for 20 min (Davies et al., 1998). However, while relatively resistant 
to passage through the acidic conditions in the stomach, nisin can be digested by 
pancreatin in the small intestine (Gough, O'Connor, et al., 2017; Heinemann & 
Williams, 1966), primarily by its trypsin and chymotrypsin components and 
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therefore may not reach the lower gastrointestinal tract (GIT) in an intact form (Chan 
et al., 1996; Jarvis & Mahoney, 1969). 
Few in vivo studies (Table 7.1) have investigated how dietary 
supplementation with nisin affects the microbiota of the lower GIT (Bernbom et al., 
2006; Józefiak et al., 2013; Kieronczyk et al., 2016; Lauková et al., 2014) and no 
previous in vivo study has employed a high throughput sequencing (HTS)-based 
approach to examine the impact of nisin on the entire microbiota. Nisin has been 
consumed in vivo at up to 239 mg per kg body weight per day without any adverse 
effects on food consumption, body weight, haematology, ophthalmology or gross 
pathology (Hagiwara et al., 2010). Although nisin doses of up to 173.9 mg per kg 
body weigh per day had no impact on the microbiota in a study on rats (Bernbom et 
al., 2006), nisin has been seen to influence the microbiota in some way in the 
majority of in vivo studies including those on mice, chickens and rabbits and in in 
vitro bovine and human microbiota studies (Table 7.1). However, the variation in 
methods used, and the previous absence of detailed HTS-based investigations, make 
direct comparisons difficult (Table 7.1). 
 
Table 7.1. Comparison of selected in vivo and in vitro models of nisin activity. 






















    


















161 mg (starch 
dough diet), 54 
mg (starch gel 
diet) 
Yes Faeces 
16S rRNA MiSeq 
sequencing 
Yes No change This paper 
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Starch is the primary carbohydrate source in the adult western diet (Sibley, 
2004). Starch is comprised of the carbohydrate polymers amylose and amylopectin, 
and in plants these are arranged into semi-crystalline starch granules, which are of 
0.1 to 200 μm in diameter. When ‘raw’ starch granules are suspended in water and 
heated, the amylose and amylopectin disassociate, with the granules leaching 
amylose and absorbing water causing them to swell and ultimately dissipate. When 
the solution is subsequently cooled, the amylose and amylopectin re-associate, 
turning the solution into a starch gel, with the gel strength primarily determined by 
amylose content. These two stages are referred to as gelatinization and retrogradation 
(Alcázar-Alay & Meireles, 2015; Wang et al., 2015). Many types of food processing, 
including cooking, can cause starch to undergo gelatinization and retrogradation 
(Delcour et al., 2010) with co-present substances becoming entrapped in the 
resulting starch gel (Forssell, 2004). 
The portion of starch that resists digestion in the small intestine is termed 
‘resistant starch’ and varies between starch source and type. In the case of the type of 
starch used in this study (70% amylose starch from maize), the resistant starch 
content has been reported as 46% on a w/w basis (McCleary, McNally, & Rossiter, 
2002). Starch that is resistant due to its granular nature is classified as type 2 
resistant starch (RS2), whereas starch that is resistant due to retrogradation is 
classified as type 3 resistant starch (RS3) (Sajilata, Singhal, & Kulkarni, 2006). Due 
to the capacity of the resistant starch portion of a starch to resist digestion in the 
upper GIT and subsequently be fermented by colonic bacteria, starch based systems 
have been proposed for the colonic delivery of drugs and bioactive materials; these 
systems frequently use ethyl cellulose as a binder and are frequently produced 
through spray coating (Desai, 2005; Dimantov, Greenberg, Kesselman, & Shimoni, 
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2004; Freire et al., 2010; Milojevic et al., 1996; Pu et al., 2011; Recife, Meneguin, 
Cury, & Evangelista, 2017; Situ, Chen, Wang, & Li, 2014; Wilson & Basit, 2005). 
The aim of this study was to determine the effect, in vivo, of orally consumed 
nisin on the lower GIT microbiota (as determined by 16S rRNA HTS of faecal 
samples (Suzuki & Nachman, 2016)) when nisin was incorporated into two different 
starch based matrices; a dough based on raw starch (RS2) and a gel based on starch 
that had undergone gelatinization and retrogradation (RS3). Additionally the 
potential of the starch matrices themselves to impact on the microbiota was 
examined. 
 




High amylose corn starch (HACS) was obtained from Sigma Aldrich (S4180, 
Sigma Aldrich, Arklow, Ireland). Dextrose equivalent 12 maltodextrin (DE12 MD) 
was obtained from Roquette (Glucidex® 12, Roquette, Corby, UK). All other 
reagents were from Sigma Aldrich (Arklow, Ireland) unless otherwise specified.  
 
7.3.2. Preparation of nisin 
 
The nisin A preparation used in this study was Nisaplin
®
 (DuPont, 
Beaminster, UK). This preparation was concentrated by salting out as previously 
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described (Gough, Gómez-Sala, et al., 2017). This resulted in a 57.7% nisin 
preparation which will subsequently be referred to in the text as enriched nisin. 
 
7.3.3. Preparation of test diet pellets 
 
Starch gels were prepared with and without nisin as follows. Starch gels with 
nisin were composed of 1% (w/w) enriched nisin, 44% (w/w) HACS and 55% (w/w) 
dilute HCl, with a final pH of 3. Starch gels without nisin were composed of 45% 
(w/w) HACS and 55% (w/w) dilute HCl, with a final pH of 3. The suspensions were 
split into 10 mL aliquots, heated at 115 °C for 15 min and subsequently incubated at 
4 °C for a minimum of 16 h to ensure thorough retrogradation. Starch dough was 
prepared with and without nisin as follows. The starch dough balls with nisin 
comprised 1% (w/w) enriched nisin, 51.5% (w/w) HACS, 22.5% DE12 MD and 
25% (w/w) dilute HCl. The starch dough balls without nisin contained 52.5% (w/w) 
HACS, 22.5% DE12 MD and 25% (w/w) dilute HCl. For the preparation of the nisin 
containing starch dough balls, the dilute HCL and enriched nisin (at pH 3) were 
heated at 115 °C for 15 min and allowed cool to room temperature before addition to 
the rest of the ingredients, to ensure that the treatment of the nisin in the starch 
dough was comparable with that of the nisin in the starch gel. All the components of 
the starch dough balls were then mixed in a laminar flow cabinet. Each starch dough 
ball was thoroughly kneaded to achieve homogeneity and firmness. The starch dough 





7.3.4. Feeding schedule and sample collection 
 
This study was carried out in accordance with European Directive 
2010/63/EU. The protocol was approved by the University College Cork Animal 
Experimentation Ethics Committee (2011/005). Male C57BL/6JOlaHsd mice aged 
3-4 weeks (Envigo, Alconbury, UK) were group housed (5 per cage) and were 
maintained in a 12:12 h light-dark cycle. During the initial 10 day acclimatization 
period, the mice were fed a standard nutritionally complete low-fat rodent diet 
(D12450B, Research Diets, New Brunswick, New Jersey, US); this diet is henceforth 
referred to as the nutritionally complete (NC) diet. Subsequently weight matched 
mice were assigned to receive the following test diets: starch dough (SD), starch 
dough containing nisin (SD-N), starch gel (SG) and starch gel containing nisin (SG-
N) (n = 10 per test diet). 
An overview of the feeding schedule is shown in Table 7.2. The feeding 
schedule involved initially switching the NC diets with the test diets for 2 h per day 
for three days and this was gradually increased to 8 h per day over the period of the 
trial as described in Table 7.2.The test diets were introduced gradually to acclimatize 
the animals to eating the starch based diets. The exposure to the NC diets thus 
decreased from 22 h to 16 h per day over the period of the trial. The test diets were 
replaced every 4 days to ensure the freshness of the diet pellets. As mice are 
nocturnal animals and the cage room was on a 12:12 h light-dark cycle, the food 
hoppers were switched to test diets at the beginning of the dark cycle (18:00). The 
food hoppers were weighed throughout the trial as described in Table 7.2 and 
additional food hoppers in empty cages were used as controls to measure the impact 
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of diet pellet drying on diet pellet weight. The hoppers were loaded with sufficient 
pellets of the test and NC diets to ensure that a sufficient quantity of test/NC diet was 
provided to the mice for ad libitum consumption at all times. 
The mice were weighed and faecal pellets collected during the course of the 
experiment as outlined in Table 7.2. At these time points faecal pellets were obtained 
from each mouse and stored at -80 °C individually for 16S RNA sequencing. For 
MALDI TOF mass spectroscopy, HPLC and activity assays composite faecal 
samples were obtained by pooling the faecal pellets by cage at each time point. To 
limit contamination of the samples, the faecal pellets were collected directly from the 
mice and not from the bedding. 
 
Table 7.2. Feeding schedule and days of faecal pellet collection and mouse and food hopper weighing. 
Day 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Faecal pellet collection                      
Mice weighed                       
Food hopper weighed                                
Hours on test diet 2 2 2 4 4 4 4 4 6 6 6 8 8 8 8 n/a 
Hours on nutritionally complete diet 22 22 22 20 20 20 20 20 18 18 18 16 16 16 16 n/a 
 
7.3.5. DNA extraction, amplification and sequencing 
 
DNA was extracted from faecal pellets using a QIAamp® Fast DNA Stool 
Kit (Qiagen, Crawley, UK) according to the manufacturer’s instructions with some 
modifications. To increase DNA yield, after the addition of InhibitEX buffer, bead 
beating (3 min × 2) and an incubation at 95 °C for 5 min, were performed. The 
samples were quantified using a Qubit
®
 dsDNA High Sensitivity Assay Kit (Fisher 
Scientific, Dublin, Ireland) in conjunction with a Qubit
®
 2.0 fluorometer (Invitrogen, 
170 
 
Paisley, UK). The initial amplification PCRs were performed as outlined in the 
Illumina 16S Metagenomic Sequencing Library Preparation Guide (Illumina, Saffron 
Walden, UK) with the following alterations; 30 amplification cycles were used and 
the amplification PCRs were each performed in a total volume of 60 μL which 
contained 25 ng DNA and 1 μL of each primer at a 10 µM concentration. The 
subsequent clean up using the AMPure
®
 XP purification system (Labplan, Dublin, 
Ireland) was scaled up appropriately to account for the greater volume. The index 
PCRs and subsequent AMPure
®
 XP clean up were as outlined in the Illumina 
protocol. The samples were quantified using the Qubit
®
 procedure and the 
concentrations normalized to 20 nM and pooled as per the Illumina protocol. The 
pooled sample (100 μL) was purified using AMPure
®
 XP beads and the sample 
eluted using 50 μL of a 10 mM Tris solution. The pooled sample was quantified 
using the Qubit
®
 procedure and sample quality was determined using an Agilent 
2100 Bioanalyzer (Agilent, Cork, Ireland). The pooled sample was denatured and 
sequenced using a 500 cycle v2 kit on the MiSeq™ sequencing platform (Illumina, 
Saffron Walden, UK) following protocols outlined by Illumina, at the Teagasc 
Sequencing Centre, Moorepark. 
 
7.3.6. Bioinformatics analysis 
 
Sequences were filtered on the basis of quality (removal of low quality 
nucleotides at the 3' end) and length (removal of sequences with less than 200 nt) 
with PRINSEQ (Schmieder & Edwards, 2011) and joined using fastq-join (Aronesty, 
2011). The sequences were clustered with 97% identity level (calculated at the 
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operational taxonomic unit; OTUs) using closed-reference USEARCH v7.0 
algorithm (Edgar, 2010) against the Ribosomal Database Project (Wang, Garrity, 
Tiedje, & Cole, 2007). Alpha and beta-diversity was determined using QIIME 
(Caporaso et al., 2010). The results of principal coordinates analysis (PCoA) of the 
beta-diversity when it was calculated using distance matrices built from unweighted 
UniFrac distances, were visualized using EMPeror (Vazquez-Baeza, Pirrung, 
Gonzalez, & Knight, 2013). 
 
7.3.7. Preparation of faecal pellets for detection of nisin 
 
To detect nisin in the faecal pellets, the nisin was extracted from the pellets 
as described by Rea et al. (2014) with minor modifications as follows: composite 
faecal samples were suspended in 1 mL of 0.1% TFA and 70% IPA, vortexed 
thoroughly and allowed to stand at room temperature for 30 min and centrifuged for 
5 min at 16,000 × g and the supernatant retained. The centrifugation step was 
repeated a further three times with the supernatant retained each time. In order to 
bring the IPA content of the samples to <7%, IPA was removed using a Centrivap 
Console (Labconco, Kansas City, US) and the samples were then restored to their 








7.3.8. Reversed phase - high performance liquid chromatography (RP-
HPLC) 
 
RP-HPLC was carried out on a Jupiter, 5 μm, C18, 300 Å, 250 mm × 4.6 mm 
column from Phenomenex (Macclesfield, UK) with an acetonitrile (Thermo Fisher 
Scientific, Dublin, Ireland) gradient as described previously (Gough, Gómez-Sala, et 
al., 2017). 
 
7.3.9. Matrix-assisted laser desorption/ionization time of flight mass 
spectroscopy (MALDI TOF MS) 
 
The molecular mass of the HPLC fraction corresponding to the nisin peak 
was determined using MALDI TOF MS using an Axima TOF
2
 (Shimadzu Biotech, 
Kyoto, Japan) as previously described (Field et al., 2012). 
 
7.3.10. Activity assay 
 
Antibacterial activity was estimated by agar diffusion activity assays (Ryan, 
Rea, Hill, & Ross, 1996) in agar plates seeded with Lactococcus lactis subsp. 
cremoris HP as described previously (Gough, Gómez-Sala, et al., 2017). Nisin was 
extracted from the faecal pellets as described above and Tween
®
 80 was added to a 
final concentration of 1% to prevent nonspecific adsorption of the nisin. The samples 
were dispensed into the wells of the seeded agar in 50 µL aliquots and the plates 
incubated overnight at 30 °C. Antibacterial activity resulted in zones of inhibition 
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surrounding the wells. Nisin was quantified based on a published method (Bernbom 
et al., 2006) by plotting the area of the zone of inhibition against the log of the nisin 
concentration of a serial dilution of Nisaplin
®
 that was suspended in an equivalent 
solution to the samples (6% IPA, 0.1% TFA, 1% Tween
®
 80), to generate a linear 
standard curve. 
 
7.3.11. Statistical analysis 
 
Data was tested for normality of distribution using the Shapiro-Wilk test. For 
comparing two groups Student’s t-test or Mann-Whitney U test were used as 
appropriate and for comparison of multiple groups one-way ANOVA or Kruskal-
Wallis test were used as appropriate, additionally analysis of  beta diversity was 
performed using the Adonis function in the R package Vegan (Oksanen et al., 2015). 
Analysis of the bioinformatics data was performed using the R statistical package (R 
Core Team, 2015) and all other analysis was performed using the SigmaStat 





7.4.1. Quantity of diets consumed and effect on weight gain 
 
The cumulative consumption of the NC and test diets and resultant body 
weight gain are shown in Fig. 7.1. There were no significant differences in body 
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weight gain or in NC diet consumption between diet groups over the trial period with 
three exceptions, each of which occurred only at a single measurement time point; 
the consumption of the NC partner diet for SD and SG-N in the 6 h consumption 
period was significantly different (p = 0.02, n = 6), the weight gain for the mice on 
the SG and SG-N diets from days 4 to 7 of the trial was significantly different (p = 
0.02, n = 10) and the weight gain for the mice on the SD and SG diets from days 11 
to 15 of the trial was significantly different (p = 0.0004, n = 10). The total 
consumption per cage of the SD-N and SG-N test diets was 20.8 ± 2.5 g and 6.5 ± 
2.0 g, respectively, and the daily consumption of these diets were significantly 
different during the 6 h (p = 0.00007, n = 6) and 8 h (p = 0.00003, n = 8) 
consumption period. The total nisin consumption per cage over the course of the trial 
was 144 ± 14 mg and 52 ± 11 mg for the SD-N and SG-N diet groups, respectively, 
and the daily consumption of the nisin portion of those diets were also significantly 
different during the 6 h (p = 0.0003, n = 6) and 8 h (p = 0.00002, n = 8) consumption 
period. The average nisin consumption per day per cage during the 8 h consumption 
period was 17 ± 1 mg and 6 ± 2 mg for the SD-N and SG-N diets groups, 
respectively. Therefore there was approximately a threefold greater consumption of 
nisin by mice on the SD-N diet compared to mice on the SG-N diet. For SD-N 
compared to SD, SG-N compared to SG and SD compared to SG there were no 
statistically significant differences during the 6 h (p = 0.134, 0.101 and 0.217 
respectively, n = 6) and 8 h (p = 0.507, 0.442 and 0.54, n = 8) consumption periods 







Fig. 7.1. Consumption of each diet and the relationship between diets and weight gain. (A) cumulative 
consumption of nutritionally complete (NC) partner diets for each diet group, (B) cumulative consumption of test 
diets for each diet group, (C) cumulative weight gain for each diet group. Diet groups are defined by their test 
diet as follows:  starch dough (SD),  starch dough containing nisin (SD-N), ▲ starch gel (SG),  starch gel 
containing nisin (SG-N). 
 
7.4.2. Identification and quantification of intact nisin and nisin 
fragments in the faeces 
 
The activity assays of the faecal pellets from mice consuming SD, SD-N, SG 
and SG-N diets (Fig. 7.2A) showed antibacterial activity in faeces from mice that 
consumed the SD-N and SG-N diets. MALDI TOF MS was performed on faecal 
pellets to determine their intact nisin and nisin fragment composition (Fig. 7.2B and 
C). Their primary nisin components were then determined by RP-HPLC in 
conjunction with MALDI TOF MS (Fig. 7.2D and E). For comparison purposes 
intact nisin was also analysed by RP-HPLC in conjunction with MALDI TOF MS 
(Fig. 7.2F and G). 
MALDI TOF MS of the faecal pellets of mice on the SD-N (Fig. 7.2B) and 
SG-N diets (Fig. 7.2C) showed masses that correlated with intact nisin and nisin 
fragments 22-31 (i.e., corresponding to amino acids 22 to 31 of intact nisin) and 21-
31; these nisin fragments are the products of the digestion of nisin and have 



















































































Liskamp, & Rijkers, 2013). Versions of nisin fragment 22-31 with a Na adduct ion 
(+22 Da) and a K adduct ion (+38 Da) were also detected. Intact nisin, extracted 
from the faecal pellets, was seen in its doubly charged form at 1676.46 Da and 
1675.61 Da for the SD-N diet and for the SG-N, respectively. 
 RP-HPLC of the faecal pellets of mice on the SG-N diet showed a single 
dominant peak (Fig. 7.2D) that eluted at 41% acetonitrile and MALDI TOF MS of 
this peak revealed it to be nisin fragment 22-31 (Fig. 7.2E). A similar result was 
obtained for the faecal pellets of mice on the SD-N diet (result not shown). 
Therefore, the primary nisin component of the faeces was fragment 22-31, as 
opposed to intact nisin. 
 Intact nisin normally elutes from a RP-HPLC at 36% acetonitrile (Fig. 7.2F) 
and subsequent MALDI TOF MS of this elution peak shows both singly (3354.46 
Da) and doubly (1677.68 Da) charged intact nisin (Fig. 7.2G). However, while no 
intact nisin was detected by HPLC, antibacterial activity was detected in the faeces 
of those groups fed the SD-N and SG-N diets (Fig. 7.2A). This would suggest that 
the nisin concentration in the faecal pellets was below the level of detection by 
HPLC. 
 Quantifying the intact nisin in the faeces at the final time point based on 
antibacterial activity showed significantly more (p = 0.031, n = 3) nisin in the faeces 
of the group fed SG-N (1.7 ± 0.2 ng/mg) compared to the groups fed SD-N (0.8 ± 
0.1 ng/mg), despite the fact that less nisin was consumed by the group fed the SG-N 
diet, which would indicate that more intact nisin reached the lower GIT in SG-N-fed 
mice. Therefore, at the final time point (8 hour test diet period), despite the 
significantly (p = 0.00002, n = 8) greater nisin consumption of the mice on the SD-N 
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diets, there was significantly (p = 0.031, n = 3) greater amount of nisin in the faeces 






Fig 7.2. Analysis of faecal pellets of mice consuming starch dough (SD), starch dough containing nisin (SD-N), 
starch gel (SG) and starch gel containing nisin (SG-N) diets. Activity assay of faecal pellets from mice 
consuming SD, SD-N, SG and SG-N diets (A). Mass spectroscopy of faecal pellets from mice consuming SD-N 
(B) and SG-N diets (C). RP-HPLC chromatogram of faecal pellets from mice consuming SG-N (D) and mass 
spectroscopy of the elution peak (E). RP-HPLC chromatogram of intact nisin (F) and mass spectroscopy of the 
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7.4.3. HTS-based analysis of microbiota 
 
Following total metagenomic DNA extraction from the faecal pellets from 
day 15, 16S rRNA gene amplicons (V3-V4 region) were generated and sequenced 
using the Illumina MiSeq™ platform. The mean number of sequence reads and alpha 
diversity indices for each diet group are shown in Table 7.3. There were no statistical 
differences in the alpha diversity indices: Observed operational taxonomic units 
(unique operational taxonomic units), Chao1 (richness), ACE (richness), Simpson 
(richness and evenness) and Shannon (richness and evenness), between the diet 
groups (Table 7.3). However, when the beta diversity was calculated using distance 
matrices built from unweighted UniFrac distances and the PCoA results visualized 
using EMPeror (Vazquez-Baeza et al., 2013), the four treatment groups formed 
distinct clusters based on diet (Fig. 7.3), which were significantly different (p = 
0.001, n = 10). 
 
Table 7.3. Mean sequence reads and alpha diversity indices for starch dough (SD), starch dough containing nisin 
(SD-N), starch gel (SG) and starch gel containing nisin (SG-N) diet groups (mean ± standard error, n = 10). 
 SD SD-N SG SG-N 
Sequence Reads 43,465 (± 7,276) 52,311 (± 4,629) 39,848 (± 3,909) 42,903 (± 4,969) 
Observed Operational 
Taxonomic Units  
267 (± 19) 300 (± 12) 246 (± 11) 296 (± 22) 
Chao1 277 (± 18) 309 (± 12) 254 (± 12) 303 (± 22) 
ACE 279 (± 18) 310 (± 12) 256 (± 11) 304 (± 22) 
Shannon 3.58 (± 0.03) 3.58 (± 0.05) 3.57 (± 0.04) 3.69 (± 0.10) 
Simpson 0.947 (± 0.002) 0.941 (± 0.005) 0.947 (± 0.003) 0.940 (± 0.007) 







Fig. 7.3. Principal coordinates analysis (PCoA) of the unweighted UniFrac distances of the 16S sequencing data. 
The four diet groups are represented by colored circles: blue – starch dough (SD), green – starch dough 
containing nisin (SD-N), red – starch gel (SG), brown – starch gel containing nisin (SG-N). The groups are 
significantly different (p = 0.001, n = 10). 
 
Sequence analysis revealed that the microbiota were primarily comprised of 
six phyla and that Bacteroidetes and Firmicutes were the dominant phyla showing a 
relative abundance of 54-62% and 25-33% respectively. There were no significant 
differences between the relative abundance of Bacteroidetes and Firmicutes across 
the diet groups (Fig. 7.4), however there were significant differences (p < 0.001, n = 
10) in the relative abundance between diet groups in the phyla Actinobacteria, 
Tenericutes and Verrucomicrobia (Fig. 7.4). 
 
 
Fig. 7.4. Relative abundance at phylum level with respect to each diet. Diet groups are as follows: starch dough 


































A number of statistical differences were found at genus level between the 
different dietary groups (Fig. 7.5 and Table 7.4). The mice fed the SG-N diet had 
significantly lower relative abundance of the genera Allobaculum, Bifidobacterium, 
Lachnospiracea incertae sedis and Clostridium cluster XIVa and significantly higher 
relative abundance of the genera Escherichia/Shigella, Lactococcus and 
Corynebacterium compared to the mice fed the SG diet (p < 0.001, n = 10). These 
changes were reflected at the corresponding family level. However, there was also a 
significantly higher (p = 0.0005, n = 10) relative abundance of the family 
Ruminococcaceae (Table 7.4) in mice fed the SG-N diet that did not correspond to a 
significant increase of any genus related to the Ruminococcaceae family. This likely 
reflects the combined increases (not individually statistically significant) in the 
proportions of the genera Anaerotruncus and Hydrogenoanaerobacterium, i.e., 
members of the Ruminococcaceae family, in mice that consumed the SG-N diet. 
Relative to the SD diet, the SD-N diet significantly (p < 0.001, n = 10) affected the 
relative abundance of only three genera; i.e. Lactobacillus and Bifidobacterium, 
which were lower, and Escherichia/Shigella, which were higher (Table 7.4). 
 There were also differences between the diet groups when compared on the 
basis of starch matrix. The relative abundance of the genera Anaeroplasma, 
Bifidobacterium and Odoribacter were significantly (p < 0.001, n = 10) greater in the 
mice fed the SD diet compared to the SG diet, whereas the relative abundance of the 
genera Akkermansia, Lachnospiracea incertae sedis and Parabacteroides were all 
significantly (p < 0.001, n = 10) greater in the mice fed the SG diet relative to the SD 
diet (Fig. 7.5 and Table 7.4). In addition, Clostridium cluster XIVb and 
Desulfovibrio had greater relative abundance in the mice fed the SG and SG-N diets 
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compared to the mice fed the SD and SD-N diets (Table 7.4) and this was 
significantly different (p < 0.001, n = 10) for the SG-N diet group compared to the 
SD-N diet group. 
 
 
Fig. 7.5. Relative abundance at genus level with respect to each diet. Diet groups are as follows: starch dough 


























































Table  7.4. Bacterial taxa whose relative abundance was significantly different between diet groups. Diet groups 
are as follows: starch dough (SD), starch dough containing nisin (SD-N), starch gel (SG) and starch gel 
containing nisin (SG-N). The relative abundance of each bacterial taxon is expressed as mean ± standard error. 
The same letter after a pair of values in a single row indicates these values are significantly different (p < 0.001, n 
= 10): (a) SD compared to SG, (b) SD-N compared to SG-N, (c) SD compared to SD-N and (d) SG compared to 
SG-N. 
 SD SD-N SG SG-N 
Significant at genus level     
Akkermansia 0.499 (± 0.111) a 2.120 (± 1.077) 11.943 (± 2.369) a 15.879 (± 4.789) 
Allobaculum 4.764 (± 0.827) 11.690 (± 2.107) b 7.018 (± 1.245) d 1.504 (± 0.528) bd 
Anaeroplasma 7.307 (± 1.905) a 14.442 (± 2.667) b 0.799 (± 0.180) a 0.385 (± 0.174) b 
Bifidobacterium 10.317 (± 0.902) ac 0.005 (± 0.001) bc 4.894 (± 0.602) ad 0.090 (± 0.030) bd 
Clostridium cluster XIVa 7.777 (± 1.044) 6.731 (± 0.577) b 8.003 (± 1.261) d 1.685 (± 0.646) bd 
Clostridium cluster XIVb 0.289 (± 0.095) 0.226 (± 0.045) b 0.777 (± 0.117) 0.831 (± 0.145) b 
Corynebacterium 0.007 (± 0.002) 0.021 (± 0.007) 0.007 (± 0.003) d 0.091 (± 0.018) d 
Desulfovibrio 0.222 (± 0.058) 0.119 (± 0.031) b 0.350 (± 0.076) 0.415 (± 0.058) b 
Escherichia/Shigella 0.009 (± 0.005) c 3.860 (± 1.971) c 0.011 (± 0.002) d 3.771 (± 1.795) d 
Lachnospiraceae incertae sedis 1.248 (± 0.375) a 0.126  (± 0.091) 7.579 (± 1.410) ad 0.336 (± 0.281) d 
Lactobacillus 3.536 (± 0.470) c 0.643 (± 0.330) c 1.378 (± 0.351) 4.828 (± 3.140) 
Lactococcus 0.168 (± 0.024) 0.533 (± 0.080) 0.095 (± 0.014) d 0.580 (± 0.143) d 
Odoribacter 18.711 (± 2.515) a 21.817 (± 1.322) b 1.164 (± 0.186) a 6.058 (± 2.205) b 
Parabacteroides 0.996 (± 0.160) a 0.835 (± 0.108) 3.042 (± 0.662) a 4.597 (± 1.200) 
Not significant at genus level 
but significant at family level 
    
Ruminococcaceae 2.285 (± 0.468) 3.296 (± 0.420) 2.157 (± 0.273) d 7.759 (± 0.684) d 




 The aim of this study was to determine if orally ingested nisin could be 
delivered to the lower GIT in two different starch matrices and subsequently impact 
on the lower GIT microbiota. Additionally, it was examined whether the type of 
starch itself could modulate the lower GIT microbiota. 
To the authors’ knowledge (Table 7.1) the only study that has examined the 
effect of orally ingested nisin on the rodent microbiota is the study on rats by 
Bernbom et al. (2006), in which the highest amount of nisin consumed was 174 mg 
nisin per kg body weight per day and, while nisin was detected in the faeces, no 
183 
 
changes in the microbiota were detected which may be due to the sensitivity of the 
molecular methods used in that study. In this study it was hoped that using a 16s 
HTS approach and similar levels of nisin as described by Bernbom et al. (2006), it 
would be possible to determine the impact of nisin on the microbiota. All test diets 
were increased at intervals over the trial to acclimatize the mice to consuming starch 
and nisin. At the 8 h consumption period the mice consumed 161 and 54 mg nisin 
per kg body weight per day for the SD-N and SG-N diets respectively. To limit the 
stress on the mice they were allowed unrestricted access to a diet within a given 
consumption period, however this approach limited a more precise matching of the 
amount fed to the Bernbom et al. (2006) study. 
Numerous studies have shown that nisin is susceptible to digestion by the 
enzymes in the upper GIT and a previous study by our group using the in vitro 
INFOGEST digestion model for the human GIT, detected nisin fragments 
corresponding to the N-terminus of nisin (amino acids 1-11, 1-12, 1-20, 1-21, 1-29 
and 1-32) post digestion, while no intact nisin was detected (Gough, O'Connor, et al., 
2017). In this study, low levels of biologically active nisin (ng/mg of faeces) were 
detected in the faeces of mice fed SG-N and SD-N, but, in contrast to the in vitro 
study, the primary nisin component of the faeces was fragment 22-31, which is not 
biologically active as the N-terminus is required for nisin activity (Hsu et al., 2004). 
It is also notable that the fragments produced by the in vivo digestion had a 
significant portion of their C-terminal present whereas those produced by the in vitro 
digestion had a significant portion of their N-terminal present. These differences can 
most likely be attributed to species-related differences in digestive enzymes. 
More nisin was detected in the faecal samples of the mice on the SG-N diet 
despite them having consumed less nisin than those on the SD-N diet; implying that 
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more intact nisin reached the lower GIT on the SG-N diet and that the starch gel may 
have afforded some protection to the nisin from digestion in the upper GIT. To the 
authors’ knowledge there are no reported studies of the in vivo effect of nisin on the 
gut microbiota using HTS techniques. The results of 16S rRNA compositional 
sequencing showed that alpha diversity indices for all diet groups were comparable 
to those seen in previous studies on faecal samples from C57BL/6J mice on low-fat 
diets (Allen et al., 2015; Javurek et al., 2017). Notably, however, beta diversity 
analysis showed that the murine microbiotas clustered together on the basis of diet. 
With respect to taxonomy, significant differences in the relative abundance between 
diet groups were observed for the phyla Actinobacteria, Tenericutes and 
Verrucomicrobia (p < 0.001, n = 10). In each case a single genus, i.e. 
Bifidobacterium, Anaeroplasma and Akkermansia, respectively, comprised the 
majority (>98%) of the genera detected belonging to these phyla. 
There were differences between the cumulative consumption of SD 
compared to SG (Fig. 7.1B), however as detailed above, those differences were not 
statistically significant for the 6 h and 8 h consumption periods (days 9 to 15 of the 
trial). Resistant starch is known to effect satiety (Lockyer & Nugent, 2017). The 
hormones glucagon-like peptide 1 (GLP-1) and peptide tyrosine-tyrosine (PYY) 
which are involved in the regulation of satiety and glycemic response (D'Alessio, 
2008) have been demonstrated to be elevated by resistant starch consumption in 
studies on mice (Zhou et al., 2008). Although to the authors knowledge while the 
relative ability of difference resistant starch types to effect satiety has not been 
elucidated, it has been shown that different types of resistant starch elicit 
significantly different glycemic responses (Haub et al., 2010). Therefore it may be 
possible that the differences in consumption of the SD and SG are due to differences 
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in the effect of RS2 and RS3 on satiety, however this was not investigated further in 
this study given our focus on the effects of nisin on the gut microbiota. 
There were also differences between the cumulative consumption of SG-N 
compared to SG, and SD-N compared to SD (Fig. 7.1B), however as detailed above, 
those differences were not statistically significant for the 6 h and 8 h consumption 
periods (days 9 to 15 of the trial). This reduction in consumption is unlikely to be 
due to an effect of nisin on the microbiota as such a change in the microbiota would 
also affect the consumption of the NC diets and there were no statistically significant 
differences between the consumption of their respective partner NC diets throughout 
the trial (Fig. 7.1A).While high protein diets have been shown to increase satiety, the 
level of protein in the nisin containing diets (~0.58%) is unlikely to have had an 
effect on satiety in this case (Batterham et al., 2006; Wiessing, Xin, Budgett, & 
Poppitt, 2015; Yu, South, & Huang, 2009). However, it is possible that the 
palatability of nisin may have contributed to the reduced consumption of the nisin 
containing diets. 
A limitation of this study is that the mice consumed different quantities of 
each of the test diets (Fig. 7.1B). While this could have confounded the effect of 
nisin on the microbiota of the diet groups when SD is compared to SD-N and SG is 
compared to SG-N (Table 7.4), the changes in the microbiota, nonetheless, are 
consistent with the specific effect of nisin on these microorganisms. The difference 
in the amount of starch consumed and resistant starch type could have confounded 
the effects of the nisin. However, when comparing diets containing dough and gel 
(Table 7.4), of the eight genera that showed a significant difference (p < 0.001, n = 
10) in relative abundance, only two genera were also significantly different (p < 
0.001, n = 10) in relative abundance when SD-N was compared to SD and SG-N was 
186 
 
compared to SG. Additionally, of these two genera, Lachnospiraceae incertae sedis 
was only significantly different (p < 0.001, n = 10) in relative abundance in SG-N 
compared to SG, while Bifidobacterium showed significantly lower (p < 0.001, n = 
10) relative abundance in both the SD-N compared to SD and SG-N compared to 
SG. It has been reported previously that Bifidobacterium are particularly sensitive to 
nisin relative to other intestinal bacteria (Le Blay, Lacroix, Zihler, & Fliss, 2007). 
Furthermore nisin primarily targets Gram positive bacteria. Interestingly the genera 
that were significantly lower (p < 0.001, n = 10) in relative abundance in SD-N 
compared to SD and SG-N compared to SG (Table 7.4) were Gram positive or 
primarily Gram positive (Clostridium cluster XIVa), whereas the genera and family 
that significantly increased (p < 0.001, n = 10) in relative abundance in SD-N 
compared to SD and SG-N compared to SG (Table 7.4) were either Gram negative 
(Escherichia/Shigella), contained Gram negative members (Ruminococcaceae) or 
may have had nisin resistant mechanisms that are known to be present in some 
strains (Lactococcus and Corynebacterium) (Brenner, Krieg, Staley, & Garrity, 
2005; De Vos et al., 2009; Draper, Cotter, Hill, & Ross, 2015; Gharsallaoui, Oulahal, 
Joly, & Degraeve, 2016; Goodfellow et al., 2012; Zhou, Fang, Tian, & Lu, 2014). 
Taking these points together, we hypothesize that one reason for the differences in 
relative abundance between SD-N compared to SD and SG-N compared to SG is the 
presence or absence of nisin in the test diets. 
 Starch based doughs have been proposed for use for the oral delivery of 
drugs to laboratory rodents as a stress free alternative to oral gavage (Corbett et al., 
2012). We observed in preliminary in vitro studies, that SD-N when placed in water 
rapidly dissociated releasing the nisin, whereas SG-N did not dissociate and nisin 
release was limited. Therefore it is possible that the nisin would be released earlier 
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and more rapidly from the SD-N than from the SG-N, which would in turn result in 
more of the nisin being digested in the upper GIT by the digestive enzymes secreted 
there and therefore impacting less on the microbiota in the lower GIT than nisin 
incorporated into the SG-N. While it is acknowledged that there are difficulties 
discerning the effect of the rate of release of the starch matrices from the effect of the 
level of consumption and resistant starch type, the compositional sequencing 
provides some evidence that nisin was released from the SD-N early in GIT transit 
and from the SG-N late in GIT transit. The relative abundance of Lactobacillus, 
which are primarily residents in the upper GIT that in turn transiently populate the 
lower GIT (Denev, 2006; Walter, 2008), was reduced in the SD-N fed group but 
were unaffected in the SG-N fed group, which may point to an earlier release in the 
upper GIT resulting in fewer lactobacilli reaching the colon. Additionally the SG-N 
diet affected the relative proportion of more than three times as many genera that are 
primarily resident in the lower GIT than were affected by the SD-N diet (when 
comparing both with their respective ‘starch only’ controls); this indicates that the 
SG-N delivered more nisin to the lower GIT than the SD-N. Furthermore, despite 
there being approximately three fold lower consumption of nisin by the mice on the 
SG-N diet compared to the mice on the SD-N diet, there was approximately twice as 
much nisin detected in the faeces of the mice that consumed the SG-N diet compared 
to those that consumed the SD-N diet. 
 Bifidobacterium and Escherichia/Shigella were the only two genera 
significantly (p < 0.001, n = 10) different in both the SD-N and SG-N diet groups 
compared to the SD and SG diet groups. Bifidobacteria have been demonstrated to 
attenuate Escherichia/Shigella in several studies, including in mice (Cheikhyoussef, 
Pogori, & Zhang, 2007; Gibson & Wang, 1994; Shu & Gill, 2001). It is possible that 
188 
 
a nisin mediated reduction in the relative abundance of bifidobacteria allowed 
Escherichia/Shigella to increase in relative abundance; particularly as these were the 
only two genera resident in the lower GIT that were significantly different when the 
SD-N and SD diet groups were compared. 
 While it would be interesting to determine whether the changes in the 
microbiota seen in this study could occur at substantially lower levels of nisin 
consumption such as those found in food, a dose response study would be required to 
evaluate this. The current acceptable daily intake (ADI) is 1 mg nisin per kg body 
weight per day (Younes et al., 2017) while typical levels added to foods range from 
2.5-25 mg/kg (Delves-Broughton, 2005). 
 Resistant starch is capable of modulating the microbiota in the lower GIT and 
its effect depends on the type of resistant starch (Bird, Brown, & Topping, 2000; 
Martinez et al., 2010). Many of the genera whose relative abundance was 
significantly different (p < 0.001, n = 10) when compared on the basis of resistant 
starch type including Akkermansia, Anaeroplasma, Bifidobacterium, 
Lachnospiracea, Odoribacter and Parabacteroides have positive health associations 
(Gomez-Gallego et al., 2016; Kverka et al., 2011; Leahy, Higgins, Fitzgerald, & van 
Sinderen, 2005; Noor et al., 2010; Reeves, Koenigsknecht, Bergin, & Young, 2012; 
Vital, Howe, & Tiedje, 2014; Zeng et al., 2015). Of particular interest was the 
alteration in the relative abundance of Akkermansia which has been described as a 
“next generation probiotic” (Cani & Van Hul, 2015) and is associated with numerous 
health benefits including treating type 2 diabetes, reducing the occurrence of 
autoimmune diseases and in weight management (Gomez-Gallego et al., 2016). 
Akkermansia in the murine gut is generally low (Schubert, Sinani, & Schloss, 2015). 
Diets that include resistant starch have been shown previously to increase the relative 
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abundance of Akkermansia (Tachon et al., 2013). There was less SG (RS3) 
consumed than SD (RS2) over the course of the study (Fig. 7.1B), although as 
detailed above, this difference in consumption was not significant during the 6 h or 8 
h consumption periods (days 9 to 15 of the trial), however the relative abundance of 
Akkermansia was significantly (p = 0.0002, n = 10) greater in mice fed the SG (RS3) 
than the SD (RS2) diet (12 and 0.5% relative abundance respectively). This may be 
attributable to the type of starch, however confirmation of this would require further 
investigation using NC diets incorporating the various starch types. 
 Overall, while it may be possible to attribute the differences in the microbiota 
between the diet groups to the effects of the diet components, it is important to 
highlight that these may not all be direct effects. The GIT microbiota is an 
interdependent community and the effect of a diet component on members of that 
network may promote other members that were not directly affected by the diet 
component (Scott, Antoine, Midtvedt, & van Hemert, 2015; Willing, Russell, & 
Finlay, 2011). 
 Increased body weight gain due to nisin consumption has been demonstrated 
in previous studies involving chickens and rabbits (Table 7.1). However, in this 
study, no effect of nisin on body weight was observed, regardless of the matrix used 
for delivery. This is consistent with studies involving rats and quails and the majority 
of studies involving mice (Table 7.1). 
 
7.6. Conclusions 
This study showed that by using a starch matrix, nisin can be delivered to the 
lower GIT and will impact on the lower GIT microbiota. All four diets altered the 
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mouse microbiota differently, with the differences between the two nisin containing 
diets may be attributable to differences in how nisin was released and protected by 
the two starch matrices, while the differences between the starch matrices may be 
attributable to the type of resistant starch (type 2 and type 3) favouring the 
abundance of different bacterial taxa. It was particularly notable how the relative 
abundance of the probiotic Akkermansia differed between the two resistant starch 
diets however the difference in consumption between starch diets makes 
comparisons more difficult and this would need to be addressed in a further study. 
Despite greater consumption of the SD-N diet, the SG-N diet resulted in larger 
amounts of intact nisin in the faeces and appeared to affect a greater number of lower 
GIT bacterial taxa. This highlights the importance of the matrix when studying the 
activity of a bioactive peptide either as a food additive or as a therapeutic for 
gastrointestinal pathogens. This study also demonstrated, in an in vivo model, the 
usefulness of resistant starch, particularly in a retrograded gel, for the colonic 
delivery of a bioactive peptide. This system may be of use for other heat stable 




Abee, T., & Delves-Broughton, J. (2003). Bacteriocins - Nisin. In N. J. Russell & G. 
W. Gould (Eds.), Food Preservatives (2nd ed., Chap. 8, pp. 146-178). New York, 
US: Kluwer Academic/Plenum Publishers. 
 
Alcázar-Alay, S. C., & Meireles, M. A. A. (2015). Physicochemical properties, 
modifications and applications of starches from different botanical sources. Food 




Allen, J. M., Miller, M. E. B., Pence, B. D., Whitlock, K., Nehra, V., Gaskins, H. R., 
et al. (2015). Voluntary and forced exercise differentially alters the gut microbiome 
in C57BL/6J mice. Journal of Applied Physiology, 118(8), 1059-1066. 
 
Aronesty, E. (2011). ea-utils: command-line tools for processing biological 
sequencing data. Retrieved from https://github.com/ExpressionAnalysis/ea-utils. 
Durham, US: Expression Analysis. 
 
Batterham, R. L., Heffron, H., Kapoor, S., Chivers, J. E., Chandarana, K., Herzog, 
H., et al. (2006). Critical role for peptide YY in protein-mediated satiation and body-
weight regulation. Cell Metabolism, 4(3), 223-233. 
 
Bernbom, N., Licht, T. R., Brogren, C. H., Jelle, B., Johansen, A. H., Badiola, I., et 
al. (2006). Effects of Lactococcus lactis on composition of intestinal microbiota: role 
of nisin. Applied and Environmental Microbiology, 72(1), 239-244. 
 
Bird, A. R., Brown, I. L., & Topping, D. L. (2000). Starches, resistant starches, the 
gut microflora and human health. Current issues in intestinal microbiology, 1(1), 25-
37. 
 
Brenner, D. J., Krieg, N. R., Staley, J. T., & Garrity, G. M. (Eds.). (2005). Bergey’s 
manual of systematic bacteriology (2 ed. Vol. 2B). New York, US: Springer. 
 
Cani, P. D., & Van Hul, M. (2015). Novel opportunities for next-generation 
probiotics targeting metabolic syndrome. Current Opinion in Biotechnology, 32, 21-
27. 
 
Caporaso, J. G., Kuczynski, J., Stombaugh, J., Bittinger, K., Bushman, F. D., 
Costello, E. K., et al. (2010). QIIME allows analysis of high-throughput community 
sequencing data. Nature Methods, 7(5), 335-336. 
 
Chan, W. C., Leyland, M., Clark, J., Dodd, H. M., Lian, L. Y., Gasson, M. J., et al. 
(1996). Structure-activity relationships in the peptide antibiotic nisin: antibacterial 
activity of fragments of nisin. FEBS Letters, 390(2), 129-132. 
 
Cheikhyoussef, A., Pogori, N., & Zhang, H. (2007). Study of the inhibition effects of 
Bifidobacterium supernatants towards growth of Bacillus cereus and Escherichia 
coli. International Journal of Dairy Science, 2(2), 116-125. 
 
Chung, W. S. F., Walker, A. W., Louis, P., Parkhill, J., Vermeiren, J., Bosscher, D., 
et al. (2016). Modulation of the human gut microbiota by dietary fibres occurs at the 
species level. Bmc Biology, 14. 
 
Clarke, S. F., Murphy, E. F., Nilaweera, K., Ross, P. R., Shanahan, F., O'Toole, P. 
W., et al. (2012). The gut microbiota and its relationship to diet and obesity: new 




Corbett, A., McGowin, A., Sieber, S., Flannery, T., & Sibbitt, B. (2012). A method 
for reliable voluntary oral administration of a fixed dosage (mg/kg) of chronic daily 
medication to rats. Laboratory Animals, 46(4), 318-324. 
 
Cotter, P. D., Stanton, C., Ross, R. P., & Hill, C. (2012). The impact of antibiotics on 
the gut microbiota as revealed by high throughput DNA sequencing. Discovery 
Medicine, 13(70), 193-199. 
 
D'Alessio, D. (2008). Intestinal hormones and regulation of satiety: The case for 
CCK, GLP-1, PYY, and Apo A-IV. Journal of Parenteral and Enteral Nutrition, 
32(5), 567-568. 
 
Davies, E. A., Bevis, H. E., Potter, R., Harris, J., Williams, G. C., & Delves-
Broughton, J. (1998). Research note: The effect of pH on the stability of nisin 
solution during autoclaving. Letters in Applied Microbiology, 27(3), 186-187. 
 
de Pablo, M. A., Gaforio, J. J., Gallego, A. M., Ortega, E., Galvez, A. M., & Lopez, 
G. A. D. (1999). Evaluation of immunomodulatory effects of nisin-containing diets 
on mice. Fems Immunology and Medical Microbiology, 24(1), 35-42. 
 
De Vos, P., Garrity, G. M., Jones, D., Krieg, N. R., Ludwig, W., Rainey, F. A., et al. 
(Eds.). (2009). Bergey's manual of systematic bacteriology (2 ed. Vol. 3). New York, 
US: Springer. 
 
Delcour, J. A., Bruneel, C., Derde, L. J., Gomand, S. V., Pareyt, B., Putseys, J. A., et 
al. (2010). Fate of starch in food processing: from raw materials to final food 
products. Annual Review of Food Science and Technology, 1, 87-111. 
 
Delves-Broughton, J. (2005). Nisin as a food preservative. Food Australia, 57(12), 
525-527. 
 
Denev, S. A. (2006). Role of Lactobacilli in gastrointestinal ecosystem. Bulgarian 
Journal of Agricultural Science, 12, 63-114. 
 
Desai, K. G. H. (2005). Preparation and characteristics of high-amylose corn 
starch/pectin blend microparticles: A technical note. Aaps Pharmscitech, 6(2), E202 
-E208. 
 
Dimantov, A., Greenberg, M., Kesselman, E., & Shimoni, E. (2004). Study of high 
amylose corn starch as food grade enteric coating in a microcapsule model system. 
Innovative Food Science & Emerging Technologies, 5(1), 93-100. 
 
Draper, L. A., Cotter, P. D., Hill, C., & Ross, R. P. (2015). Lantibiotic resistance. 
Microbiology and Molecular Biology Reviews, 79(2), 171-191. 
 
Edgar, R. C. (2010). Search and clustering orders of magnitude faster than BLAST. 




Field, D., Begley, M., O'Connor, P. M., Daly, K. M., Hugenholtz, F., Cotter, P. D., et 
al. (2012). Bioengineered nisin A derivatives with enhanced activity against both 
gram positive and gram negative pathogens. PLOS One, 7(10). 
 
Forssell, P. (2004). Starch-based microencapsulation. In A.-C. Eliasson (Ed.), Starch 
in food (Chap. 16, pp. 461-473). Abington, UK: Woodhead Publishing. 
 
Freire, C., Podczeck, F., Ferreira, D., Veiga, F., Sousa, J., & Pena, A. (2010). 
Assessment of the in-vivo drug release from pellets film-coated with a dispersion of 
high amylose starch and ethylcellulose for potential colon delivery. Journal of 
Pharmacy and Pharmacology, 62(1), 55-61. 
 
Gharsallaoui, A., Oulahal, N., Joly, C., & Degraeve, P. (2016). Nisin as a food 
preservative: Part 1: Physicochemical properties, antimicrobial activity, and main 
uses. Critical Reviews in Food Science and Nutrition, 56(8), 1262-1274. 
 
Gibson, G. R., & Wang, X. (1994). Regulatory effects of bifidobacteria on the 
growth of other colonic bacteria. Journal of Applied Bacteriology, 77(4), 412-420. 
 
Gomez-Gallego, C., Pohl, S., Salminen, S., De Vos, W. M., & Kneifel, W. (2016). 
Akkermansia muciniphila: A novel functional microbe with probiotic properties. 
Beneficial Microbes, 7(4), 571-584. 
 
Goodfellow, M., Kämpfer, P., Busse, H.-J., Trujillo, M. E., Suzuki, K.-i., Ludwig, 
W., et al. (Eds.). (2012). Bergey's manual of systematic bacteriology (2 ed. Vol. 5). 
New York, US: Springer. 
 
Gough, R., Gómez-Sala, B., O’Connor, P. M., Rea, M. C., Miao, S., Hill, C., et al. 
(2017). A simple method for the purification of nisin. Probiotics and Antimicrobial 
Proteins, 9(3), 363-369. 
 
Gough, R., O'Connor, P. M., Rea, M. C., Gómez-Sala, B., Miao, S., Hill, C., et al. 
(2017). Simulated gastrointestinal digestion of nisin and interaction between nisin 
and bile. LWT - Food Science and Technology, 86, 530-537. 
 
Gupta, S. M., Aranha, C. C., & Reddy, K. V. R. (2008). Evaluation of developmental 
toxicity of microbicide nisin in rats. Food and Chemical Toxicology, 46(2), 598-603. 
 
Hagiwara, A., Imai, N., Nakashima, H., Toda, Y., Kawabe, M., Furukawa, F., et al. 
(2010). A 90-day oral toxicity study of nisin A, an anti-microbial peptide derived 
from Lactococcus lactis subsp lactis, in F344 rats. Food and Chemical Toxicology, 
48(8-9), 2421-2428. 
 
Haub, M. D., Hubach, K. L., Al-Tamimi, E. K., Ornelas, S., & Seib, P. A. (2010). 
Different types of resistant starch elicit different glucose reponses in humans. J Nutr 
Metab, 2010. 
 
Heinemann, B., & Williams, R. (1966). Inactivation of nisin by pancreatin. Journal 




Hsu, S.-T. D., Breukink, E., Tischenko, E., Lutters, M. A. G., de Kruijff, B., 
Kaptein, R., et al. (2004). The nisin-lipid II complex reveals a pyrophosphate cage 
that provides a blueprint for novel antibiotics. Nature Structural & Molecular 
Biology, 11(10), 963-967. 
 
Jandhyala, S. M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M., & 
Reddy, D. N. (2015). Role of the normal gut microbiota. World Journal of 
Gastroenterology, 21(29), 8787-8803. 
 
Jarvis, B., & Mahoney, R. R. (1969). Inactivation of nisin by alpha-chymotrypsin. 
Journal of Dairy Science, 52(9), 1448-1450. 
 
Javurek, A. B., Spollen, W. G., Johnson, S. A., Bivens, N. J., Bromert, K. H., Givan, 
S. A., et al. (2017). Consumption of a high-fat diet alters the seminal fluid and gut 
microbiomes in male mice. Reproduction Fertility and Development, 29(8), 1602-
1612. 
 
Józefiak, D., Kierończyk, B., Juśkiewicz, J., Zduńczyk, Z., Rawski, M., Długosz, J., 
et al. (2013). Dietary nisin modulates the gastrointestinal microbial ecology and 
enhances growth performance of the broiler chickens. PLOS One, 8(12). 
 
Kieronczyk, B., Pruszynska-Oszmalek, E., Swiatkiewicz, S., Rawski, M., Dlugosz, 
J., Engberg, R. M., et al. (2016). The nisin improves broiler chicken growth 
performance and interacts with salinomycin in terms of gastrointestinal tract 
microbiota composition. Journal of Animal and Feed Sciences, 25(4), 309-316. 
 
Kverka, M., Zakostelska, Z., Klimesova, K., Sokol, D., Hudcovic, T., Hrncir, T., et 
al. (2011). Oral administration of Parabacteroides distasonis antigens attenuates 
experimental murine colitis through modulation of immunity and microbiota 
composition. Clinical and Experimental Immunology, 163(2), 250-259. 
 
Lauková, A., Chrastinová, L., Plachá, I., Kandricáková, A., Szabóová, R., 
Strompfová, V., et al. (2014). Beneficial effect of lantibiotic nisin in rabbit 
husbandry. Probiotics and Antimicrobial Proteins, 6(1), 41-46. 
 
Le Blay, G., Lacroix, C., Zihler, A., & Fliss, I. (2007). In vitro inhibition activity of 
nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. 
Letters in Applied Microbiology, 45(3), 252-257. 
 
Le Lay, C., Fernandez, B., Hammami, R., Ouellette, M., & Fliss, I. (2015). On 
Lactococcus lactis UL719 competitivity and nisin (Nisaplin ®) capacity to inhibit 
Clostridium difficile in a model of human colon. Frontiers in Microbiology, 6. 
 
Leahy, S. C., Higgins, D. G., Fitzgerald, G. F., & van Sinderen, D. (2005). Getting 




Lillie, L. E., Temple, N. J., & Florence, L. Z. (1996). Reference values for young 
normal Sprague-Dawley rats: Weight gain, hematology and clinical chemistry. 
Human & Experimental Toxicology, 15(8), 612-616. 
 
Lockyer, S., & Nugent, A. P. (2017). Health effects of resistant starch. Nutrition 
Bulletin, 42(1), 10-41. 
 
Martinez, I., Kim, J., Duffy, P. R., Schlegel, V. L., & Walter, J. (2010). Resistant 
starches types 2 and 4 have differential effects on the composition of the fecal 
microbiota in human subjects. PLOS One, 5(11). 
 
McCleary, B. V., McNally, M., & Rossiter, P. (2002). Measurement of resistant 
starch by enzymatic digestion in starch and selected plant materials: collaborative 
study. Journal of AOAC International, 85(5), 1103-1111. 
 
Milojevic, S., Newton, J. M., Cummings, J. H., Gibson, G. R., Botham, R. L., Ring, 
S. G., et al. (1996). Amylose as a coating for drug delivery to the colon: Preparation 
and in vitro evaluation using 5-aminosalicylic acid pellets. Journal of Controlled 
Release, 38(1), 75-84. 
 
Nicholson, J. K., Holmes, E., Kinross, J., Burcelin, R., Gibson, G., Jia, W., et al. 
(2012). Host-gut microbiota metabolic interactions. Science, 336(6086), 1262-1267. 
 
Noor, S. O., Ridgway, K., Scovell, L., Kemsley, E. K., Lund, E. K., Jamieson, C., et 
al. (2010). Ulcerative colitis and irritable bowel patients exhibit distinct 
abnormalities of the gut microbiota. BMC Gastroenterology, 10. 
 
Oksanen, J., Blanchet, F. G., Kindt, R., Legendre, P., Minchin, P., O’Hara, R. B., et 
al. (2015). Vegan: community ecology package, version 2.2-1. Retrieved from 
https://CRAN.R-project.org/package=vegan. Accessed 22/09/2015. 
 
Ozdogan, M., & Ustundag, A. O. (2015). Effects of bacteriocin and organic acids on 
growth performance of Japanese quails. Scientific Papers: Series D, Animal Science, 
58, 164-169. 
 
Pu, H. Y., Chen, L., Li, X. X., Xie, F. W., Yu, L., & Li, L. (2011). An oral colon-
targeting controlled release system based on resistant starch acetate: synthetization, 
characterization, and preparation of film-coating pellets. Journal of Agricultural and 
Food Chemistry, 59(10), 5738-5745. 
 
R Core Team. (2015). R: A language and environment for statistical computing. 
Retrieved from https://www.r-project.org/. Accessed 22/09/2015. 
 
Rea, M. C., Alemayehu, D., Casey, P. G., O'Connor, P. M., Lawlor, P. G., Walsh, 
M., et al. (2014). Bioavailability of the anti-clostridial bacteriocin thuricin CD in 




Recife, A. C. D., Meneguin, A. B., Cury, B. S. F., & Evangelista, R. C. (2017). 
Evaluation of retrograded starch as excipient for controlled release matrix tablets. 
Journal of Drug Delivery Science and Technology, 40, 83-94. 
 
Reddy, K. V., Gupta, S. M., & Aranha, C. C. (2011). Effect of antimicrobial peptide, 
nisin, on the reproductive functions of rats. ISRN Vet Sci, 2011. 
 
Reddy, K. V. R., Aranha, C., Gupta, S. M., & Yedery, R. D. (2004). Evaluation of 
antimicrobial peptide nisin as a safe vaginal contraceptive agent in rabbits: in vitro 
and in vivo studies. Reproduction, 128(1), 117-126. 
 
Reeves, A. E., Koenigsknecht, M. J., Bergin, I. L., & Young, V. B. (2012). 
Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice 
inoculated with a murine isolate from the family Lachnospiraceae. Infection and 
Immunity, 80(11), 3786-3794. 
 
Ryan, M. P., Rea, M. C., Hill, C., & Ross, R. P. (1996). An application in cheddar 
cheese manufacture for a strain of Lactococcus lactis producing a novel broad-
spectrum bacteriocin, lacticin 3147. Applied and Environmental Microbiology, 
62(2), 612-619. 
 
Sajilata, M. G., Singhal, R. S., & Kulkarni, P. R. (2006). Resistant starch - a review. 
Comprehensive Reviews in Food Science and Food Safety, 5(1), 1-17. 
 
Schmieder, R., & Edwards, R. (2011). Quality control and preprocessing of 
metagenomic datasets. Bioinformatics, 27(6), 863-864. 
 
Schubert, A. M., Sinani, H., & Schloss, P. D. (2015). Antibiotic-induced alterations 
of the murine gut microbiota and subsequent effects on colonization resistance 
against Clostridium difficile. mBio, 6(4). 
 
Scott, K. P., Antoine, J. M., Midtvedt, T., & van Hemert, S. (2015). Manipulating 
the gut microbiota to maintain health and treat disease. Microbial Ecology in Health 
and Disease, 26. 
 
Shen, J. S., Liu, Z., Yu, Z. T., & Zhu, W. Y. (2017). Monensin and nisin affect 
rumen fermentation and microbiota differently in vitro. Frontiers in Microbiology, 8. 
 
Shtenberg, A. J., & Ignatev, A. D. (1970). Toxicological evaluation of some 
combinations of food preservatives. Food and Cosmetics Toxicology, 8(4), 369-380. 
 
Shu, Q., & Gill, H. S. (2001). A dietary probiotic (Bifidobacterium lactis HN019) 
reduces the severity of Escherichia coli O157:H7 infection in mice. Medical 
Microbiology and Immunology, 189(3), 147-152. 
 
Sibley, E. (2004). Carbohydrate digestion and absorption. In L. R. Johnson (Ed.), 




Situ, W., Chen, L., Wang, X. Y., & Li, X. X. (2014). Resistant starch film-coated 
microparticles for an oral colon-specific polypeptide delivery system and its release 
behaviors. Journal of Agricultural and Food Chemistry, 62(16), 3599-3609. 
 
Slootweg, J. C., Liskamp, R. M. J., & Rijkers, D. T. S. (2013). Scalable purification 
of the lantibiotic nisin and isolation of chemical/enzymatic cleavage fragments 
suitable for semi-synthesis. Journal of Peptide Science, 19(11), 692-699. 
 
Suzuki, T. A., & Nachman, M. W. (2016). Spatial heterogeneity of gut microbial 
composition along the gastrointestinal tract in natural populations of house mice. 
PLOS One, 11(9). 
 
Tachon, S., Zhou, J. N., Keenan, M., Martin, R., & Marco, M. L. (2013). The 
intestinal microbiota in aged mice is modulated by dietary resistant starch and 
correlated with improvements in host responses. FEMS Microbiology Ecology, 
83(2), 299-309. 
 
US Food and Drug Administration. (1988). Nisin preparation; affirmation of GRAS 
status as a direct human food ingredient. Federal Register, 53(66), 11247-11251. 
 
van Staden, D. A., Brand, A. M., Endo, A., & Dicks, L. M. T. (2011). Nisin F, 
intraperitoneally injected, may have a stabilizing effect on the bacterial population in 
the gastro-intestinal tract, as determined in a preliminary study with mice as model. 
Letters in Applied Microbiology, 53(2), 198-201. 
 
Vazquez-Baeza, Y., Pirrung, M., Gonzalez, A., & Knight, R. (2013). EMPeror: a 
tool for visualizing high-throughput microbial community data. Gigascience, 2(16). 
 
Vital, M., Howe, A. C., & Tiedje, J. M. (2014). Revealing the bacterial butyrate 
synthesis pathways by analyzing (meta)genomic data. mBio, 5(2). 
 
Walter, J. (2008). Ecological role of Lactobacilli in the gastrointestinal tract: 
implications for fundamental and biomedical research. Applied and Environmental 
Microbiology, 74(16), 4985-4996. 
 
Wang, Q., Garrity, G. M., Tiedje, J. M., & Cole, J. R. (2007). Naive Bayesian 
classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. 
Applied and Environmental Microbiology, 73(16), 5261-5267. 
 
Wang, S. J., Li, C. L., Copeland, L., Niu, Q., & Wang, S. (2015). Starch 
retrogradation: a comprehensive review. Comprehensive Reviews in Food Science 
and Food Safety, 14(5), 568-585. 
 
Wiessing, K. R., Xin, L., Budgett, S. C., & Poppitt, S. D. (2015). No evidence of 
enhanced satiety following whey protein- or sucrose-enriched water beverages: a 





Willing, B. P., Russell, S. L., & Finlay, B. B. (2011). Shifting the balance: antibiotic 
effects on host-microbiota mutualism. Nature Reviews Microbiology, 9(4), 233-243. 
 
Wilson, P. J., & Basit, A. W. (2005). Exploiting gastrointestinal bacteria to target 
drugs to the colon: An in vitro study using amylose coated tablets. International 
Journal of Pharmaceutics, 300(1-2), 89-94. 
 
Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., et al. 
(2017). Safety of nisin (E 234) as a food additive in the light of new toxicological 
data and the proposed extension of use. EFSA Journal, 15(12). 
 
Yu, Y. H., South, T., & Huang, X. F. (2009). Inter-meal interval is increased in mice 
fed a high whey, as opposed to soy and gluten, protein diets. Appetite, 52(2), 372-
379. 
 
Zeng, B., Han, S. S., Wang, P., Wen, B., Jian, W. S., Guo, W., et al. (2015). The 
bacterial communities associated with fecal types and body weight of rex rabbits. 
Scientific Reports, 5. 
 
Zhou, H., Fang, J., Tian, Y., & Lu, X. Y. (2014). Mechanisms of nisin resistance in 
Gram-positive bacteria. Annals of Microbiology, 64(2), 413-420. 
 
Zhou, J., Martin, R. J., Tulley, R. T., Raggio, A. M., McCutcheon, K. L., Shen, L., et 
al. (2008). Dietary resistant starch upregulates total GLP-1 and PYY in a sustained 
day-long manner through fermentation in rodents. American Journal of Physiology-






























The aim of this study was to develop a system to allow oral delivery of a 
bioactive peptide to the colon. As a model peptide for testing the system, the 
antimicrobial peptide nisin was used as it is well characterised, commercially 
available and digested during gastrointestinal transit if taken orally. To achieve 
colonic delivery a starch matrix was used that resisted digestion in the upper 
gastrointestinal tract but could be digested by colonic bacteria.  
Bioactive peptides have demonstrable health benefits treating a range of 
conditions including osteoporosis (calcitonin) (Karsdal et al., 2011), ulcerative colitis 
(ciclosporin) (Laharie et al., 2012) and Clostridium difficile infections (thuricin CD) 
(Rea et al., 2014). However when taken orally the majority of bioactive peptides, 
including the aforementioned peptides, have poor bioavailability (Karsdal et al., 
2011; Keohane, Rosa, Coulter, & Griffin, 2016; Rea et al., 2014; Segura-Campos, 
Chel-Guerrero, Betancur-Ancona, & Hernandez-Escalante, 2011). 
Despite there being a large range of food derived bioactive peptides 
(Hartmann & Meisel, 2007), there has been dearth of systems to ensure these 
functional food components are bioavailable (Mohan et al., 2015). Systems 
developed by the pharmaceutical industry tend to be complex and non clean-label, 
such as the systems developed for delivery of insulin by Diabetology and by Oramed 
Pharmaceuticals, which are comprised of a protective outer coat with pH triggered 
release, protease inhibitors and absorbance enhancers (Diabetology, 2017; Oramed 
Pharmaceuticals, 2018). 
The colon is a privileged place for bioactive peptides due to the reduced 
protease activity, with a 20 to 60 fold decrease in protease activity relative to the 
small intestine (Washington, Washington, & Wilson, 2001). Additionally colonic 
delivery is essential for bioactive peptides that have a local effect in the colon, 
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particularly antibacterial peptides that can be used to modulate the colonic 
microbiota. 
To the authors knowledge there is only one delivery system in commercial 
development for colonic delivery (ciclosporin, SmPill®, Keohane et al. (2016)) and 
there are currently no encapsulation based delivery systems being used commercially 
in food for bioactive food peptides (Mohan et al., 2015). It is possible that if a 
colonic based delivery system for bioactive peptides was sufficiently simple it may 
become commercially viable for use in the food industry. 
The initial challenge in using a bioactive peptide is having a sufficient 
quantity of the peptide for study and in Chapter 2 a simple purification process was 
developed, based on a salting-out approach which allowed production of sufficient 
feedstock. This process produced a powder containing ∼33% nisin, from a nisin 
producing culture and also enriched a commercial nisin preparation over 30-fold to a 
purity of ∼58%. These are higher purities than comparable published methods, 
whereas the simplicity of the approach facilitates its use and scale-up. 
To accurately gauge the protection offered by the delivery system it was 
necessary to model the digestion of nisin. In vitro digestion (Chapter 3) established 
which nisin fragments, several of which maintain a low level of antimicrobial 
activity, are produced by digestion. Although it has been previously established that 
there are nisin fragments with antibacterial activity (Chan et al., 1996) this is the first 
study to establish which nisin fragments occur under natural digestion conditions. It 
is noted that the nisin concentration used in this digestion was limited by the 
detection limits of the reversed phase - high performance liquid chromatography 
(RP-HPLC) approach used to analyse the nisin fragments; using a concentration 
closer to that found in food may have yielded different fragments. The European 
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Food Safety Authority (EFSA) have set the acceptable daily intake (ADI) of nisin to 
1 mg/kg body weight (Younes et al., 2017) based primarily on toxicity studies in rats 
(Hagiwara et al., 2010). However, this toxicity study did not look at changes in the 
microbiota (Hagiwara et al., 2010). It is possible that these bioactive nisin fragments 
could negatively affect the microbiota without having a significant toxicological 
effect. Therefore in circumstances where these bioactive fragments of nisin would be 
present after a small intestinal digestion and reach the colon, the ADI may have to be 
re-evaluated to take into consideration their effect on the microbiota. In their most 
recent review on nisin (Younes et al., 2017) the EFSA acknowledged the findings of 
Chapter 3, that several of the products of nisin digestion have limited bioactivity, 
without further comment. 
The presence or absence of bile in a digestion alters the relative proportions 
of the nisin fragments in the digestion products (Chapter 3). The presence of bile 
increases the portion of fractions with antibacterial activity. This highlights the 
importance, when modelling the digestion of a peptide, to include all the digestion 
components as opposed to just the proteases. We hypothesise that the reduced 
digestion of the N-terminal of nisin in the presence of bile is due to the insertion of 
the hydrophobic N terminal of nisin into the hydrophobic core of the bile micelle and 
thus gaining a degree of protection from proteases. 
When starch (or its component polymers) are used as a protective coating for 
colonic delivery, they are normally combined with a binder, most commonly ethyl 
cellulose, to control swelling in aqueous solution and increase structural integrity and 
they are frequently applied by compression coating, spray coating and co-spray 
drying (Desai, 2007; Desai, 2005; Dimantov, Greenberg, Kesselman, & Shimoni, 
2004; Freire et al., 2010; Krogars et al., 2003; McConnell et al., 2007; Milojevic et 
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al., 1996; Moussa & Cartilier, 1997; Palviainen et al., 2001; Pu et al., 2011; Recife, 
Meneguin, Cury, & Evangelista, 2017; Situ, Chen, Wang, & Li, 2014; Wilson & 
Basit, 2005). In Chapter 5 a simple starch gel approach was demonstrated to be 
capable of colonic delivery. In this approach, the peptides were blended with starch 
and water which was heated and cooled to form a starch gel. There was no additional 
binder, only the natural gelling capacity of the starch. The simplicity of this approach 
enhances its commercial applicability. 
 One straightforward way to improve on the efficiency of the gels produced in 
Chapter 5 would be to reduce the concentration of peptide. In this study the lowest 
amount of nisin used in the gels was 0.58% (w/w) due to the detection limitations of 
the reversed phase - high performance liquid chromatography (RP-HPLC) technique 
used to validate the gels. A lower proportion of peptide would likely result in a 
greater entrapment efficiency. 
 One limitation of the gel entrapment system is that it is only suitable for 
peptides that are heat tolerant. One approach would be to produce the gel using a 
lower temperature, however this would also likely result in a gel with poorer 
entrapment and digestion resistance due to less amylose being released from the 
granules. There are still many bioactive peptides that are known to be heat tolerant 
including antibacterials, antioxidants and antihypertensives (Casteels et al., 1989; 
Deraz et al., 2005; Singh & Vij, 2018). 
 To increase the range of peptides for which the starch gel delivery system 
could be used would be to include absorbance enhancers. This would allow the 
delivery of peptides that require systemic delivery. Many absorbance enhancers, 
such as the cell penetrating peptide, trans-activator of transcription (TAT) and the 
surfactant, tetradecyl maltoside (TDM), function better in the colon (Chen et al., 
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2017; Petersen et al., 2013). However the inclusion of absorbance enhancers would 
take away from the clean-label low-cost ingredients and simplicity of the system. 
These are major strengths of the system as it is comprised of only starch and water 
and produced by simply heating and cooling. 
In Chapter 6 nisin was labelled with Alexa Fluor
®
 647 Hydrazide to 
determine its localisation in the starch gel. The high stability of this particular label 
allowed it to remain bound to nisin and retain its fluorescence after the high heat and 
low pH of the gel entrapment process. The labelled nisin showed no antibacterial 
activity despite previous reports (Scherer et al., 2013) of this label binding nisin 
without affecting antibacterial activity. Additionally, the labelled nisin behaved 
differently to native nisin in ion exchange and hydrophobic interaction chromatography 
columns. Due to these differences between the native and labelled nisin, the localisation 
of the labelled nisin may not be representative of native nisin. There are other dyes in the 
Alexa Fluor
®
 range that have a lower molecular mass and are less negatively charged 
than Alexa Fluor
®
 647; these may be more suitable for labelling nisin (Anderson & 
Nerurkar, 2002; Panchuk-Voloshina et al., 1999; Sobek, Aquino, & Schlapbach, 
2011). Another approach would be to entrap native nisin in a starch gel, section the 
gel and then label the nisin, such as in the approach by Laridi et al. (2003). The 
surface labelling of the sections may limit the information on the three dimensional 
localisation of the nisin, however as the nisin is entrapped in a native state, this 
approach could be more accurate in determining the localisation of nisin in the starch 
gel. 
In Chapter 7 it was seen in a mouse model that the entrapment of nisin in a 
starch gel enhanced its colonic delivery relative to a control comprising of nisin in a 
starch dough. Despite threefold greater nisin consumption on the control diet, the 
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nisin in starch gel diet resulted in the relative abundance of three times as many 
genera from the lower gastrointestinal tract (GIT) being significantly different (p < 
0.001, n = 10) and twice as much nisin was detected in the faeces compared to the 
control diet. In Chapter 7 the mice consumed less nisin per kg body weight on both 
nisin in starch diets than the aforementioned rat trial (Hagiwara et al., 2010) that the 
EFSA used to set the current ADI (Younes et al., 2017). However, in both nisin in 
starch diets (Chapter 7), the microbiota was affected by nisin, whereas the effect on 
the microbiota was not examined in the Hagiwara et al. (2010) study. Further studies 
would be required to establish the greatest amount of nisin that can be consumed 
without affecting the microbiota. 
It is well documented that the resistance starch content of a diet effects the 
composition of the colonic microbiota (Maier et al., 2017). There are 4 types of 
resistant starch based on whether their resistance is due to physical inaccessibility, 
granular structure, retrogradation or chemical modification (types 1, 2, 3 and 4 
resistant starch respectively) (Sajilata, Singhal, & Kulkarni, 2006). There has been 
limited study of the difference in effect on the microbiota between different starch 
types (Martinez et al., 2010), or between polymorphs of a type, such as different 
thermal processing resulting in different type 3 structures (Lesmes et al., 2008). In 
Chapter 7 the type of resistant starch effected the microbial composition of the lower 
gastrointestinal tract of mice. Of particular interest was the probiotic Akkermansia 
which is known to increase in diets that include resistant starch (Gomez-Gallego et 
al., 2016; Tachon et al., 2013). In Chapter 7 the relative abundance of Akkermansia 
was 0.5% and 11.9% on the diets containing type 2 and 3 resistant starch 
respectively which is significantly different (p = 0.0002, n = 10). 
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To accurately establish the health benefits of resistant starch the relationship 
between an effect and the type and polymorph of the resistant starch needs to be 
established. The 16S rRNA compositional sequencing approach used in this study 
would be an ideal system to study how resistant starch types and polymorphs affect 
the microbiota of the lower gastrointestinal tract. Additionally, as the starch could be 
included as a component in the standard (nutritionally complete) diet, the diets 
would be simpler to setup and compare than in Chapter 7. 
 It is hoped that the system developed during the course of this thesis will 
enable further study into the use of food grade matrices to enhance the health 
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